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Abstract 
 
The importance of selenium to skeletal muscle health is well established. 
Selenoproteins are a family of 25 mammalian proteins which exert the biological effect 
of selenium, through the incorporation of the selenocysteine (Sec) amino acid. The 
specific biological function of many of these proteins remains poorly characterised 
however, Selenoproteins are thought to be potent antioxidants. Particular interest 
surrounds the seven endoplasmic reticulum (ER)-resident selenoproteins, due to their 
emerging importance in regulation of oxidative, ER and inflammatory stress, 
metabolism and intracellular calcium (Ca2+) homeostasis. Selenoprotein S (Seps1) is 
a ubiquitously expressed ER-resident antioxidant associated with oxidative, ER and 
inflammatory stress regulation in an array of cells types in vitro. In humans, single 
nucleotide polymorphisms (SNPs) of SEPS1, including the 105G>A promotor 
polymorphism, thought to reduce SEPS1 expression are associated with increased pro 
inflammatory cytokines. In addition to its implication in cellular and inflammatory 
stress regulation, Seps1 is highly responsive to nutrient stress as it’s suppressed by 
glucose and insulin and upregulated by lipids. Thus, the involvement of Seps1 in 
metabolic dysfunction and Type 2 diabetes (T2D) has gained much research attention. 
However, the mechanism of action and biological significance of Seps1 in vivo is 
poorly characterised. Seps1 is highly expressed in metabolically active tissues 
including skeletal muscle, however, the physiological function of Seps1 in skeletal 
muscle is yet to be investigated. Given the implication of Seps1 in cellular and 
inflammatory stress regulation and in response to nutrient availability, it was 
hypothesised that Seps1 is important for skeletal muscle stress regulation, metabolism, 
contractile function and ultimately skeletal muscle health and performance.  
Therefore, this thesis explores the following aims: 
1) The effect a reduction of Seps1 (siRNA) has on cellular stress in proliferating 
myoblast and differentiated myotubes in vitro, following nutrient stress by 
palmitate.  
2) The effects the genetic reduction or deletion of Seps1 has on whole body 
muscle metabolism and fast and slow twitch muscle contractile function (ex 
vivo) using a novel Seps1 global knockout (GKO) mouse model.   
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3) The effects the genetic reduction or deletion of Seps1 has on exercise 
performance and fast twitch muscle contractile function (in situ) using Seps1 
GKO mice.   
4) Whether SEPS1 protein levels in blood cell pellets are associated with skeletal 
muscle health in a human population, representative of the wider Australian 
population and whether SEPS1 would be an appropriate biomarker of skeletal 
muscle health. 
Results from aim 1 demonstrate that Seps1 regulates cellular stress in skeletal muscle 
cells in vitro, however this appears dependent on cell phenotype. In glycolytic, 
proliferating C2C12 myoblasts, the reduction of Seps1 amplified oxidative and ER 
stress in the basal state, resulting in reduced cell viability and transition to cell cycle 
arrest. The addition of metabolic stressor, palmitate augmented this cellular stress 
response. However, the more oxidative C2C12 myotube presented with a mild 
depression of reactive oxygen species (ROS) and increase in cell death, suggesting 
myotubes are more resilient to the reduction of Seps1. 
In aim 2, SEPS1 was identified to be preferentially localised in fast twitch fibres of 
human vastus lateralis muscle. Using Seps1 GKO mice, the genetic reduction or 
deletion of Seps1 reduced spontaneous physical activity without affecting whole body 
metabolism, while contractile function of isolated fast twitch extensor digitorum 
longus (EDL), but not slow twitch Soleus muscles, were impaired ex vivo. These 
observations are analogous to findings in Seps1 reduced C2C12 muscle cells, 
suggesting that metabolic phenotype may modulate the protection against cellular 
stress permitted by Seps1. In addition to an impairment of isometric strength, the 
genetic deletion of Seps1 was associated with differential regulation of gene markers 
of ER stress and the thioredoxin antioxidant system.  
Given that the genetic reduction or deletion of Seps1 reduced spontaneous physical 
activity and impaired the contractile function of fast twitch hindlimb muscles ex vivo, 
the effects of Seps1 on muscle performance were further investigated in Seps1 GKO 
mice with the addition of an exercise protocol. Seps1 GKO mice undertook three bouts 
of increasing intensity treadmill running on consecutive days, before contractile 
function of the fast twitch Tibialis Anterior (TA) muscle was assessed in situ, where 
blood and nerve supply remain intact. In aim 3 the reduction or deletion of Seps1 was 
associated with a reduction in running distance, exercise completion rate and isometric 
strength in sedentary mice. However, muscle strength was unaffected by the addition 
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of exercise, irrespective of Seps1 expression. Exercise had no significant effect of TA 
muscle fatigability and force recovery of wildtype mice. However, exercise appeared 
to compromise muscle endurance with the reduction of Seps1, such that the rate of 
fatigue was increased, and force recovery was reduced when compared to exercised 
wildtype and sedentary Seps1 reduced mice. By contrast, TA muscle endurance of 
sedentary Seps1 deleted mice were compromised when compared with wildtype 
littermates; however, the addition of exercise stimulated adaptive processes such that 
fatigueability and force recovery were no longer different from wildtype littermates. 
While the mechanism underpinning the effects of Seps1 on exercise capacity and TA 
muscle performance are future directions of this research, they are not mediated by 
increased muscle damage or inflammation, as indicated by muscle morphology, 
inflammatory cell infiltration and circulating cytokines.  
Given the role Seps1 in skeletal muscle cellular stress responses in cultured C2C12 
cells and muscle performance in Seps1 global knockout mice, the translational 
potential of Seps1 in skeletal muscle health in a human population was investigated in 
a subset of patients from the Geelong Osteoporosis Study (GOS). In aim 4, 306 
participants representative of the wider Australian population underwent measures of 
muscle health including muscle mass and strength/endurance, by means of dual-energy 
x-ray absorptiometry (DXA) and grip dynamometer, respectively. SEPS1 protein 
levels were measured in blood cell pellets, containing erythrocytes and leukocytes. 
SEPS1 protein expression has previously been measured in human serum, however 
serum levels are not representative of SEPS1 in skeletal muscle, as only liver cell 
secrete Seps1. SEPS1 is however closely associated with circulating inflammatory 
cells, which have more recently been identified as markers of skeletal muscle strength, 
respiration and physical function. Thus, whole blood cell pellets, including leukocytes, 
were used as a non-invasive measure of SEPS1 in skeletal muscle health. Grip strength 
analysis was a strength of this study, aligning with that of the literature, as grip strength 
was positively associated with appendicular lean mass, while inversely associated with 
age and percent body fat. However, SEPS1 protein levels in blood cell pellets were not 
significantly associated with measures of muscle health, including mass, strength and 
endurance, suggesting SEPS1 blood levels may not be a suitable biomarker of skeletal 
muscle health. 
Results obtained in this thesis identify the physiological role of Seps1 as an antioxidant 
important to skeletal muscle cellular stress regulation, strength and exercise 
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performance. Together, the novel findings of this thesis make a significant contribution 
to the emerging body of knowledge surrounding the importance of ER-resident 
selenoproteins to skeletal muscle health, metabolism and exercise performance. This 
work has however identified new gaps of knowledge that future research should aim 
to investigate. These include the role of Seps1 in Ca2+ homeostasis, which may have 
downstream implication on known determinants of muscle health and performance, 
including, mitochondrial function and muscle contraction. 
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Chapter One 
Review of the literature  
The majority of this chapter was incorporated into a manuscript which was published 
in March 2018. Details of the publication are as follows:  
Addinsall AB, Wright CR, Andrikopoulos S, van der Poel C & Stupka. N. (2018). 
Endoplasmic reticulum resident Selenoproteins: Cellular stress regulation and 
metabolic disease. Biochemical Journal. 10.1042/BCJ20170920.  
Mr. AB Addinsall critically reviewed the literature, formulated study direction and 
wrote and revised this manuscript with editorial feedback from the co-authors   
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1.1. Introduction 
Selenium is an important macronutrient for a range of tissues and systems within the 
body, including skeletal muscle and has been implicated in the pathogenesis of 
metabolic disease. Selenoproteins are a family of antioxidative proteins characterised 
by the incorporation of selenium via the Sec amino acid. A subset of these proteins 
localised to the ER have been shown to regulate oxidative, ER and inflammatory 
stress, as well as Ca2+ signalling. Tight homeostatic regulation of these stressors is 
important for the efficient function of a wide array of tissues, yet is specifically 
important to skeletal muscle health and function. Skeletal muscle requires transient 
increases in cellular stress, such as those which are experienced during exercise, to 
prompt muscle growth and adaptation. However, chronic increased in cellular stress 
leads to metabolic and contractile dysfunction, weakness and wasting.  
One such ER-resident selenoprotein, Seps1 regulates oxidative, ER and inflammatory 
stress in a variety of cells in vitro, however its biological function in vivo is less well 
described. In this chapter we aim to examine the importance of ER-resident 
selenoproteins to metabolic and skeletal muscle health. This review identifies the 
strengths and gaps of knowledge, highlighting the importance of further research to 
better understand the potential this subgroup of antioxidants may possess in metabolic 
and skeletal muscle health and disease. We start the literature review by highlighting 
the importance of the ER in metabolic disease and the implication of ER-resident 
selenoproteins in oxidative and ER stress, inflammation and Ca2+ homeostasis. We 
then extensively review the role of Seps1 in cellular and inflammatory stress 
regulation, before discussing the potential of these selenoproteins in metabolic and 
skeletal muscle function and disease. We conclude by discussing the role of cellular 
and inflammatory stress in skeletal muscle and identify the research gaps that we aim 
to study in this thesis.   
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1.2. ER-resident selenoproteins and metabolic health  
Chronic metabolic disease, including obesity, cardiovascular disease and diabetes, is 
a leading cause of morbidity and mortality in developed and developing countries and 
is associated with a large financial burden on our health care systems [1-3]. Genetic 
predisposition, excess dietary caloric intake and physical inactivity all contribute to 
the complex clinicopathology of these diseases [4]. Metabolic disease is associated 
with heightened cellular and inflammatory stress [5, 6] and to date no treatments exist 
that successfully target this chronic increase in cellular stress. Previous research has 
focused on understanding mitochondrial dysfunction [7]. However, emerging 
evidence is recognising the importance of the ER in regulating cellular and 
inflammatory stress responses and as such the development of metabolic disease [8, 
9]. 
The ER is involved in intracellular signalling, protein synthesis and protein folding, 
glycosylation and secretion. The ER is also critical for lipid biosynthesis and the 
regulation of intracellular Ca2+ homeostasis [10-12]. Protein folding is dependent upon 
the oxidation of disulphide bridges via reactive oxygen species (ROS), specifically, 
hydrogen peroxide (H2O2), which is produced by the ER-resident oxidoreductase 
enzymes ER oxidoreductin 1 (Ero1) [13-15]. For correct protein folding, the redox 
state of the ER lumen must be carefully regulated [16]. A heightened oxidative 
environment will impair protein folding, leading to the accumulation of unfolded or 
misfolded proteins and ultimately ER stress [14, 17].  
Maintaining ER redox state and function is also key for regulating Ca2+-dependent cell 
signalling and homeostasis [18]. Depending on cell type, through the release and re-
uptake of intracellular Ca2+, the ER regulates signalling pathways relevant to 
inflammation [19], energy metabolism (glucose transport, glycolysis, TCA cycle) [20] 
and insulin release [21]. ER Ca2+ handling is pivotal to mitochondrial homeostasis, 
regulating free Ca2+ by acting as a sink for excess mitochondrial Ca2+. Additionally, in 
skeletal, cardiac and smooth muscle, a specialised smooth ER, known as the 
sarcoplasmic reticulum (SR), regulates Ca2+ handling during muscle contraction and 
relaxation. Oxidative stress can disrupt Ca2+ homeostasis at the ER [10]. ER/SR 
proteins regulating Ca2+ release and re-uptake, the ryanodine receptor (RyR) [22, 23], 
the inositol 1,4,5-trisphosphate (IP3) receptor [24], and the sarcoplasmic/endoplasmic 
reticulum ATPase (SERCA) pump [25-27] are highly susceptible to oxidative 
modifications [10, 28].  
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There is emerging evidence for the seven ER-resident selenoproteins in regulating ER 
redox state, ER stress responses and Ca2+ signalling. These resident selenoproteins 
include the 15-kDa selenoprotein, type 2 iodothyronine deiodinase and selenoproteins 
S, N, K, M and T [18]. Like all selenoproteins, they are characterised by the 
incorporation of selenium, an essential antioxidant micronutrient [29, 30], in the form 
of the 21st amino acid Sec. Given their role in regulating oxidative, ER and 
inflammatory stress, a greater understanding of these ER-resident selenoproteins may 
offer novel insight into the development of metabolic dysfunction and in turn 
metabolic disease.  
 
1.3. Dietary selenium intake and chronic metabolic disease risk  
Selenoprotein synthesis is dependent upon dietary selenium intake. The recommended 
daily intake of selenium is 55 µg/day for adults, but may increase to 70 µg/day in 
lactating women, the majority of which is obtained through selenium-rich foods such 
as dairy, seafood, organ meats, grains and cereals [31, 32]. Low dietary selenium 
intake is commonly the result of poor diet, however variation in agricultural soil 
selenium also contributes to a low selenium status [33-35]. Despite the wide variety of 
accessible selenium-rich foods, selenium deficiency remains surprisingly prevalent in 
developed nations [36, 37]. Selenium deficiency has been shown to be associated with 
a number of chronic diseases characterised by increased oxidative and inflammatory 
stress, including mood disorders [33], cancer [38-40], degenerative osteoarthropathy 
[41], congestive heart failure [35] and metabolic dysfunction, including T2D [42-46]. 
However the therapeutic benefit of selenium supplementation remains in dispute [47-
53]. 
Selenium is incorporated into selenoproteins in the form of Sec [18, 54, 55] and is 
involved in various biological processes including immune function, thyroid 
metabolism, energy metabolism and skeletal and cardiac muscle contractile function 
[30, 56-66]. However, selenium intake needs to be carefully regulated. Excess dietary 
intake of selenium is associated with muscular fatigue, blind stagers, neurological 
damage, liver damage, gastrointestinal disturbances and metabolic dysfunction 
(including insulin resistance and increased risk of developing T2D) [56, 67-77]. While 
toxicity or extreme deficiency are rare in humans, lesser changes in dietary selenium 
5 | P a g e  
 
can significantly affect human health. Selenium likely functions best in a bell shaped 
dose response curve, where too little or too much may be detrimental to health [76]. 
Selenium is circulated throughout the body via Selenoprotein P (SelP), as in it its full 
length form, SelP possesses a Sec-rich catalytic domain of 10 Sec residues, which 
govern its role in selenium transportation [78-80]. Selenium is taken up by the liver 
and incorporated as Sec, where up to 70% of circulating selenium is secreted as SelP. 
The remaining selenium is expressed as glutathione peroxidases (GPx) 3 (20–40%) or 
bound to albumin, forming selenomethionine [81]. SelP is expressed in a wide array 
of tissues, including the liver, kidney, brain, testis and skeletal muscle [82, 83]. 
However, like many other non-essential selenoproteins, its expression is highly 
responsive to fluctuation in dietary selenium [84]. Given its presence in circulation, 
SelP is thought to be vital for selenium transport to peripheral tissues, and 
consequently selenoprotein synthesis [82]. Therefore, SelP has been commonly used 
as a marker of dietary selenium intake in epidemiological studies [32, 85, 86].  
 
1.4. Transcriptional regulation of selenoproteins and associated research 
challenges 
The highly catalytic Sec residue of selenoproteins is encoded by the TGA codon, a 
nucleotide triplet that commonly signals termination of translation [18, 55]. In the 
presence of secondary mRNA structures called selenocysteine insertion sequence 
(SECIS) elements, Sec is transcribed [87-90], however in the absence of SECIS, Sec 
production is terminated, leading to the loss of functional information and ultimately 
compromised selenoprotein antioxidant activity [91, 92](For greater understanding of 
selenoprotein biosynthesis see review [93]). It is worth noting that the gene 
transcription of selenoproteins is variably responsive to dietary selenium intake [94]. 
However, not all selenoproteins are equally affected by fluctuations in dietary 
selenium, rather nonessential selenoproteins, including Seps1, SelM and glutathione 
peroxidase 1 are suppressed, while essential selenoproteins, such as thioredoxin 
reductase 1 and SelK are preFferentially preserved [94-96]. Nonetheless, optimal 
selenoprotein expression is likely desirable.  
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Dietary, selenium supplementation of selenoproteins is challenging to achieve, as 
selenium has a narrow therapeutic window and variations of selenium levels are 
attributed to various health complications. Therefore, future therapeutic manipulation 
of selenoproteins should surpass dietary selenium supplementation in favour of more 
targeted approaches, thus allowing new avenues to potentiate the power of 
selenoproteins. Existing biochemical, molecular and cellular studies investigating 
selenoprotein function have utilised cell culture or transgenic mice models, where 
selenoproteins of interest are overexpressed, knocked down or deleted. The best 
characterised selenoproteins are glutathione peroxidase and thioredoxin reductase, 
which catalyse thiol-dependent reactions and regulate the vital glutathione and 
thioredoxin antioxidant pools. However, approximately half of the selenoprotein 
family is yet to be fully characterised [97]. This is especially true for the seven ER-
resident selenoproteins: selenoprotein K (SelK), selenoprotein 15 (Sep15), 
selenoprotein M (SelM), selenoprotein T (SelT), type 2 iodothyronine deiodinase 
(Dio2), SelN and Seps1.  
Of the ER-resident selenoproteins, SelN and Seps1 are the most characterised and have 
been linked to human disease. For example, mutations in the SelN gene causes a 
myopathy characterised by axial muscle weakness, respiratory insufficiency and 
insulin resistance [60-63], while, SEPS1 gene sequence variations have been 
associated with diseases characterised by a heightened pro-inflammatory state [98]. 
Given the proven translation of ER-resident selenoproteins to human health, the 
characterisation of these less known selenoproteins is desirable.   
 
1.5. Characterising the Potential of ER-Resident Selenoproteins in Metabolic 
Health and Disease. 
Emerging research is elucidating a role for ER-resident selenoproteins in regulating 
oxidative and ER stress responses, Ca2+ signalling and inflammation (Figure 1.1) [100, 
103, 110, 111].  The importance of these protective roles on homeostatic ER function 
is becoming increasingly apparent, as the dysregulation of these stressors are 
detrimental to metabolic health. Reduced expression of ER-resident selenoproteins in 
vitro and in vivo is associated with increased cellular stress and inflammation and have 
been implicated in a range of processes including ER stress and the retrograde 
translocation of misfolded proteins out of the ER, Ca2+ homeostasis, inflammation, β-
cell function, thyroid hormone synthesis and muscle development [99-105]. Thus, 
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these selenoproteins have the potential to be highly relevant to the pathophysiology of 
various metabolic conditions including diabetes [104], obesity [106, 107], 
atherosclerosis [108] and Alzheimer’s disease [109]. However, further research is 
needed to investigate the cellular mechanism of action of these ER-resident 
selenoproteins, their relevance to the pathophysiology of metabolic disease and 
strategies to target their expression.  
Selenoprotein abundance in metabolically active tissues may be highly variable due to 
variable dietary selenium intake (including selenium source), gene sequence 
variations, and the complex nature of selenoprotein synthesis [89, 94, 112, 113]. 
Whilst selenoprotein synthesis is indeed influenced by dietary selenium intake, how 
this regulates the expression of the seven ER-resident selenoproteins proteins is not 
well understood [114, 115]. Given the importance of ER-resident selenoproteins in 
cellular and inflammatory stress responses and the causative involvement of these 
stressors in metabolic disease, optimal selenoprotein expression is likely desirable.  
Given the emerging evidence for the ER in metabolic disease, the importance of the 
SR to muscle function and the close association with oxidative and inflammatory stress 
and Ca2+ homeostasis, these lesser characterised selenoproteins, which reside within 
the ER may be important to muscle function and in the development of metabolic 
disease. Here we briefly review the characterisation of the known structural 
organisation and function of SelK, Sep15, SelM, SelT, Dio2 and SelN to provide 
insight into the potential role of ER-resident selenoproteins in metabolism and muscle 
function and disease (Figure 1.2 and 1.3).  
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Figure 1.1: Function of the characterised ER-resident Selenoproteome. While 
characterisation of the ER-resident selenoproteins is currently limited, here we outline 
the known gross functions of SelK, Sep15, SelM, SelT, Dio2, SelN and Seps1 in redox 
regulation, ER stress, inflammation, thyroid metabolism and Ca2+ homeostasis. 
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Figure 1.2: Structural organisation of the less well characterised ER-resident 
selenoproteins. These ER residents possess oxidoreductase capabilities through the 
incorporation of selenocysteine (Orange) and cysteine (Green) residues. SelT and Dio2 
oxidoreductase capabilities may be further enhanced by the inclusion of thioredoxin 
folding motifs, while SelM and Sep15 possess thioredoxin-like domains. SelK and 
Dio2 and possibly SelT contain a transmembrane domain, whilst Sep15 and SelM 
reside within the ER lumen. Other domains include: the disordered domain within the 
SelK C-terminus for protein-protein interactions, a signal sequence on Sep15 and SelM 
which is thought to be cleaved upon their entrance into the ER, a cysteine-rich UGGT-
binding domain of Sep15, thought to assess quality of disulphide bonding, an ER 
retention signal on SelM and Sep15, and a lysosomal α-L-iduronidase (IDUA)-like 
sequence within the thioredoxin fold of Dio2. 
 
1.5.1 Selenoprotein K  
SelK (SELENOK) is an 11 kDa, 94 amino acid protein that has a single trans-
membrane helix with a cytoplasmic C-terminus and the N-terminal sequence of 
approximately 20 amino acids protruding into the lumen of the ER [87, 88]. Similar to 
Seps1, SelK has a single transmembrane domain responsible for ER targeting and 
retention, a glycine, proline and positively charged amino acid segment and a Sec 
residue, which is situated within the lumen of the ER close to the C-terminus [89]. 
SelK appears to have high redox potential via diselenide bond formation and the 
incorporation of a functional ER stress response element (ERSE) within its promoter 
suggests a role in regulating ER stress responses. SelK binds to Seps1 [90], as part of 
the ER membrane complex, which facilitates the translocation of misfolded proteins 
out of the ER during the unfolded protein response (UPR) [18]. SelK has a higher 
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affinity for Derlin-1, whilst Seps1 has a higher affinity for Derlin-2, suggesting that 
these selenoproteins could recognise and regulate the translocation of different 
substrates through the Derlin channel in the ER membrane [89]. SelK is ubiquitously 
expressed but is especially abundant in the heart. Overexpression of SelK in cardiac 
myocytes protects them from oxidative-stress in vitro [91]. SelK is also important for 
Ca2+ homeostasis, as it appears to control the release of intracellular Ca2+ from the ER 
in Drosophila, however to date Ca2+ regulation has not been assessed in the heart in 
vivo [92]. In transgenic mice, the loss of SelK disrupts intracellular Ca2+ flux in T-
cells, neutrophils and macrophages during immune cell activation leading to impaired 
immune function [93]. T-cell proliferation and neutrophil migration is also decreased 
in cells from SelK null mice [93].  
Bone marrow transplants from SelK-/- knockout mice also show decreased formation 
of atherosclerotic plaques [94]. This resulted from reduced foam cell accumulation 
during plaque formation, potentially mediated by a reduced pro-inflammatory 
response in SelK deficient mice [94]. This suggests that SelK may contribute to 
atherosclerosis and vascular disease, through its effects on macrophage proliferation 
and cytokine production. Conversely, the same research group have shown that 
overexpression of SelK protects cardiomyocytes from apoptosis through its 
antioxidant properties [94]. Further research is needed to delineate the role of SelK as 
an antioxidant and a regulatory protein controlling Ca2+ flux and to better understand 
the functional implications for cardiomyocytes, immune cells and blood vessels. SelK 
has also been identified in skeletal muscle [91], where it may also regulate 
inflammation, oxidative and ER stress and Ca2+ flux and consequently may have 
significant implications for muscle myopathy.  
 
1.5.2. 15-kDa selenoprotein  
Sep15 (SELENOF) is a 15 kDa, 164 amino acid protein identified in 1998 as an ER-
resident selenoprotein with unknown function, which still to this day remains relatively 
uncharacterised [95]. Due its intraluminal localisation within the ER, Sep15 has been 
proposed to facilitate protein folding and regulate oxidative stress via its Trx-like fold 
[96]. In cultured chicken splenocytes, selenium deficiency reduced Sep15 expression 
resulting in increased susceptibility to H2O2 and reduced cell viability [97]. In liver 
tissue from Sep15-/- global knockout mice, oxidative stress and lipid and protein 
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peroxidation were increased [98]. Sep15 interacts with UDP-glucose, glycoprotein 
glucosyltransferase, a quality control mechanism for glycoprotein folding in the ER 
[99, 100]. Thus, it is not surprising that Sep15 deficient mice develop cataracts, a 
condition commonly the result of ER stress and improper protein folding [98].  
Expression of Sep15 in metabolically active tissues and those with a high secretory 
function such as the liver, prostate, kidneys, brain, lungs, thyroid and adipose is highly 
variable [101]. However, deficiency of Sep15 in mice has no effect on the regulation 
of glucose metabolism [98]. Given the limited characterisation of Sep15, its 
physiological function remains poorly understood. In light of its regulatory capacity 
and the highlighted importance of balanced maintenance of the ER and protein folding, 
its importance to metabolic function is intriguing.  
 
1.5.3. Selenoprotein M 
Similar to Sep15, SelM (SELENOM) is a 15 kDa, 145 amino acid protein closely 
related to the thioredoxin superfamily, containing a Trx-like fold, suggestive of 
oxidoreductase function [96]. Whilst they do possess a high degree of homology, 
sequence and structural comparisons clearly indicate SelM and Sep15 are part of a 
distinct evolutionary family [102, 103]. The presence of residues known to influence 
the activity of other redox proteins suggests that SelM and Sep15 are thiol-disulphide 
oxidoreductases capable of forming reversible mixed selenenylsulphide bonds during 
the catalytic cycles of oxidation and reduction [102].  
SelM is highly expressed in the brain [104], the pituitary gland and pancreas, with low 
to undetectable levels in the adrenal gland, kidney, thyroid and liver [105]. SelM-/- 
mice develop adult onset weight gain and adiposity, which is exacerbated by a 
selenium deficient diet [105]. This has been attributed to increased leptin levels and 
reduced sensitivity to leptin [105]. Leptin binds to its hypothalamic receptors to 
regulate food intake and energy expenditure [106]. ER stress plays an important role 
in leptin resistance [107]. Interestingly, SelM is highly expressed in the regions of 
the brain that are involved in energy homeostasis [105]. Therefore, loss of SelM in 
the brain may exacerbate ER stress leading to reduced leptin sensitivity, increased 
caloric intake and weight gain. However, it is unknown whether SelM contributes 
to human obesity or metabolic disease. In rodents, increased SelM expression is 
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protective against the development of Alzheimer’s disease [108] Alzheimer’s not only 
encompasses neurological deficits, but commonly incorporates metabolic 
dysfunctions including, progressive weight loss and abnormal glucose tolerance [109-
111]. However whether these metabolic insufficiencies are a cause or a consequence 
of the neurological disease progression is unknown. Interestingly, SelM has been 
shown to regulate Ca2+ flux in cerebral astrocytes [112]. Altogether, this may indicate 
tissue specificity of selenoproteins where SelM is required for optimal brain function.  
 
1.5.4. Selenoprotein T 
SelT (SELENOT) is a 22 kDa, 195 amino acid protein, also assigned to the thioredoxin-
like family of proteins due to the presence of a Trx-like catalytic domain [113]. The 
length of the α-helical insertion of 67 amino acids may be sufficient to pass the ER 
membrane twice and form the globular Trx-fold domain on either the ER lumen or the 
cytosolic sides. Conversely, it has been proposed that SelT is bound to only one leaflet 
of the lipid bilayer via an amphipathic helix [114]. In addition to the ER [115], SelT 
has also been localised to the Golgi apparatus [113] and the plasma membrane [116]. 
SelT is ubiquitously expressed, but is found especially highly expressed in the testes 
[57] and pancreatic islet β and δ cells [117].  
Grumolato et al. initially identified SelT to be a novel target gene of the neuropeptide 
pituitary adenylate cyclase-activating polypeptide (PACAP), with PACAP up-
regulating SelT expression in PC12 pheochromocytoma cells and MIN6 β-cells [115, 
117]. The interactions between SelT and PACAP are thought to be Ca2+ dependent. 
Overexpression of SelT provoked an increase in intracellular Ca2+concentration, whilst 
gene reduction inhibited the PACAP-induced Ca2+ increase [115]. Maintaining ER 
function and normal intracellular Ca2+ homeostasis is critical for β-cell viability, 
insulin synthesis and secretion. In a β-cell specific SelT-/- knockout mouse, glucose 
tolerance was impaired as a result of reduced insulin production and secretion and was 
associated with islets which were smaller and more numerous than those of their 
wildtype littermates [117]. These findings further highlight the potential importance 
of SelT to metabolic regulation, as an increasing body of evidence demonstrates the 
involvement of PACAP in lipid and carbohydrate metabolism [118-122]. Specifically, 
PACAP augments glucose induced insulin secretion [118, 119], enhances insulin-
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induced glucose uptake in 3T3-L1 adipocytes [120] and regulates adipogenesis in 3T3-
L1 cells and PACAP transgenic mice [121, 122]. 
1.5.5. Type 2 iodothyronine deiodinase 
Dio2 is a 31 kDa, 272 amino acid protein belonging to the deiodinase enzyme family. 
It is important for the regulation of thyroid hormones, specifically the conversion of 
T4 to the more active T3 hormone [123]. Dio2 single spanning membrane protein with 
a short N-terminus of approximately 20 kDa in the ER lumen and a cytosolic globular 
domain with catalytic activity. In contrast to the other ER selenoproteins, Dio2 
contains two Sec residues at positions 134 and 265, with the latter positioned close to 
the C-terminus. However, only the first Sec residue is required for enzymatic function 
[124]. 
In addition to its role in the thyroid gland, Dio2 is highly expressed in skeletal muscle 
[125]. In rodents, expression is highest shortly after birth, suggesting a potential role 
in muscle development. Dio2 acts under the control of the Forkhead box O3 (FoxO3), 
a transcription factor that regulates diverse cellular functions, such as muscle growth, 
development and metabolism [126, 127]. Therefore, not surprisingly, Dio2 is 
implicated in skeletal muscle development where Dio2 deficient mice show impaired 
differentiation and elevated myocyte precursor cells. Interestingly, FoxO3 plays a 
central role in skeletal muscle metabolism by regulating glycolytic and lipolytic flux 
and mitochondrial metabolism. It is also central to muscle plasticity through activation 
of protein breakdown via the ubiquitin-proteasome and autophagy-lysosomal 
proteolytic pathways [128]. As further evidence of its role in metabolism, Dio2 is 
essential for thermogenesis in rodent brown adipose tissue [129]. Although rodent 
models are contradictory with regards to a role in muscle metabolism, for example, 
whole body Dio2 deficient mice are insulin resistant [130], Dio2 deficient myoblasts 
similarly have insulin signalling impairment [131], while no phenotype was identified 
in the muscle specific knockout model [132]. In 2012 Nair et al [133], identified 12 
SNPs in DIO2 associated with early onset type 2 diabetes in Pima Indians. Although 
a systematic review and meta-analysis supports the use of DIO2 polymorphisms as a 
predictor of T2D [134], more studies with much larger populations are needed to 
consolidate its potential use as a predictor.  
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1.5.6. Selenoprotein N (SelN) 
SelN (SELENON) has a single transmembrane domain, a short N–terminus 
cytoplasmic tail, with the majority of the protein residing within the ER lumen, 
including its Sec residue (458aa)[135](Figure 1.3). The intraluminal Sec residue is part 
of the thioredoxin reductase-like motif that is thought to provide SelN with its 
oxidoreductase activity [136]. Cells devoid of SelN demonstrate a more overall 
oxidised cellular redox state [137, 138]. SelN also has five putative N-glycosylation 
sites [139] and a Ca2+ binding EF-hand motif, which are thought to contribute to overall 
protein structure rather than Ca2+ signalling [136]. Within its promoter region, SelN 
possesses a putative ERSE [135] and multiple NFκB binding sites [140], supporting 
the hypothesis that SelN may be regulated in response to oxidative, ER and 
inflammatory stress. 
 
 
Figure 1.3: Selenoprotein N structure. SelN is a transmembrane glycoprotein 
located in the ER membrane. The Sec incorporated thioredoxin-like motif provides 
SelN its antioxidative properties to neutralise ROS, whilst the N-glycosylation sites 
categorise SelN as a putative glycoprotein. 
 
SelN is ubiquitously expressed in foetal tissues, with particularly high expression in 
the developing myotome during early embryogenesis, where it is thought to have a 
role in myoblast proliferation [139] and muscle organisation [141]. SelN expression 
decreases during myoblast differentiation and myofibre formation [139]. In mature 
muscle, SelN expression might be fibre type dependent, with mouse fast twitch EDL 
muscles having higher SelN protein levels than slow twitch Soleus muscles [142]. 
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1.5.6.1. SelN regulation of skeletal muscle health and function 
Despite ubiquitous expression, mutations in the SEPN1 gene have a predominant effect 
on skeletal muscle, leading to the development of a range of pathologies termed 
SEPN1-related myopathies. To date, all mutations associated with SelN are autosomal 
recessive and consistent with a loss of protein function [143]. SEPN1-related 
myopathies are characterised by a consistent clinical phenotype of axial muscle 
weakness (neck, trunk and diaphragm), spinal rigidity and scoliosis leading to 
respiratory complications [60-64]. There is a relative sparing of proximal muscles 
allowing patients to remain ambulant [60]. The underlying skeletal muscle pathology 
is more variable. Mitochondrial depletion and the presence of minicores are a common 
finding. Sarcomere dysregulation, fibre type disproportion and type I muscle fibre 
hypotrophy have also been reported [61, 143]. Only a few patients with SEPN1-related 
myopathies present with cardiovascular comorbidities, including mild right ventricular 
hypertrophy or mild pulmonary hypertension, which are likely a secondary 
consequence of respiratory insufficiency [64]. Interestingly, patients with SelN 
myopathy can present with insulin resistance, although it is unclear whether this is a 
specific effect of SelN on insulin sensitivity or simply a consequence of reduced 
muscle mass [61, 144]. The only demonstrated association of SelN with human disease 
is within the SEPN1-related myopathies and this highlights the fact that, despite 
ubiquitous expression, ER-resident selenoproteins can have a very specific 
physiological function. 
 
1.5.6.2. SelN regulation of oxidative stress 
Given the association with SEPN1-related myopathies, much of the literature has 
focused on how SelN regulates cellular stress responses in skeletal muscle, with an 
emphasis on identifying the redox-sensitive target proteins. Oxidation of skeletal 
muscle contractile proteins, including myosin and actin, is associated with SEPN1 null 
mutations [137]. In primary myotube cultures established from patients with SEPN1 
mutations, increased oxidative and nitrosative stress was observed, which was not 
compensated for by an upregulation of endogenous antioxidants, such as superoxide 
dismutase (MnSOD) or catalase [137]. As such, SelN deficient myotubes are more 
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vulnerable to cell death in response to exogenous H2O2 compared to healthy, control 
myotubes [137].  
 
1.5.6.3. SelN regulation of SR/ER Ca2+ homeostasis 
The increase in skeletal muscle oxidative and nitrosative stress due to a loss of SelN 
expression is associated with irregularities in Ca2+ homeostasis in cultured myotubes 
from patients with SEPN1-related myopathies. Specifically, a loss of SelN expression 
is associated with an increase in resting cytosolic Ca2+ concentrations and a reduction 
in SR Ca2+ load [137]. In skeletal muscle, Ca2+ release occurs via the RyR and Ca2+ 
uptake via the SERCA pumps. Both are highly sensitive to modifications by ROS and 
reactive nitrogen species (RNS), which has implications for excitation-contraction 
coupling (E-C Coupling) and muscle function [27, 145, 146].  
There is evidence for RyR and SERCA dysfunction with SelN deficiency. 
Immunoprecipitation studies using rabbit skeletal muscles have shown a physical 
interaction between SelN and the RyR [143]. The RyR has over 400 Cys residues, 
which has complex downstream implications for the redox regulation of SR Ca2+ 
release. In SelN depleted zebrafish embryos and in muscle biopsies from patients with 
SEPN1-related myopathies, the biochemical properties of the RyR were altered due to 
increased oxidation [143]. Moreover, in isolated fast twitch flexor digitorum brevis 
(FDB) muscle fibres from SelN-/- deficient mice, caffeine activated Ca2+ release was 
reduced compared to isolated FDB muscle fibres from wild type mice, which was 
attributed to altered RyR function rather than decreased SR Ca2+ re-uptake [147].  
Like the RyR, SERCA pumps are also highly sensitive to redox mediated regulation 
via oxidation of their luminal and transmembrane Cys residues [27, 148]. Oxidation 
of these Cys residues contributes to contractile dysfunction by decreasing Ca2+ 
reuptake into the SR [148, 149]. SelN can bind SERCA2a, which is predominantly 
expressed in slow muscle fibres and SERCA2b, which is expressed ubiquitously [138]. 
This physical association between SelN and SERCA2 is thought to enhance Ca2+ 
uptake into the ER/SR [138]. In support of this hypothesis (and in contrast to findings 
by Moghadaszadeh et al. in isolated FDB myofibres [147]), in isolated mouse 
embryonic fibroblasts (MEFs) from SelN global knockout mice, steady state Ca2+ 
uptake and the rate of Ca2+ accumulation into the ER were reduced, leading to elevated 
cytoplasmic Ca2+. Importantly, re-introduction of the SelN protein restored ER Ca2+ 
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levels to wild type levels [138]. Marino et al. proposed that SelN protects SERCA2 
from oxidative modification by H2O2.  
A significant source of H2O2 in the ER is Ero1α [138]. As the main ER/SR protein 
disulphide oxidase, Ero1α is important for protein folding and its expression is 
upregulated as part of the UPR [150]. Data from HeLa cells indicate that Ero1α also 
plays a key role in ER Ca2+ homeostasis [151]. In C2C12 myoblasts, co-regulation of 
SelN with Ero1α is observed during ER stress [138]. To date, Ero1α function in 
skeletal muscle is not well described. Whilst oxidative and ER stress are increased in 
skeletal muscle with strenuous/unaccustomed exercise [152, 153] or disease [154 1, 
155], whether Ero1α expression or activity are similarly regulated is not known. 
Nonetheless, when Ero1α is overexpressed in SelN-/- global knockout mice, minicore 
lesions, characteristic of SEPN1-related myopathies, were observed and these were 
associated with a reduction in mitochondrial protein content. All together, these 
observations demonstrate the potential of SelN to modulate the redox state of Ca2+ 
regulatory proteins, including RyR and SERCA2, perhaps via Ero1α and as such play 
a major role in regulation of Ca2+ homeostasis. However, the downstream implications 
on skeletal muscle performance are yet to be fully resolved. 
The effects of SelN on skeletal muscle contractile properties and exercise capacity 
have been studied using SelN-/- global knockout mice. Unlike patients with SEPN1-
related myopathies, these mice have a subtle phenotype, with no minicore lesions and 
areas of degeneration, with additional oxidative stress being needed to tease out 
impairment in muscle structure and function [138, 147]. The genetic deletion of SelN 
did not affect the maximal force normalised to muscle size output (specific force (sPo)) 
of isolated EDL and Soleus muscles ex vivo, [147] or of fast twitch tibialis anterior 
muscles in situ (where the muscle nerve and blood supply remained intact) [156]. 
Interestingly, in isolated Soleus, but not EDL muscles, the loss of SelN did enhance 
resistance to fatigue. This was associated with an increase in fatigue resistance during 
five consecutive bouts of treadmill running exercise [147]. This result is consistent 
with that found with Selenoprotein reduction, as SelP deficient mice demonstrate 
increased exercise tolerance, while in a model of exercise overload, selenoprotein 
reduced mice increased muscle growth [39, 157]. It is important to highlight that mice 
housed in standard laboratory conditions are sedentary, which may contribute to the 
mild pathology of SelN deficient mice. When these mice were stressed with three 
months of forced swimming and limited mobility, spinal rigidity and progressive 
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spinal curvature were observed. This exacerbated pathology is characteristic of 
SEPN1-related myopathies and lead to a reduction in the TA absolute force (Po) [156]. 
To date, these in vivo observations in SelN deficient mice, with regards to exercise 
performance, have not been linked to alterations in SERCA or RyR function, or 
oxidisation of the contractile apparatus. 
Of the seven ER-resident selenoproteins, the function of SelN is the most 
characterised, as the loss of SelN in patients’ manifests itself in very specific skeletal 
muscle defects (Figure 1.4). Yet the inconsistencies between the effects of SelN 
deficiency on Ca2+ homeostasis within cell culture models, SelN knockout fish and 
mice and patients with SEPN1-related myopathy emphasise the complexity of 
studying selenoprotein function.  
 
Figure 1.4: Functional mechanisms of Selenoprotein N in skeletal muscle. As the 
most highly characterised ER resident, the mechanisms of SelN action is linked to a 
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broad range of conditions, termed, SEPN1-related myopathies. The SelN functions of 
redox regulation and Ca2 handling have been well defined biochemically, in vitro and 
in vivo, with the redox potential of SelN also investigated in cells of patients with 
mutation of the SEPN1 gene. The oxidative potential of SelN is defined by is 
mechanistic relationship with ER oxidoreductin 1 (ERO1), which has downstream 
Redox modification of Ca2 handling proteins, ryanodine receptor and sarcoplasmic 
reticulum Ca2 ATPase (SERCA) leading to loss of skeletal muscle health.  
 
The role of ER-resident selenoproteins in cellular and inflammatory stress regulation 
and Ca2+ signalling is becoming apparent. Skeletal muscle growth, metabolism and 
contractile function are highly respondent to variation of cellular and inflammatory 
stress which disrupt Ca2+ signalling. Provided the well-established role of SelN in 
skeletal muscle health and the role of Seps1 in cellular and inflammatory stress 
regulation in a range of tissues, we sought to characterise the importance of Seps1 in 
skeletal muscle health and contractile function.  
 
1.6. Selenoprotein S (Seps1) 
Seps1 (SELENOS, also known as SelS, Tanis or VIMP) is an intrinsically disordered 
single pass transmembrane protein [90, 158]. Due to its transmembrane domain, Seps1 
has a short ER luminal section and a longer cytosolic tail containing the Sec amino 
acid residue. The incorporation of a Sec amino acid within its catalytic domain, in 
addition to one cysteine (Cys) residue and another Cys in the transmembrane domain, 
is thought to give Seps1 its antioxidant properties (Figure 1.5) [18, 88, 90]. Two Seps1 
isoforms exist, with the more common transcript variant successfully transcribing the 
Sec residue to form the full Seps1protein (189 amino acids). Conversely the other 
variant is truncated, leaving it absent of Sec (187 amino acids) and its full 
oxidoreductase capabilities [158]. The presence of a coil-coiled domain and a 
disordered region within the cytosolic tail allows Seps1 to bind to over 200 proteins 
involved in various biological processes [90]. The incorporation of an ER stress 
response element (ERSE) and two NF-kB binding sites within the promoter region 
further supports a role of SEPS1 in oxidative, ER and inflammatory stress responses 
[159-163]. 
 
 
 
20 | P a g e  
 
  
Figure 1.5: Selenoprotein S structure. Seps1 is a single pass transmembrane protein. 
The Sec and Cys residues provides Seps1 its antioxidant properties, whilst the coiled-
coil domain and disordered regions enables protein to protein binding. 
 
1.6.1. Seps1 regulation of oxidative stress 
Significant in vitro evidence exists supporting the antioxidant function of Seps1. 
Overexpression of Seps1 in HepG2 hepatoma cells protects against oxidative stress 
induced by H2O2 [159]. In rat primary aortic vascular smooth muscle cells, Seps1 gene 
suppression enhanced H2O2-induced apoptosis. This was associated with increased 
ROS and activation of stress responsive signalling pathways (p38 MAPK and JNK). 
Interestingly, in these primary vascular smooth muscle cells, Seps1 knockdown had 
differential effects on key cellular antioxidant defence enzymes following H2O2 
treatment, with increased superoxide dismutase activity and decreased glutathione 
peroxidase compared to H2O2 treated control cells. Similarly, in astroglial cells 
exposed to an in vitro model of ischemia, Seps1 suppression increased ROS and 
cellular degradation [160]. Conversely, SEPS1 overexpression was protective against 
H2O2 induced cell toxicity in Min6 pancreatic β-cells [164] and human umbilical vein 
endothelial (HUVEC) cells [165].  
There is a close association in the cellular responses to oxidative, inflammatory and 
ER stress and cells rarely experience these stressors in isolation [166, 167]. For 
example, in a lipopolysaccharide (LPS) induced model of inflammatory stress using 
HepG2 cells, Seps1 gene knockdown increased oxidative stress, as well as 
inflammatory stress [159]. Following Seps1 knockdown and LPS treatment of HepG2 
cells, ROS, nitric oxide and enzyme activity of nitric oxide synthase (NOS)-2 (iNOS) 
were all increased [159], as were the gene and protein expression of serum amyloid A 
(SAA), an acute-phase protein [159]. Similarly, in rat primary aortic vascular smooth 
muscle cells, Seps1 gene knockdown was associated with increased CCAAT-
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enhancer-binding protein homologous protein (CHOP) expression and 
phosphorylation of protein kinase R-like endoplasmic reticulum kinase (PERK) 
following H2O2 treatment and in the basal state [168] highlighting that increased ROS 
are a cause, as well as a consequence, of ER stress [167, 169].  
Whilst the observation that Seps1 is protective against oxidative stress has been 
replicated in various mammalian cell lines, in vitro studies are typically limited by the 
artificial, highly oxidative environment that cells are maintained in (e.g. ambient air 
with 20% O2 and 5% CO2) and the proliferative cell cycle state in vitro versus a 
differentiated tissue in vivo [170]. As such, there is an urgent need for in vivo studies 
that will increase our understanding of how Seps1 regulates redox signalling and 
oxidative stress. 
The quenching of H2O2 by Seps1 is thought to involve the formation of a disulphide 
bond between the Cys (175aa) and the Sec (188aa) amino acid residues [171]. Optimal 
oxidoreductase activity of Seps1 is dependent upon its interactions with thioredoxin 
and thioredoxin reductase, where the selenylsulfide bond of Seps1 is reduced by 
thioredoxin, allowing the selenolate within the reduced segment to degrade disulphide 
bonds by forming a mixed selenosulfide [114, 172, 173]. Thioredoxin is then reduced 
by thioredoxin reductase allowing complete reduction of Seps1. Thioredoxin has been 
linked to the pathogenesis of metabolic and cardiovascular disease [174] and it is a 
redox regulator of key stress responsive signalling pathways mediating inflammation 
and oxidative stress, including NFκB [172, 175, 176]. Cytosolic thioredoxin-1 
prevents NFκB translocation to the nucleus by blocking the degradation of IκB 
proteins, thus restricting NFκB activation and cytokine production [177]. However, 
when induced by increased oxidative stress, NFκB and thioredoxin-1 translocate to the 
nucleus, where thioredoxin-1 increases NFκB transcriptional activity and potentiates 
inflammatory stress [177]. Given the interaction between Seps1 and thioredoxin and 
the anti-inflammatory function of Seps1, it is tempting to speculate that Seps1 may 
modulate NFκB activation in response to increased cellular stress. Indeed, 
overexpression of Seps1 in HepG2 hepatocytes attenuated NFκB activation in 
response to treatment with the pro-inflammatory cytokine IL-1β or overexpression of 
a mutant Z α1-antitrypsin (ZAAT) transgene, which is known to cause ER stress [178]. 
Thus, in the context of chronic metabolic disease, the potential interactions between 
Seps1, the thioredoxin antioxidant system and NFκB, highlight the level of integration 
between cellular responses to ROS and inflammatory stress. 
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1.6.2. Seps1 regulation of ER stress 
In the ER, Seps1 is part of a transmembrane multiprotein complex consisting of Derlin, 
Valosin-containing protein-interacting membrane protein (VIMP), P97 ATPase, E3 
ubiquitin ligases and SelK [18]. This complex facilitates the translocation of misfolded 
proteins out of the ER and into the cytosol for degradation by the ubiquitin proteasome 
pathway [18, 179-181]. Seps1 is thought to reduce particularly stable disulphides in 
ER-associated degradation (ERAD) substrates, which were not reduced prior to retro-
translocation [173]. This retrograde-translocation process is key for ERAD and part of 
the unfolded protein response (UPR), which alleviates ER stress and facilitates the 
restoration of ER homeostasis [18, 179].  
In vitro studies support a role for Seps1 in ER stress responses. A promoter reporter 
assay of Seps1, demonstrated substantial activation of ERSE sequence in response to 
ER stress induced by tunicamycin (a N-glycosylation inhibitor) and thapsigargin (a 
SERCA inhibitor) [163]. This was associated with a 2-3 fold increase in Seps1 gene 
and protein expression in HepG2 liver cells [163]. In response to tunicamycin and 
thapsigargin, Seps1 protein expression was also increased in RAW264.7 macrophages, 
MIN6 beta cells and HEK293 cells [161]. Seps1 gene knockdown exacerbated cellular 
stress responses following the pharmacological induction of ER stress, as indicated by 
increased glucose regulated protein (GRP) 78 protein expression and a reduction in 
cell viability in RAW264.7 macrophage [161] and HepG2 liver cells [162]. 
Overexpression of Seps1 protected RAW264.7 macrophages from ER stress induced 
apoptosis, as indicated by reduced caspase 3 activity and greater cell viability [161]. 
However, the association between Seps1 and ER stress is not a consistent observation 
in vitro, as Seps1 gene knockdown in various gastrointestinal epithelial cell lines 
(LS174T, HT29 and Caco-2 cells) does not cause or modulate ER stress responses, nor 
does it affect H2O2-induced cell death [182]. While most in vitro studies support the 
involvement of Seps1 in the regulation of ER homeostasis, these findings require 
validation in vivo.  
 
1.6.3. Seps1 regulation of inflammation 
Much research has focused on the role of Seps1 as a mediator of inflammation. Curran 
et al. provided the initial evidence that genetic variation in SEPS1, in particular the -
105G>A SEPS1 promotor polymorphism, is associated with elevated circulating 
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levels of the pro-inflammatory cytokines interleukin (IL)-1β, IL-6 and TNF-α [180]. 
In line with this result, Seps1 expression was increased in HepG2 cells following 
treatment with TNF-α, IL-1β [163] and in mouse livers in response to bacterial LPS 
induced sepsis [183].  
In stimulated RAW267.4 macrophages, Seps1 gene knockdown increased the 
secretion of IL-1β and TNF-α [180]. In mice, Seps1 siRNA also increased pro-
inflammatory cytokine levels and organ damage following LPS induced sepsis [184]. 
Furthermore, in mdx mice, the murine model of Duchenne muscular dystrophy 
characterised by chronic muscle damage and inflammation, the genetic reduction of 
Seps1 exacerbated the inflammatory profile of fast twitch hindlimb muscles. 
Specifically, a 50% reduction in Seps1 protein content increased the mRNA transcript 
abundance of monocyte chemoattractant protein 1 (Mcp-1), the macrophage marker 
F4/80 and transforming growth factor-β1 (Tgf-β1) [185]. Combined, the experimental 
data suggest that Seps1 forms a regulatory loop between pro-inflammatory cytokines 
(Il-6 and Tnf-α), NFκB and control of the inflammatory responses. Unlike the 
postulated role of Seps1 in oxidative and ER stress responses, there exists supporting 
in vivo data for the role of Seps1 in inflammation. However, inflammation, ER stress 
and oxidative stress should not be considered in isolation and it is likely that depending 
on the disease state and/or model being utilised to study Seps1, inflammation could 
either be a cause of oxidative/ER stress or a consequence of an underlying condition.  
 
1.6.4. Seps1 regulation of metabolic and cardiovascular disease 
Following the discovery of Seps1 as a candidate gene for type 2 diabetes in the Israeli 
sand rat (Psammomys obesus) [186] and the initial observation of an association 
between SEPS1 gene polymorphisms and elevated plasma levels of pro-inflammatory 
cytokines [180], the role of Seps1 in the pathophysiology of metabolic and 
cardiovascular disease has gained research attention. Whilst Seps1 is highly responsive 
to nutrient stress, it is unclear whether Seps1 has a direct effect on metabolic function 
or is secondarily associated with cellular stress responses. In cultured HepG2 
hepatocytes and 3T3-L1 adipocytes, Seps1 expression is suppressed by glucose and 
insulin [164, 186]. In Psammomys obesus, there is a negative correlation between 
hepatic Seps1 gene expression and circulating glucose or insulin concentrations and a 
positive association with plasma triglyceride concentration [186]. This association is 
further exacerbated by metabolic stress, as the upregulation of Seps1 was greater in 
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the livers from diabetic versus non-diabetic Psammomys obesus following 24 hours of 
fasting, when compared to the fed state. Furthermore, Seps1 mRNA transcript 
abundance is lower in livers from diabetic Psammomys obesus compared to glucose 
tolerant animals. A detailed understanding of how Seps1 expression is regulated by 
nutrient availability in the liver and whether Seps1 is similarly dysregulated in skeletal 
muscle and adipose tissue in diabetes in vivo is lacking.  
In human studies, sampling constraints have limited studies into the association 
between SEPS1 and metabolic dysfunction to adipose tissue [187-189], skeletal 
muscle [187] and serum [190], but not the liver. Karlsson et al. report similar SEPS1 
mRNA transcript abundance in skeletal muscle and adipose tissue from patients with 
type 2 diabetes and healthy individuals. Unlike in the Psammomys obesus, SEPS1 
expression did not correlate with glucose, insulin or blood lipid levels, nor was it 
correlated with insulin-mediated peripheral glucose utilisation during steady-state 
hyperinsulinemia in a diabetic or healthy state [187]. This is in contrast to findings by 
Du et al., who reported greater SEPS1 mRNA transcript abundance in omental adipose 
tissue of people with type 2 diabetes, which was positively correlated with the HOMA-
insulin resistance index [188]. This is consistent with the finding of increased SEPS1 
mRNA in isolated human adipocytes of obese subjects [189].  Interestingly, Karlsson 
et al. did observe that hyperinsulinemia increased SEPS1 gene expression in cultured 
adipose tissue biopsies from patients with T2D, but not healthy individuals, 
strengthening the association between SEPS1 and metabolic dysregulation [187]. To 
date, the effects SEPS1 has on metabolic disease in human tissues has primarily been 
limited to gene expression studies, with investigations measuring SEPS1 protein 
expression restricted to serum samples. Yu et al. observed decreased SEPS1 serum 
protein levels in patients with T2D compared to healthy controls [190]. Furthermore, 
in the presence of clinical and subclinical atherosclerosis, T2D was associated with 
higher SEPS1 serum levels, suggesting a rather complicated relationship between 
SEPS1, diabetes and vascular disease [190]. Cox et al. proposed that SEPS1 may 
provide a link between vascular complications and glycaemic control based on the 
associations found between five SEPS1 gene polymorphisms and coronary and carotid 
artery calcified plagues, blood glucose levels and glycated haemoglobin (HbA1c) in 
European Americans with type 2 diabetes [191]. Considering that SEPS1 is highly 
expressed in vascular smooth muscle [168] and endothelial cells [165] and the 
presence of oxidative, ER and inflammatory stress in cardiovascular disease (CVD) 
and diabetes, this hypothesis warrants further investigation.  
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The association between SEPS1 and cardiovascular disease has also been investigated 
in non-diabetic populations. To date, this research has focused on SEPS1 gene 
sequence variations, rather than mRNA, protein levels and downstream cellular stress 
responses. The findings to date are variable and contradictory, which may be overcome 
by the use of larger population cohorts [192]. Nonetheless, in Chinese non-diabetic 
subjects, the SEPS1 rs1291054 gene polymorphism was found to be independently 
associated with plasma triglyceride levels, a well-established CVD risk factor [193]. 
In Finnish women, the SEPS1 rs7178239 and rs8025174 SNPs are associated with 
chronic heart disease and ischemic stroke [194]. In a case-controlled study using 
healthy individuals of Chinese Han descent and those with a history of ischemic stroke, 
the SEPS1 rs4965814 SNP was shown to modulate the susceptibility to ischemic 
stroke, whilst no association was observed for the rs34713741 SNP [192]. However, 
Hyrenbach et al. found no relationship between the well described -105G>A SEPS1 
polymorphism and the development of atherothrombotic ischemia and stroke [195]. 
Whilst intriguing, these SNP associations lack evaluation of how these modifications 
affect protein expression and function. 
The potential link between Seps1 and CVD is potentially strengthened by the 
interaction between Seps1 and low density lipoproteins (LDL), a well-known risk 
factor in the development of CVD [196]. The functional significance of this 
association is unclear, however, it may be related to the antioxidant function of Seps1, 
as oxidised LDL particles are especially atherogenic [197]. Secreted SelP, comprises 
most of the plasma selenium pool and has been shown in biochemical assays to protect 
LDL particles against oxidation. While, SAA, the putative Seps1 binding partner, has 
also recently been shown to reduce LDL oxidation [198]. Altogether, this indicates 
that further investigation is warranted into the mechanistic link between Seps1, SAA 
and CVD.  
Through the use of cell culture models and biochemical assays, a role of Seps1 in 
regulating oxidative, ER and inflammatory stress responses has been well established 
(Figure 1.6). However, in the context of metabolic disease, a role for Seps1 in 
regulating cellular and inflammatory stress responses in liver, adipose tissues, skeletal 
muscle, vasculature and the heart is still mostly unknown. More mechanistic, in vivo 
investigations are required to supplement the published in vitro data in order to 
elucidate how Seps1 might influence metabolic disease states. 
 
26 | P a g e  
 
 
 
Figure 1.6: Functional mechanisms of Selenoprotein S. Current literature has 
unearthed four functional roles for Seps1. Oxidative regulation via biochemical and in 
vitro analysis, protein integrity and ER stress regulation through cell culture and 
biochemical assay, while its role in inflammation mediation has been validated in vitro, 
in vivo and within human population studies. Recently a role in calcium signalling was 
discovered for Seps1 via biochemical experiments investigating its many binding 
partners. Interestingly many of these functions have relationships which overlap, thus 
it's tantalising to speculate that the mechanism of most interest involves the 
Thioredoxin (Txr) - NF-κB interaction, as it may manipulate the oxidative and cellular 
stress functions of Seps1, leading to a pronounced effect on skeletal muscle health and 
function. Solid line refers to factual evidence, while the dotted line refers to 
speculation, which should be further investigated. 
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1.7. The implication of ER-resident selenoproteins to skeletal muscle health. 
Skeletal muscle is the largest metabolic organ of the body, equating to approximately 
40% of total body weight. Proper skeletal muscle contractile function is important for 
metabolic health and measures of muscle strength are associated with morbidity and 
mortality, suggesting sound contractile function is a predictor of independence and 
quality of life [199].  
Skeletal muscle is a highly plastic tissue and responds well to transient increases in 
cellular stress. Muscle contractile activity, during exercise, transiently increases 
cellular stress through oxidative, ER and inflammatory stress signalling pathways 
[152]. These acute cellular stressors are necessary stimuli for muscle adaptation, 
growth and repair [152, 200]. Yet in the presence of chronic stress, as seen in various 
disease states, cellular responses are maladaptive and muscle contractile function is 
compromised due to muscle weakness, wasting and fibrosis [201, 202] [203-206]. The 
contractile apparatus are also sensitive to cellular stress, in particular oxidative stress, 
thus, to understand these disruptions we must appreciate the fundamental processes of 
E-C Coupling.  
We lose fast twitch muscle fibres as we age due to denervation and increased cellular 
stress caused by sedentary lifestyles and obesity [207-209]. This loss of fast muscle 
fibres increases the risk of falls, fractures and fragility [210]. Much interest surrounds 
the modification of these factors through nutritional and exercise strategies. However 
much of the literature is complex and contradictory [211, 212]. The exploration of ER-
resident selenoproteins for the improvement of age-related skeletal muscle contractile 
function are an interesting mechanistic target. Selenoproteins are responsive to dietary 
selenium intake and regulate signalling pathways relevant to cellular stress, 
inflammation and Ca2+ homeostasis, pathways critical for optimal contractile and 
metabolic function of skeletal muscle [213, 214]. Therefore the aim of this thesis and 
second part of literature review focuses on Seps1 and its potential role in skeletal 
muscle health and contractile function.  
 
1.7.1. Skeletal muscle structure and function 
Skeletal muscle can be categorised broadly into type 1and type II muscle fibres [215]. 
Type I muscle fibres are categorised as a ‘slow twitch’ fibre type, typical of postural 
and endurance muscles [215]. This fibre type produces energy aerobically, through a 
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higher mitochondrial density and therefore type I muscles possess a greater resistance 
to fatigue [216, 217]. However, this is at the expense of force production when 
compared to type II muscle. In contrast to type 1 muscle fibres, type II muscle fibres 
generate energy through both oxidative phosphorylation and anaerobic glycolysis 
[216-219]. Type II muscles, known as ‘fast twitch’ muscles, are characterised by their 
powerful, explosive ability and reduced resistance to fatigue [219]. In mammals three 
fast myosin heavy chain (MyHC) isoforms (IIA, IIX, and IIB) have been identified 
[220], although IIB abundance is reduced in larger mammals and absent in humans 
[221]. Structural and functional divergence of skeletal muscle determines the MyHC 
expression of muscle and thus its functional characteristics, consequently fast MyHC 
isoforms can be co-expressed, signifying a hybrid fibre population (IIAX).  
Whilst these muscles are primarily characterised by the MyHC isoform expressed, 
muscle fibre types also differ in their expression of other contractile function related 
proteins, such as the SERCA isoforms, which facilitate Ca2+ reuptake [222, 223]. The 
primary expression of SERCA2 and SERCA1 isoforms within type I and type II 
muscle fibres, respectively, governs force production by the contractile apparatus 
[224], with the only co-expression of SERCA isoforms occurring in the hybrid IIAX 
muscle fibres. In human skeletal muscle, type I fibres possess a higher affinity of Ca2+, 
boasting increased Ca2+ loading than that of type II fibres, highlighting SR properties 
as another determinant of muscle function and performance [224].  
In fast and slow twitch skeletal muscles, contraction involves the depolarisation of the 
motor neuron, which causes neurotransmitters (specifically, acetylcholine) to cross the 
neuromuscular junction, triggering excitation at the muscle motor end plate [225, 226]. 
Subsequent depolarisation of muscle transverse tubules (t-tubules) causes Ca2+ voltage 
gated RyR to release Ca2+ from the SR, leading to a rapid rise in cytoplasmic free Ca2+. 
Ca2+ then binds to the regulatory protein troponin C on the actin filament activating 
the myosin binding sites [227, 228]. Binding site activation allows attachment of the 
myosin filament to actin, which is required for contraction at the sarcomere, the 
contractile unit of skeletal muscle [229, 230].  In the presence of adenosine 
triphosphate (ATP), the myosin head is activated, causing movement along the actin 
filament, generating muscle contraction, an action known as cross-bridge cycling 
[230]. Muscle contraction continues until the stimulus is removed, causing the RyR to 
close and SERCA pumps to actively re-uptake Ca2+ back into the SR, initiating muscle 
relaxation [227, 231] (Figure 1.7).  
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Figure 1.7: Excitation Contraction Coupling in skeletal muscle. Depolarisation of 
muscle t-tubules causes RyR to release Ca2+ from the sarcoplasmic reticulum (SR), 
leading to a rapid rise in cytoplasmic free Ca2+. Actin bound Ca2+ activates the 
contractile apparatus and in the presence of ATP, contraction occurs. Contraction 
ceases upon the removal of stimulus, causing closure of RyR and activation of SERCA 
pumps, which actively re-uptake Ca2+ into the SR, initiating muscle relaxation. Thus, 
it is evident how alteration of Ca2+ release and reuptake machinery can affect skeletal 
muscle performance.  
 
E-C Coupling and is sensitive to ROS, as imbalance in ROS levels disrupt the Ca2+ 
handling apparatus [22, 232]. Acute increases in oxidative stress can affect Ca2+ 
handling, and in turn muscle contractile function in fast muscle fibres, whilst slow 
twitch fibres are rather insensitive to acute ROS imbalance [22]. However, prolonged 
exposure to oxidative stress, presents profound alteration at the muscle fibre causing 
reduced Ca2+ sensitivity, disrupted Ca2+ coupling and altered Ca2+ dependent cellular 
processes [25, 233]. This leads to decrease force production, Ca2+ homeostasis and 
fatigue resistance, resulting in an overall decline in muscle performance [22, 232]. 
Research has implicated ER-resident selenoproteins in the regulation of these 
processes, specifically the role of SelN in the regulation of SERCA and RYR function, 
as discussed in section (1.5.6.3.). Interestingly, Seps1 may also be involved in E-C 
coupling due to its association with SERCA in Human HEK 293T cells in vitro, 
however to date nothing is known in skeletal muscle.  
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1.7.2. Skeletal muscle, reactive oxygen species and antioxidants 
The oxidative stress, induced by exercise or disease and ageing can have positive or 
negative effects, respectively, on muscle strength and endurance [210, 234, 235]. 
During exercise, skeletal muscle contractile activity acutely increases the production 
of superoxide (O2
−) and H2O2 as a by-product of oxidative phosphorylation and in turn 
regulates muscle function [22, 236, 237]. Whereas in disease, NADPH oxidase, 
inflammation and mitochondrial dysfunction increase ROS levels [238]. RNS are free 
radicals derived from a reaction of nitric oxide (NO) with O2
− [239]. RNS and NO are 
also implicated in skeletal muscle health, including vasodilation and glucose 
metabolism and are produced in response to contractile activity [240], however their 
actions are beyond the scope of this project.  
Produced as a waste product from the mitochondrial electron transport chain reaction, 
O2
− is then catalysed by superoxide dismutase to H2O2 [241]. H2O2 can diffuse through 
cell membranes and is active in many signalling pathways [242-245]. By regulating 
signalling pathways relevant to contractile function, cellular defences, metabolism, 
protein synthesis and degradation, ROS are important in many skeletal muscle 
adaptations [237, 246]. However, long term accumulation of excessive ROS, is 
detrimental to cell function and survival, disrupting cellular signalling and damaging 
membrane lipids, protein, and DNA [205],[237, 247-249]. 
Increases in oxidation, for example H2O2, will have positive or negative effects on 
muscle contractile function depending on the dose and the duration of exposure [25, 
233]. The effects of ROS on muscle contractile function have predominantly been 
focused on apparatus of Ca2+ release, via RYR [250-253] and reuptake by SERCA 
[254, 255]. When treated with H2O2 or other oxidising agents fast muscle is more 
sensitive to Ca2+ induced Ca2+ release, potentiating greater Ca2+ release [23, 256], 
while action potential induced Ca2+ release remains unaffected [25] [23].  
Oxidation of the Ca2+ reuptake pump, SERCA can also disrupt Ca2+ homeostasis, 
leading to reduced Ca2+ uptake, thus preventing muscle relaxation [23]. Although 
speculation resides, as SR Ca2+ depletion, where contraction cannot occur, could be a 
product of either reduced Ca2+ uptake or increased efflux of Ca2+ from SR during 
uptake [25]. While majority of this research is based on single muscle fibre models, 
these findings are translated into whole muscle effects. Thus, these data suggest that 
oxidation affects skeletal muscle contractile function in various ways, therefore it is 
evident that dysregulation via oxidation can alter skeletal muscle performance.  
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Antioxidant enzymes and molecules that neutralise ROS, return the muscle to 
homeostasis, preventing disruption to cell signalling and damage to cellular constitutes 
[257] [258]. Specific antioxidant enzymes regulate specific redox molecules and, like 
ROS, are also important in cell signalling [259, 260]. Of the few selenoproteins 
investigated in muscle, glutathione peroxidase (GPx), found within the mitochondria 
and cytosol neutralise H2O2 and lipid peroxides [261]. GPx has been show to increase 
in blood and muscle tissue following aerobic exercise and anaerobic training [262, 
263] in some, but now all studies [264]. ER-resident selenoproteins are known for their 
antioxidative capacity, however with the exception of SelN, little is known about their 
effect in skeletal muscle or exercise performance.  
Dietary supplementation, with antioxidants such as vitamin E and C, has attracted 
much investigation [265-268]. In healthy populations, the overexpression of 
antioxidant enzymes or supplementation with antioxidants appear to have limited 
benefit in exercise adaptation and may actually be detrimental [265, 266]. While, 
antioxidant enhancement may have benefits in disease models, targeting cellular stress 
responses is complex and antioxidant supplementation must be tightly regulated, as 
they have shown to increase the incidence of disease [67, 68, 269].  
 
1.7.3. Skeletal muscle and ER Stress 
Oxidative stress is not the only cellular stress elicited by contractile activity, as the ER 
can also be challenged by contractile activity and disease. Structurally the ER is highly 
malleable, enabling a high degree of plasticity leading to an array of functions, detailed 
previously [270]. There is growing evidence that skeletal muscle can express proteins 
associated with the ER stress response [271] and exercise may trigger ER stress and 
UPR activation in fast and slow twitch skeletal muscle [272]. In mice, acute and 
endurance treadmill exercise increased abundance of UPR transcripts in active fast 
hindlimb muscles, but not less active postural back muscle [273]. Equally, extreme 
endurance exercise and resistance exercise stimulated ER stress in human vastus 
lateralis muscle biopsies, resulting in UPR activation, indicating that exercise initiates 
the UPR, irrespective of fibre or exercise type [153, 274]. Whilst exercise initiates 
UPR activation, evidence also exists demonstrating immobility can also trigger the 
UPR in human skeletal muscle, signifying that both extremely low or high levels of 
contractile activity activates ER stress, and in turn, the UPR [275]. With ageing, many 
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of the components of the UPR decline, leading to a less efficient response to these 
stressors, and an upregulation of apoptotic processes which can result in or intensify 
existing diseases [276-278]. While the role of ER stress in ageing skeletal muscle is 
less known, increased apoptosis is evident in skeletal muscle of older mice [279, 280].  
Skeletal muscle requires synchronous Ca2+ release and reuptake for effective muscle 
contraction and relaxation [281]. Therefore dysregulation of ER homeostasis and 
promotion of ER stress leads to dysregulation of Ca2+ homeostasis in the lumen of the 
SR, impairing Ca2+ signalling and in turn skeletal muscle health and contractile 
function [281, 282]. Thus, like oxidative stress, dependent on context, ER stress can 
have adaptive or deleterious consequences on skeletal muscle leading to poor health 
and performance outcomes (Figure 1.8) [152].  
 
 
Figure 1.8: ER stress and the Unfolded Protein Response. ER stress stimulates the 
UPR via increased accumulation of misfolded proteins in the ER lumen. GRP78 is 
recruited as a chaperone protein to increase misfolded protein degradation. 
Dissociation of GRP78 from its dormant binding site on ER stress transcription factors 
activates adaptive processes to cellular stress, enhancing the ER’s protein-folding 
capacity. If increased ER protein folding and misfolded protein degradation cannot 
combat the stressful environment the ER will undergo apoptosis via CHOP. 
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1.7.4. Skeletal muscle and Inflammation  
Skeletal muscle can initiate an acute inflammatory response following strenuous, 
physical activity [283-285]. The exercise stimulated immune response removes 
damaged tissue and stimulates satellite cell (muscle stem cells) activation, proliferation 
and differentiation to aid in muscular repair [200, 286], muscle growth and adaptation 
to exercise induced damage [287]. Acute bouts of endurance exercise increase 
cytokines and chemokines such as TNF-α, IL-6 and IL-1β in plasma concentration of 
humans [288] and skeletal muscle tissue of mice [289] [290]. Infiltrating inflammatory 
cells, such as macrophages and neutrophils, are a major contributor to cytokine and 
chemokine production during exercise, however skeletal muscle fibres themselves can 
synthesise and secrete pro and anti-inflammatory cytokines, such as IL-6 and IL-1β, 
as shown in C2C12 cultures of skeletal muscle cells [290]. Whilst an acute 
inflammatory response following strenuous exercise is necessary for skeletal muscle 
regeneration, growth and adaptations [287], chronic inflammation is associated with 
muscle disease and dysfunction [291, 292]. 
 
1.8. Seps1: a potential novel regulator of cellular stress responses in skeletal 
muscle  
Seps1 is highly expressed in skeletal muscle, however, its physiological functions in 
skeletal muscle is not well characterised [293]. Provided its regulation of cellular stress 
in a myriad of cell types in vitro and the importance of stringent regulation of cellular 
stress responses to skeletal muscle health and performance, we hypothesise that Seps1 
may regulate the cellular stress responses to modulate skeletal muscle contractile 
function, metabolism, and exercise performance. Within skeletal muscle the smooth 
ER is specialised, re-termed the SR, where it regulates Ca2+ signalling, important for 
a number of processes including muscle contraction. In support of this hypothesis, a 
recent proteomics analysis identified Seps1 to bind to a number of multiprotein 
complexes including, SERCA2A and calmodulin/dependent protein kinase (CaMK) II 
δ [90]. Further support of this role was identified recently as the reduction of Seps1 in 
liver cells resulted in dysregulated ER Ca2+ homeostasis and subsequent mitochondrial 
Ca2+ uptake [294]. Combined these data support the hypothesis that Seps1 could play 
a role in Ca2+ homeostasis in skeletal muscle. 
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Previously, Seps1 expression has been shown to be regulated by macronutrients 
including glucose, lipid and selenium intake, suggesting possible targeting with dietary 
intervention [164, 186, 295]. The genetic reduction of Seps1 in cells and humans by 
siRNA or promoter gene polymorphism, respectively, are also associated with 
mediating inflammation [180]. It should be highlighted that these processes have 
implication on muscle performance and metabolism. Therefore, the knowledge 
obtained from this thesis will increase the understanding of how Seps1 may impact 
muscle health and provide important evidence supporting its potential targeting for 
optimal skeletal muscle health and contractile function.  
To ascertain if the regulatory role of Seps1 on cellular stress is evident in skeletal 
muscle, two siRNA constructs will be used to genetically reduce Seps1 in C2C12 
mouse muscle cells. Proliferating myoblasts and differentiated myotubes will be used 
here as they differ with regards to their metabolic phenotype. The lipid stressor 
palmitate will be applied to gain insight into whether Seps1 protects from cellular 
stress in these different cellular states.  
Secondly, to determine if the genetic reduction or deletion of Seps1 affects physical 
and metabolic activity, Seps1 GKO mice will undergo calorimetric cage analysis. Fast 
and slow muscle contractile function will also be examined ex vivo to ascertain if the 
reduction or deletion of Seps1 impairs contractile function. To validate the regulatory 
capacity of Seps1 in vivo, we will assess how the genetic reduction and deletion of 
Seps1 affects cellular stress in hindlimb muscle.  
To understand if the reduction or deletion of Seps1 mars exercise performance, Seps1 
GKO mice will undergo 3 consecutive bouts of treadmill running. Following which, 
fast twitch contractile function will be assessed in a more physiological model, in situ, 
allowing us to examine if the physiological stress of exercise would further impair fast 
twitch contractile function. 
Finally, to obtain a greater understanding and relevance of SEPS1 to human muscle 
health, the association between SEPS1 protein levels and muscle mass, strength and 
endurance will be assessed in a human population. Thus, examining the translatable 
nature of SEPS1 to human muscle health and function. 
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1.8.1. Aims  
Therefore the aims of this thesis were to examine: 
1) The effect a reduction of Seps1 (siRNA) has on cellular stress in proliferating 
myoblast and differentiated myotubes in vitro, following nutrient stress by 
palmitate.  
2) The effects the genetic reduction or deletion of Seps1 has on whole body 
muscle metabolism and fast and slow twitch muscle contractile function (ex 
vivo) using a novel Seps1 global knockout (GKO) mouse model.   
3) The effects the genetic reduction or deletion of Seps1 has on exercise 
performance and fast twitch muscle contractile function (in situ) using Seps1 
GKO mice.   
4) Whether SEPS1 protein levels in blood cell pellets are associated with skeletal 
muscle health in a human population, representative of the wider Australian 
population and whether SEPS1 would be an appropriate biomarker of skeletal 
muscle health. 
1.8.2. Hypothesis  
 
The hypothesis of this thesis are: 
1) The reduction of Seps1 (siRNA) exacerbates the cellular stress profile of 
proliferating myoblast and differentiated myotubes, following nutrient stress 
by palmitate.  
2) The genetic reduction and deletion of Seps1 impairs fast and slow twitch 
muscle contractile function, ex vivo.  
3) The genetic reduction and deletion of Seps1 impairs muscle performance by 
means of reduced exercise capacity and TA strength, in situ.  
4) Low muscle health is associated with low SEPS1 protein levels in a human 
population, suggesting SEPS1 could be an appropriate biomarker of skeletal 
muscle health. 
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Chapter Two 
Differential Regulation of Cellular Stress Responses by the Endoplasmic Reticulum 
Resident Selenoprotein S in Proliferating Myoblasts versus Myotubes 
 
The results in this chapter were incorporated into a manuscript which was 
provisionally accepted in September 2018.  
 
Addinsall AB, Martin SD, Collier F, Conlan XC, Foletta VC, and Stupka N. (2018). 
Differential regulation of cellular stress responses by the endoplasmic reticulum 
resident selenoprotein S (Seps1) in proliferating myoblasts versus myotubes. 
Physiological Reports.  
Mr. AB Addinsall performed routine cell culture, siRNA knockdown and western 
blotting experiments, analysed all data, prepared all figures and wrote and reviewed 
manuscript with co-authors. The siRNA optimisation, qRT-PCR, Western Blotting 
and viability assays were undertaken by Mrs. SD Martin and Dr. N Stupka. Whereas, 
cell cycle analysis and glutathione measurements were undertaken by Dr. F Collier 
and A/Prof. Conlan XC, respectively. Dr. VC Foletta aided the publication through 
research design and preparation of manuscript for publication. Additionally, Mr. AB 
Addinsall performed additional siRNA knockdown, western blotting and fusion index 
experiments for this study that were excluded from the final manuscript in favour of 
inclusion in another study assessing the context depended role of Selenoprotein S in 
muscle growth and development.  
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2.1. Introduction  
Selenium is an essential micronutrient [29]. Cellular stress responses, metabolism and 
immunity are regulated by selenium, in the form of Sec, the 21st amino acid which is 
incorporated into selenoproteins [18, 29, 54]. There are 25 selenoproteins in the human 
genome [88], including seven ER-resident selenoproteins (DIO2, SELENOF, 
SELENOK, SELENOM, SELENON, SELENOS and SELENOT). The function of these 
selenoproteins is not well characterised, however, they have been implicated in 
oxidative and ER stress responses, inflammation, Ca2+ regulation, and the maintenance 
of membrane associated multiprotein complexes [89, 90], reviewed here [114, 213]. 
Seps1 is an ER-resident transmembrane protein. Its cytoplasmic region contains a 
coiled-coil domain which includes an intrinsically disordered region important for 
protein binding [90]. The N terminus Sec residue is also localised to this cytoplasmic 
region and contributes to protein oxidoreductase activity [171, 172]. Seps1 is 
ubiquitously expressed with particularly high expression in metabolically active 
tissues including skeletal muscle, where it has been shown to have a role in regulating 
contractile function and inflammation [185-187, 296]. Single nucleotide 
polymorphisms in the Seps1 gene have been linked to various human diseases 
associated with heightened metabolic and/or inflammatory stress [180, 186, 189, 194, 
297]. 
In vitro, Seps1 is protective against oxidative stress and ER stress in a number of cell 
types. In response to stimulation by tunicamycin (an N-glycosylation inhibitor) or 
thapsigargin (an inhibitor of ER Ca2+ ATPase activity), the activity of the ERSE in the 
Seps1 promoter region is increased [163]. Seps1 is thought to be functionally active in 
the adaptive arm of the UPR. Specifically, ERAD, where Seps1 forms a multiprotein 
complex with SelK, derlin-1, p97 ATPase and an E3 ubiquitin ligase at the ER 
membrane to facilitate the translocation of misfolded proteins to the cytosol for 
degradation by the ubiquitin proteasome pathway [18, 179, 180, 298]. As an 
antioxidant, Seps1 has oxidoreductase activity against H2O2 and is most effective when 
coupled with thioredoxin [171, 172]. This is interesting, given the regulation of various 
oxidative and inflammatory stress sensitive signalling pathways by the thioredoxin 
antioxidant system [174]. Seps1 also has the potential to reduce disulphide bonds. This 
is likely relevant to its role in adaptive ER stress responses and the retrograde 
translocation of misfolded proteins out of the ER for cytosolic degradation [179]. 
Furthermore, in a proteomics screen using HEK 293 cells, Seps1 was present in 
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various multiportion complexes, and thus may have a broad and complex role in 
regulating stress sensitive signalling pathways beyond its well described role in the 
UPR [90].  
There is good in vitro evidence to support a role for Seps1 in regulating cellular stress 
responses. Seps1 overexpression protected RAW 264.7 macrophages against ER stress 
induced apoptosis [161], whilst suppression increased cell death in RAW264.7 
macrophages [161], HepG2 hepatoma cells [162] and primary astroglial cells [160]. 
SEPS1 overexpression was also protective against oxidative stress in HUVECs treated 
with H2O2 [165]. Accordingly, SEPS1 gene knockdown was associated with increased 
ROS, altered activity of primary antioxidant defence enzymes and reduced viability in 
HUVECs [165], HepG2 cells [159] and vascular smooth muscle cells [168].  
In individuals with obesity, insulin resistance and type 2 diabetes, the excess 
accumulation of lipids, including saturated fatty acids in skeletal muscle is associated 
with increased cellular stress [299, 300]. Whilst some selenoproteins are important for 
skeletal muscle health and function (reviewed in [214]) and SEPS1 is associated with 
metabolic disease [187, 188, 190] including circulating plasma triglyceride 
concentrations in vivo [186], its specific role in response to excess saturated fatty acids 
in skeletal muscle has to date not been described. Here using two different siRNA 
constructs, Seps1 was knocked down in proliferating myoblasts and differentiated 
myotubes, which also differ with regards to their metabolic phenotype, to gain insight 
into whether Seps1 is protective against palmitate treatment in these different cellular 
states. Cell viability, cell cycle progression, ROS levels, and markers of oxidative and 
ER stress were assessed.    
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2.2. Materials and Methods  
2.2.1. Cell culture  
Murine C2C12 myoblasts (American Type Culture Collection, Manassas, VA) were 
cultured in 5% CO2 and atmospheric O2 at 37 °C in growth media consisting of 5 mM 
(low glucose) DMEM supplemented with 10% foetal bovine serum (FBS, In Vitro 
Technologies, Noble Park, AUS). To stimulate myotube formation, confluent 
myoblasts were cultured in differentiation media consisting of 5 mM DMEM 
supplemented with 2% horse serum (HS), refreshed every 24 h.  
 
2.2.2. Palmitate preparation  
Palmitic acid (250 mM, Sigma-Aldrich, Castle Hill, AUS) was dissolved in 95% 
ethanol at 50-60 C, followed by dilution to 4.5 mM in 5 mM glucose DMEM (Life 
Technologies, Mulgrave, AUS) containing 20% fatty acid-free bovine serum albumin 
(BSA, Sigma-Aldrich). BSA and palmitate were conjugated at 45 °C for 1 h with 
gentle mixing. Solutions were filter-sterilised and diluted to the appropriate 
concentration in cell culture media. Control media (vehicle) contained ethanol and 
BSA in the absence of palmitate [301].  Myoblasts and myotubes were treated with 0.1 
mM and 0.35 mM palmitate or vehicle for 21 h, respectively.  Myotubes were exposed 
to an additional 3 h incubation with serum-free media containing palmitate or vehicle 
after which the cells were collected for experimental analysis. These treatment 
protocols was optimised to minimise toxic effects of palmitate exposure [302]. 
 
2.2.3. Stealth™ siRNA transfection 
The following Stealth™ RNAi constructs were used siRNA1 (5’-
GGAAGAUCUAAAUGCCCAAGUUGAA-3’) and siRNA2 (5’-
CAUGCAAGAAGGCAGAAGUUACAAA-3’) (Invitrogen, Mulgrave, AUS). For 
the myoblast experiments, C2C12 myoblasts were transfected at 40-50% confluence 
using the Stealth™ RNAi duplexes or a Stealth™ RNAi negative control duplex 
(Invitrogen) with a 40% G/C content and lipofectamine RNAiMAX (Invitrogen), 
according to manufacturer’s instructions. The final concentration of both Stealth™ 
RNAi duplexes and the negative control was 10 nM. Twenty-four hours post 
transfection, myoblasts were treated with palmitate or vehicle as described above. For 
the myotube experiments, cells were differentiated for 72 h prior to transfection. Forty-
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eight hours post transfection, myotubes were treated with differentiation media 
containing 0.35 mM palmitate or vehicle as described above. 
 
2.2.4. Western blotting of C2C12 myoblasts and myotubes 
Cells were lysed in M-PER extraction buffer (Thermo Fisher Scientific) in the 
presence of protease inhibitors (Thermo Fisher Scientific). Five micrograms (Seps1 
and GRP 94) or 10 µg (GRP78 and Heme oxygenase-1(HO-1)) of total protein was 
separated on 4-20% acrylamide gradient gels (NuSep), and transferred to PVDF 
membranes. After blocking, membranes were incubated overnight with anti-Seps1 (in-
house [186]), anti-GRP94 (Cell Signalling, Danvers, USA, #2104), anti-GRP78 (Cell 
Signalling, #3183), or anti-HO-1 (Assay Designs, Ann Arbor, USA, #SPA-894) 
antibodies. This was followed by an incubation with a goat anti-rabbit HRP-linked 
secondary antibody (Cell Signalling, #7074). Bands were detected using ECL 
chemiluminescence (Invitrogen) and analysed using Quantity One® software (Bio-
Rad, Gladsville, AUS). The gels were stained with SimplyBlue™ SafeStain 
(Invitrogen) to validate even loading and protein expression was normalised to the 
optical density of the total protein per lane. For the myotube experiments, cells were 
seeded in duplicate with three independent biological replicates and for the myoblast 
experiments, cells were seeded in triplicated with two independent biological 
replicates. 
 
2.2.5. RNA extraction and cDNA synthesis 
Extraction and purification of RNA was performed using TRIzol reagent (Invitrogen) 
and the RNeasy® Mini kit (Qiagen). RNA was quantitated using the Agilent 
Bioanalyser and RNA 6000 Nano Assay kit (Agilent Technologies, Mulgrave, AUS). 
Complementary DNA was synthesised using the SuperScript™ III First-Strand 
Synthesis System (Invitrogen). 
 
2.2.6. Real Time Quantitative PCR (qPCR) 
Gene expression levels were determined by real-time PCR using Brilliant® SYBR® 
Green QPCR Master Mix (Agilent Technologies), with PCR conditions were as 
follows: 95 °C for 10 min (1 cycle), 95 °C for 30 sec and 60 °C for 1 min (40 cycles). 
Relative gene expression was calculated as 2-∆Ct following normalisation to 
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cyclophillin, a housekeeping gene (Table 2.1). For gene expression analysis of ER and 
oxidative stress markers, experiments were performed in triplicate with two 
independent biological replicates. 
 
Table 2.1: Primer sequences for qRT-PCR 
Gene Forward primer (5'-3') Reverse primer (5'-3') 
PPIA cccaccgtgttcttcgaca ccagtgctcagagctcgaaa 
Seps1 accgagagcctgcgattc ggatgacaatgtagagtaggatgc 
Grp78 ttcctgcgtcggtgtattca gcggttgccctgatcgt 
Grp94 gtatgtacgccgcgtattgatc tcggaatccacaacacctttg 
Chop gtccctagcttggctgacaga tggagagcgagggctttg 
HO-1 (Hmox1) gccaccaaggaggtacacat gcttgttgcgctctatctcc 
Txnip atcgtggcgtggcaagag cgtagatcagcaaggagtattcg 
Trx1 cgtggtggacttctctgctacgtggtg ggtcggtatgcatttgacttcacagtc 
 
 
2.2.7. Cell viability following Seps1 gene suppression and palmitate treatment 
The mitochondrial reduction of MTT (3-[4,5-dimethylthiazol-2-yl]-2,5- diphenyl 
tetrazolium bromide, thiazolyl blue, Sigma-Aldrich) was used to assess myotube 
viability [303] with an N = 8 wells and two independent biological replicates analysed.  
Exclusion of 7-aminoactinomycin D (7-AAD) was used to assess myoblast viability. 
Following transfection and palmitate treatment, adherent and detached myoblasts were 
collected and fixed in 1% formaldehyde containing 2% FCS and 2 µg/ml Actinomycin 
D. Cells were stored at 4°C in the dark until analysis on a FACS Calibur® system with 
Cell Quest Software (Becton Dickinson Biosciences, North Ryde, AUS) to determine 
the proportion of dead and dying cells. Myoblasts were analysed in quadruplicate with 
three biological replicates. 
 
2.2.8. Cell Cycle Progression Following Seps1 Gene Suppression 
To discriminate between the G0, G1, S and G2/M phases of the cell cycle, myoblasts 
were stained with fluorescein isothiocyanate (FITC) for cellular protein and propidium 
iodide (PI) for DNA [304]. C2C12 myoblasts were trypsinised and fixed in ethanol for 
6 h at 4 °C, then stained overnight at 4 °C with 50 µg/µl PI and 0.1 µg/ml FITC plus 
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20 µg/ml RNase in PBS followed by flow cytometry analysis using the FACS Calibur 
system and Cell Quest Software. Myoblasts were analysed in quadruplicate with two 
biological replicates. 
 
2.2.9. Oxidative stress assays  
To assess the effects of palmitate and/or Seps1 knockdown on cellular ROS, myotubes 
were incubated with 10 μM 5-(and-6)-carboxy-2’, 7’-dichlorodihydrofluorescein 
diacetate (DCFDA, Thermo Fisher Scientific). DCFDA oxidation was detected using 
a FlexStationII384 fluorometer (Molecular Devices, excitation = 485 nm and emission 
= 538 nm). H2O2 (25 µM) was used as a positive control. Myotubes were analysed 
with an N = 7 replicate wells with two independent biological replicates. 
Amplex® Red (10-acetyl-3, 7-dihydroxyphenoxazine, 50 μM, Thermo Fisher 
Scientific) and 0.1 U/mL of horseradish peroxidase (HRP) were used to measure H2O2 
production in muscle cells following Seps1 knockdown and/or palmitate treatment. 
Resorufin, the reaction product of Amplex® Red oxidation, was detected using a 
FlexStation II384 fluorometer (Molecular Devices, excitation = 570 nm and emission = 
585 nm). Glucose oxidase (25 mU/ml) was used as a positive control. The increase in 
absorbance (FU) was normalised to the protein content of each well and presented as 
a fold-change increase in H2O2. Cells were analysed in quadruplicate with three 
biological replicates. 
Reduced (GSH) and oxidised (GSSG) glutathione levels were measured, as previously 
described [305], to determine the GSH:GSSG ratio in myotubes following 24 h of 
palmitate treatment or in myoblasts following Seps1 gene suppression. Cells were 
analysed in triplicate with two independent biological replicates.  
 
2.2.10. Statistical analyses  
All values are expressed as mean ± standard error of the mean (SEM). Results were 
analysed using a 2-way GLM ANOVA with the factors being siRNA and palmitate 
treatment, and where appropriate a Tukey’s post hoc test. For single treatment studies, 
results were compared using unpaired t-test. All statistical analyses were performed 
using Minitab statistical software v17 (Sydney, AUS), with P < 0.05 being statistically 
significant. 
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2.3. Results  
2.3.1. Seps1 expression profile in differentiating and palmitate-treated muscle cells  
To first assess basal Seps1 protein levels in proliferating myoblasts and myotubes, a 
differentiation time-course was performed where myoblasts, once confluent, were 
differentiated for up to 6 days. Seps1 protein expression was transiently increased up 
to 2-fold at 24 h and 48 h post differentiation, but was not sustained revealing similar 
expression levels in myoblasts and myotubes at 72 h to 6 days post differentiation (P 
< 0.001, Fig 2.1A). Thus, the myoblast and myotube cell culture models used in this 
study appeared to have similar basal Seps1 protein levels prior to gene knockdown. 
The effect of palmitate on Seps1 expression and whether two siRNAs designed to 
target Seps1 mRNA were able to knockdown Seps1 in both myoblasts and myotubes 
was investigated next. In myoblasts, 0.1 mM palmitate increased Seps1 mRNA 
transcript abundance by 2.5-fold, irrespective of gene knockdown (P < 0.001, Fig 
2.1B). Nonetheless, in vehicle and palmitate treated myoblasts, both Seps1 siRNA 
constructs suppressed mRNA levels by approximately 75% (P < 0.001, Fig 2.1B). A 
reduction in Seps1 protein expression by both siRNAs was also measured in myoblasts 
with a 50% and 75% decrease following treatment with siRNA1 and siRNA2, 
respectively (P < 0.001, Fig 2.1C). Palmitate treatment (0.1 mM), however, did not 
significantly increase Seps1 protein expression under any conditions tested (Fig 2.1C).  
In myotubes, 0.35 mM treatment with palmitate increased Seps1 mRNA 2-fold 
regardless of siRNA treatment (P < 0.001, Fig. 2.1D), and also significantly increased 
Seps1 protein levels (P < 0.05, Fig. 2.1E). While siRNA treatment achieved 
approximately 50% knockdown of Seps1 mRNA with both siRNA1 and siRNA2 (P < 
0.001, Fig. 2.1D), significant suppression of protein levels by 50% was only observed 
with siRNA 2 (P < 0.001, Fig. 2.1E). It is worth noting that this decrease in Seps1 
protein expression achieved with siRNA2 in vehicle and palmitate treated myotubes is 
similar to the protein knockdown achieved in myoblasts transfected with the siRNA1 
construct. 
 
44 | P a g e  
 
 
Figure 2.1: Seps1 expression in differentiating, palmitate- and siRNA-treated 
C2C12 muscle cells. Cells treated with 0.1 mM (myoblasts) or 0.35 mM (myotubes) 
palmitate (black bars) or the corresponding ethanol/BSA vehicle (white bars). A, Seps1 
protein expression was assessed in proliferating and differentiating myoblasts, with a 
transient increase observed between 24 h and 48 h post differentiation when compared 
to proliferating myoblasts. C2C12 myoblasts were transiently transfected with one of 
two SEPS1 siRNA constructs or a scramble control construct prior to treatment with 
0.1 mM (palmitate, black bars) or ethanol/BSA vehicle (vehicle, white bars) for 21 h. 
To assess gene knockdown and the effect of palmitate B, Seps1 mRNA and C, protein 
levels were determined. C2C12 myotubes were also transiently transfected with one 
of two SEPS1 siRNA constructs or a scramble control construct prior to treatment with 
0.35 mM (palmitate, black bars) or ethanol/BSA vehicle (vehicle, white bars) for 24 
h. Followed by measurement of D, Seps1 gene and E, protein expression. † P < 0.0001 
compared to proliferating myoblasts (one-way GLM-ANOVA). ** P < 0.05 for vehicle 
compared to palmitate treated cells (interaction, two-way GLM-ANOVA). ++ P < 0.05 
for SEPS1 siRNA compared to scramble control following vehicle treatment 
(interaction, two-way GLM-ANOVA). ‡ P < 0.05 for Seps1 siRNA compared to 
scramble control following palmitate treatment (interaction, two-way GLM-ANOVA). 
* P < 0.05 compared to vehicle treated cells (main effect treatment, two-way GLM-
ANOVA). + P < 0.05 compared to scramble control (main effect siRNA, two-way 
GLM-ANOVA). 
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2.3.2. Reduced viability and proliferation following Seps1 knockdown in palmitate-
treated muscle cells  
To investigate how Seps1 modulates cell viability in response to lipid stress, the effect 
of Seps1 knockdown in both myoblasts and myotubes was assessed. Myoblast number 
was reduced in all palmitate treated cells (P < 0.001). Seps1 knockdown in myoblasts 
revealed a decrease in cell number up to 30% or 40% in vehicle or palmitate treated 
myoblasts, respectively (P < 0.001, Fig 2.2A). This was attributed to greater cell death 
and decreased proliferation. The proportion of dead and dying myoblasts was 
increased in myoblasts transfected with either siRNA1 or siRNA2 (P < 0.001, Fig 
2.2B). Furthermore, the proportion of proliferating myoblasts in the S phase (DNA 
synthesis) of the cell cycle was decreased in cells transfected with both siRNA 
constructs following vehicle or palmitate treatment (P < 0.001, Fig 2.2C). To 
complement this, the proportion of quiescent myoblasts in the G0 phase of the cell 
cycle was increased in vehicle and palmitate treated myoblasts transfected with 
siRNA1 (P = 0.005, Fig 2.2D). Treatment with siRNA2 also increased the proportion 
of cells in the G0 phase, even in the absence of palmitate (P < 0.02, Fig 2.2D). Thus, 
even in the absence of lipid stress, Seps1 suppression was sufficient to reduce 
proliferation and promote cell cycle exit. Indeed, there is evidence in the literature 
linking reduced selenoprotein levels to replicative senescence [306].  
In myotubes, following transfection with the siRNA2 construct, a small (3-5%) 
decrease in viability was observed in vehicle or palmitate treated myotubes (P = 0.05, 
Fig 2.2E), with no effect on cell viability observed in the siRNA1 transfected 
myotubes. As expected, palmitate also decreased myotube viability (P < 0.001, Fig 
2.2E). 
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Figure 2.2: Cell cycle state and viability of C2C12 muscle following knockdown 
of Seps1 in the presence of palmitate. Cells treated with 0.1 mM (myoblasts) or 0.35 
mM (myotubes) palmitate (black bars) or the corresponding ethanol/BSA vehicle 
(white bars). To assess the effects of Seps1 knockdown and nutrient stress on myoblast 
proliferation and differentiation, A, manual cell counts were completed and B, the 
percentage of dead and dying cells measured using 7-AAD incorporation. FITC and 
PI staining were used to assess cell cycle state, specifically, C, the proportion of 
myoblasts in S phase (DNA synthesis) and D, G0 (quiescence). E, The mitochondrial 
oxidation of MTT was used assess the viability of myotubes following Seps1 siRNA 
and/or palmitate treatment. + P < 0.05 compared to scramble control (main effect 
siRNA, two-way GLM-ANOVA). * P < 0.05 compared to vehicle treated cells (main 
effect treatment, two-way GLM-ANOVA). ++ P < 0.05 for Seps1 siRNA compared to 
scramble control following vehicle treatment (interaction, two-way GLM-ANOVA). 
 
2.3.3. Seps1 gene suppression increased cellular stress in myoblasts 
In vehicle treated myoblasts, Seps1 knockdown alone increased H2O2 levels 
significantly for both siRNAs (P < 0.001, Fig 2.3A), while the addition of palmitate 
further increased H2O2 levels (P < 0.001). Following on from these observations, 
cellular redox state was assessed, and even in the absence of lipid stress, Seps1 
suppression was associated with a more oxidised GSH:GSSG ratio (P < 0.001, Fig 
2.3B). Ho-1 expression, as a marker of second phase antioxidant responses [307], 
revealed increased mRNA transcript abundance and protein levels in the presence of 
palmitate (P < 0.001 and P < 0.001, respectively, Fig 2.3C-D). While treatment with 
siRNA2, but not siRNA1, exacerbated the upregulation of Ho-1 gene and protein 
47 | P a g e  
 
expression in the presence of palmitate when compared to cells treated with the 
scramble siRNA construct (P < 0.01 respectively, Fig 2.3C-D).  
 
 
Figure 2.3: Oxidative stress in palmitate-treated C2C12 myoblasts following 
Seps1 knockdown. Myoblasts treated with 0.1 mM palmitate (black bars) or 
ethanol/BSA vehicle (white bars). To assess the antioxidant properties of Seps1, A, 
H2O2 levels via Amplex
® Red, B, cellular redox state via the GSH:GSSG ratio and C, 
Ho-1 gene and C, protein expression were measured in palmitate and control treated 
myoblasts transfected with Seps1 siRNA or scramble control constructs. + P < 0.05 
compared to scramble control (main effect treatment, two-way GLM-ANOVA). * P < 
0.05 compared to vehicle treated cells (main effect siRNA, two-way GLM-ANOVA). 
† P < 0.05 compared to scramble control (independent T-test). ** P < 0.05 for vehicle 
compared to palmitate treated cells (interaction, two-way GLM-ANOVA). ‡ P < 0.05 
for Seps1 siRNA compared to scramble control following palmitate treatment 
(interaction, two-way GLM-ANOVA).  
 
Markers of ER stress response were also measured in the myoblasts. Seps1 knockdown 
with either siRNA1 or siRNA2 exacerbated the upregulation of Chop (C/EBP 
homologous protein) and Grp94 mRNA in the presence of palmitate (Fig 2.4A-B). 
Grp78 gene expression also tended to increase irrespective of vehicle or palmitate 
treatment with siRNA2 treatment (P = 0.054, Fig 2.4D). Despite increased Grp94 and 
Grp78 mRNA expression following Seps1 knockdown, their respective protein levels 
were not significantly altered (Fig 2.4C-E). Given the role of the thioredoxin 
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antioxidant system in regulating Seps1 oxidoreductase activity [172], metabolic stress 
[308], oxidative stress (reviewed in [309]) and ER stress [310], the effects of palmitate 
and Seps1 knockdown on thioredoxin-1 (Trx-1) and its endogenous inhibitor 
thioredoxin binding protein (Txnip) were determined. Trx-1 gene expression was 
reduced in myoblasts transfected with the siRNA1, but not the siRNA2 construct, 
when compared to scramble control transfected myoblasts (P = 0.019), with palmitate 
also decreasing Trx-1 mRNA levels (P < 0.02, Fig 2.4F). Txnip mRNA transcript 
abundance was increased in myoblasts transfected with the siRNA1 construct 
compared to scramble control transfected myoblasts, irrespective of palmitate or 
vehicle treatment (P < 0.001, Fig 2.4G). In myoblasts transfected with the siRNA2 or 
scramble control construct, palmitate increased Txnip mRNA transcript abundance (P 
< 0.001, Fig 2.4G). This increase was greater in palmitate-treated myoblasts 
transfected with the siRNA2 construct versus the scramble control construct (P < 
0.001, Fig 2.4G). Altogether, in proliferating myoblasts exposed to nutrient stress, 
Seps1 may provide greater protective effects against oxidative than ER stress. 
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Figure 2.4: ER stress response in palmitate-treated C2C12 myoblasts following 
Seps1 knockdown. Myoblasts treated with 0.35 mM palmitate (black bars) or 
ethanol/BSA vehicle (white bars). To assess whether Seps1 is associated with the 
unfolded protein response and/or the thioredoxin antioxidant system, A, Chop gene 
expression, B, Grp94 gene and C, protein expression, D, Grp78 gene and E, protein 
expression, F, Thioredoxin-1 (Trx-1) gene expression, and G, Thioredoxin inhibitor 
protein (Txnip) gene expression were measured in palmitate and control treated 
myoblasts transfected with the Seps1 siRNA or scramble control constructs. + P < 0.05 
compared to scramble control (main effect siRNA, two-way GLM-ANOVA). * P < 
0.05 compared to vehicle treated cells (main effect treatment, two-way GLM-
ANOVA). ‡ P < 0.05 for Seps1 siRNA compared to scramble control following 
palmitate treatment (interaction, two-way GLM-ANOVA).  
 
 
2.3.4. Seps1 gene suppression did not exacerbate cellular stress in myotubes 
In line with the observed decrease in myotube viability, palmitate increased ROS 
levels (P < 0.001, Fig 2.5A-B), and Ho-1 gene and protein expression (P < 0.001, Fig 
2.5C-D). Unlike in myoblasts, Seps1 knockdown in myotubes did not increase 
oxidative stress in the basal state nor in response to the lipid stress. Instead, Seps1 
knockdown reduced ROS (P < 0.001, Fig 2.5A) and H2O2 concentrations (P ≤ 0.001, 
Fig 2.5B). Furthermore, Seps1 knockdown had no significant effect on Ho-1 mRNA 
and protein levels (Fig. 2.5C-D).  
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Figure 2.5: Oxidative stress response in palmitate-treated C2C12 myotubes 
following Seps1 knockdown. Myotubes treated with 0.35 mM palmitate (black bars) 
or ethanol/BSA vehicle (white bars). To investigate whether cell cycle state or 
metabolic phenotype modulate the antioxidant properties of Seps1, A, cellular ROS 
levels via the oxidation of DCFDA, B, H2O2 via the oxidation of Amplex
® Red assay, 
C, Ho-1 gene and D, protein expression were measured in palmitate and control treated 
myotubes transfected with the Seps1 siRNA or scramble control constructs. + P < 0.05 
compared to scramble control (main effect siRNA, two-way GLM-ANOVA). * P < 
0.05 compared to vehicle treated cells (main effect treatment, two-way GLM-
ANOVA).  
 
As expected, gene markers of ER stress, Chop, Grp78 and Grp94, were increased at 
either or both mRNA and protein levels in response to palmitate treatment (P < 0.001, 
Fig. 2.6A-E), however, no additional increase in their expression was observed 
following Seps1 knockdown. In contrast to observations in myoblasts, the mRNA 
transcript abundance of Txr-1 was unaffected by Seps1 suppression or palmitate 
treatment (Fig 2.6F). While, Seps1 knockdown with siRNA1 or siRNA2 construct was 
associated with a decreased trend for Txnip gene expression (P < 0.001 and P = 0.056, 
respectively, Fig. 2.6G). Palmitate also decreased Txnip mRNA transcript abundance 
(P < 0.001, Fig. 2.6G). This is in contrast to our observations in myoblasts, where 
Seps1 gene knockdown and palmitate treatment increased Txnip expression (Fig. 
2.4G). Altogether, these data demonstrate that Seps1 has distinct effects on oxidative 
and ER stress responses and on gene markers of the thioredoxin antioxidant system in 
proliferating myoblasts versus differentiated myotubes. 
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Figure 2.6: ER stress response in palmitate-treated C2C12 myotubes following 
Seps1 knockdown. Myotubes treated with 0.35 mM palmitate (black bars) or 
ethanol/BSA vehicle (white bars). To investigate whether cell cycle state or metabolic 
phenotype differentially affect the association  between Seps1 and the unfolded protein 
response or the thioredoxin antioxidant system, A, Chop gene expression, B, Grp94 
gene and C, protein expression, D, Grp78 gene and E, protein expression, F, 
Thioredoxin-1 (Trx-1) gene expression, and G, Thioredoxin inhibitor protein (Txnip) 
gene expression were measured in palmitate and control treated myotubes transfected 
with the Seps1 siRNA or scramble constructs. * P < 0.05 compared to vehicle treated 
cells (main effect treatment, two-way GLM-ANOVA). + P < 0.05 compared to 
scramble control (main effect siRNA, two-way GLM-ANOVA).  
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2.4. Discussion  
In skeletal muscle, the sensitive regulation of cellular stress responses is essential for 
optimal metabolic and contractile function [311, 312]. The importance of 
selenoproteins, in particular glutathione peroxidase and thioredoxin reductase, in 
protection from and adaptation to cellular stress is well recognised [112]. The 
biological function of the seven ER-resident selenoproteins, which include Seps1, is 
less well described. However, there is increasing interest in this group of 
selenoproteins due to their role in regulating oxidative and ER stress responses and 
intracellular Ca2+ homeostasis [89, 135, 213, 313, 314]. Here, we report for the first 
time that in C2C12 muscle cells, Seps1 expression is upregulated in response to 
nutrient stress from the saturated fatty acid palmitate. Furthermore, in response to 
Seps1 gene knockdown, cellular stress responses to palmitate increased in proliferating 
myoblasts, however, this was not observed in differentiated myotubes. When 
compared to myotubes, proliferative myoblasts have a more glycolytic phenotype 
[170, 315], fewer mitochondria [316] [317] and are more susceptible to cellular stress 
[318, 319]. Therefore, our findings suggest that the cell cycle state, metabolic 
phenotype, or a combination of both affect the regulation of cellular stress responses 
by Seps1 (Fig. 2.7). This notion that Seps1 plays a role in modulating cellular stress 
responses in proliferating cells is further supported where increased ROS levels 
following Seps1 gene knockdown was observed with other in vitro studies using 
primary vascular smooth muscle cells  [168], HUVEC endothelial cells [165], pig 
kidney (PK-15) and endothelial cells [320], cells that still have proliferative capacity. 
Alternatively, given the Seps1 knockdown in myotubes did not change or even 
decreased ROS levels, it may suggest an alternative or perhaps redundant role for 
Seps1 in differentiated myotubes compared with observations made in proliferating 
myoblasts. 
In myotubes, ER stress was increased in response to palmitate, but not Seps1 
knockdown. Whereas in myoblasts, Seps1 knockdown, irrespective of palmitate 
treatment, increased Chop, Grp97 and Grp78 gene, but not protein, expression. GRP78 
is considered a master regulator of ER stress signalling pathways leading to the 
activation of the UPR to attenuate translation, the degradation of misfolded protein via 
ERAD and further upregulate the expression of ER chaperones (e.g. GRP78 and 
GRP94), or to apoptosis via CHOP [321]. Unlike GRP78, GRP94 has a more selective 
role in ER stress responses and facilitates the folding and/or assembly of specific 
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membrane associated and secreted proteins [322], and it is also functions as a low 
affinity, high capacity Ca2+ binding protein. The lack of increased in GRP94 and 
GRP78 protein content in response Seps1 knockdown, suggests a secondary or 
redundant role for Seps1 in regulating ER stress responses in differentiated muscle 
cells. Cross-talk between the ER and mitochondria is important in regulating cellular 
homeostasis [323, 324]. During ER stress, as part of an adaptive response, 
mitochondria can buffer the excess Ca2+ released from the ER. Emerging evidence 
suggests that increased mitochondrial content and respiratory capacity can promote 
survival from ER stress [325]. Perhaps, the greater mitochondrial content and 
oxidative capacity of myotubes versus myoblasts [316, 317] attenuates the importance 
of Seps1 in protecting against cellular stress.   
 
 
Figure 2.7: Seps1 protects the glycolytic proliferative myoblasts from lipid 
induced cell death. The genetic reduction of Seps1 by siRNA1 or siRNA2 in 
myoblasts and myotubes, respectively result in a 50% reduction in Seps1 protein 
expression. In the more glycolytic myoblast, reduction of Seps1 causes increased ROS 
and ER stress, leading to increased cell death and cell cycle exit (quiescence). However 
in the more oxidative myotubes, Seps1 reduction reduced ROS and has mild change 
in ER stress and cell death. Thus the reduction of Seps1 effects the more glycolytic 
myoblasts, suggesting Seps1 may protect muscle of a glycolytic phenotype.  
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Seps1 is most potent as an antioxidant when coupled with thioredoxin, which is known 
to regulate various stress responsive signalling pathways including NF-κB. Together, 
they have an important role in maintaining cell viability and homeostasis [172, 175, 
326]. Thioredoxin is inhibited by Txnip and increased Txnip expression is associated 
with impaired cell viability and metabolic dysfunction [327, 328]. Furthermore, there 
is evidence linking Txnip with ER stress and inflammation [310, 329]. In proliferating 
myoblasts, Seps1 suppression and/or palmitate treatment decreased the mRNA 
transcript abundance of Trx-1, whilst increasing Txnip gene expression. Whereas in 
myotubes, Seps1 suppression and/or palmitate treatment decreased Txnip mRNA 
transcript abundance, with no change in Trx-1 gene expression. Perhaps, this 
differential regulation of Txnip and Trx-1 in response to excess lipid, also contributes 
to the observed increase in oxidative stress and associated reduction in cell viability in 
myoblasts, but not myotubes, following Seps1 knockdown. This study highlights a 
novel association found between Seps1, Trx-1 and Txnip and our data lend support to 
earlier biochemical studies demonstrating a functional association between Seps1 and 
thioredoxin [172]. Given the relevance of these proteins to metabolic disease, this 
association warrants further mechanistic and in vivo investigation.   
The idea that glycolytic cells might be more reliant on Seps1 is in concordance with 
observations in dystrophic mdx mice, where the genetic reduction of Seps1 
exacerbated the inflammatory profile of fast, glycolytic EDL but not slow, oxidative 
Soleus muscle [185]. As an end point marker of heightened cellular stress, Seps1 
reduction decreased myofibre cross-sectional area in EDL, but not soleus, muscles 
[185]. Furthermore, in Seps1 global knockout mice on a C57BL/6 background, the 
genetic reduction (by 50%) or deletion of Seps1 was associated with impaired 
contractile function, specifically force producing capacity, in fast phenotype EDL, but 
not slow phenotype Soleus muscles [296]. To date, the majority of cell culture studies 
investigating Seps1 function, with the exception of preliminary work in adipocytes, 
have not accounted for cell cycle state or metabolic phenotype. Adipogenic 
differentiation of cultured 3T3-L1 cells depends on the degradation of Seps1 by 
dexamethasone. In these cells, this resultant increase ER stress is necessary for 
adipocyte maturation in vitro [330]. The observations that the cell cycle state and/or 
metabolic phenotype affect how Seps1 modulates cellular stress responses has 
significant biological implications. Vascular smooth muscle cells (VSMCs), for 
example, can also transition between a proliferating or differentiated, contractile 
phenotype depending on biological context or disease pathology [331]. Seps1 is highly 
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expressed in blood vessels, in particular in smooth muscle [168], and genetic studies 
of SEPS1 gene sequence polymorphisms have revealed an association with 
cardiovascular disease [190, 191]. Similar to our observations in C2C12 myoblasts, in 
proliferating rat primary VSMCs, Seps1 gene knockdown increased cellular 
susceptibility to oxidative and ER stress and was associated with activation of stress 
responsive signalling pathways [168]. Whether Seps1 modulates cellular stress 
responses in differentiated VSMCs has to date not been determined.  
In summary, we have shown that Seps1 gene and protein expression is upregulated in 
cultured muscle cells in response to excess palmitate. However, the protection against 
lipid-induced cellular stress afforded by Seps1 is more significant in proliferating, 
glycolytic C2C12 myoblasts compared to differentiated, more oxidative myotubes. 
The functional significance and underlying mechanism of how Seps1 regulates cellular 
stress responses to nutrient stress in muscle cells, especially those with different 
metabolic and proliferative capacities potentially has interesting implications for 
metabolic and musculoskeletal disease.   
. 
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Chapter Three 
Deficiency of Selenoprotein S, An Endoplasmic Reticulum Resident Oxidoreductase, 
Impairs The Contractile Function Of Fast Twitch Hindlimb Muscles. 
 
The results in this chapter were incorporated into a manuscript which was published 
in April 2018.  
Addinsall AB, Wright CR, Shaw CS, McRae NL, Forgan LG, Weng C, Conlan XA, 
Francis PS, Smith ZM, Andrikopoulos S, and Stupka N. (2018). Deficiency of 
selenoprotein S, an endoplasmic reticulum resident oxidoreductase, impairs the 
contractile function of fast twitch hindlimb muscles. American Journal of Physiology- 
Reg Int Comp. 10.1152/ajpregu.00244.2017. 
Mr. AB Addinsall performed majority of experiments, analysed all of the data, and 
prepared all figures and wrote and reviewed manuscript with co-authors. Exceptions 
to this include the Selenoprotein S GKO mice were a kind gift from A/Prof S 
Andrikopoulos and Dr. C Weng. While, ex vivo contractile function, Citrate synthase 
and glutathione measurement experiments were undertaken in conjunction with Dr. N 
Stupka, Dr. Craig Wright and Dr. Zoe Smith, respectively. All other authors aided in 
the experimental design and review of the manuscript. 
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3.1 Introduction 
Selenoproteins are characterised by their inclusion of a Sec amino acid residue which 
accounts for their antioxidant function and bioactivity [18]. In humans, there are 25 
selenoproteins with glutathione peroxidases and thioredoxin reductases being the most 
highly characterised [88]. These maintain the redox state of the glutathione and 
thioredoxin antioxidant pools, and thereby regulate an array of stress responsive 
signalling pathways [332]. There are seven selenoproteins localised to the ER, whose 
cellular mechanism of action is still poorly understood (reviewed here [18]). 
Selenoproteins are important for skeletal muscle development and growth [139, 141], 
and their role in regulating contractile function is increasingly recognised [137, 138, 
147]. There is emerging interest in the ER-resident selenoproteins, because of the 
importance of the ER in intracellular Ca2+ signalling and homeostasis [213] [11]. In 
skeletal muscle, the SR, a specialised smooth ER, is responsible for the storage and 
release of Ca2+ during contractile activity. In various cells types, a role for Ca2+ 
regulation has been identified for SelT [115], SelK [92] and SelN [137, 138]. 
Mutations in the SEPN1 gene and the resultant loss of SelN expression, increases 
skeletal muscle oxidative stress [137] and dysregulates SR Ca2+ release and/or 
reuptake [138, 143, 147], causing a myopathy associated with early onset axial and 
neck muscle weakness, spinal rigidity and respiratory failure [333]. 
Like SelN, Seps1 is highly expressed in skeletal muscle, although its function is not 
well described. It is also one of few selenoproteins where mutations or gene variants 
have been linked to human disease (reviewed here [334]). Using family association 
studies, Curran et al. showed that SEPS1 gene variants, in particular the -105G>A 
polymorphism in the promotor region, were associated with increased plasma levels 
of pro-inflammatory cytokines [180]. Since these initial studies, SEPS1 gene 
polymorphisms have been associated with a range of conditions characterised by a 
heightened inflammatory state, including metabolic disease [180, 186, 189, 194, 297], 
cardiovascular disease [189, 191, 194, 335], pre-eclampsia [336], spontaneous preterm 
birth [337], cancer [338, 339] and Hashimoto's thyroiditis [340, 341]. 
Seps1 is a single pass transmembrane protein [18, 90]. The incorporation of a Sec 
residue in the cytosolic C terminus (Sec188), in combination with two Cys residues 
localised to the transmembrane (Cys41) and cytosolic catalytic domains (Cys174), 
provide Seps1 with its antioxidant activity [18, 88, 90]. According to biochemical 
assays, Seps1 can reduce disulphide bonds and has oxidoreductase activity against 
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H2O2, primarily through its actions as a thioredoxin-dependent reductase [171-173]. 
This is interesting, as thioredoxin regulates various stress-responsive signalling 
pathways including NFκB [175], and NFκB regulated genes mediate cellular responses 
to inflammation and oxidative stress.  
The promotor region of Seps1 contains a functional ERSE and two putative NFκB 
binding sites, indicating the potential for transcriptional regulation of Seps1 in 
response to ER, oxidative and inflammatory stress [18, 163, 180]. In vitro ER stress 
has been shown to increase Seps1 gene and protein expression [161, 163]. Seps1 is 
part of an ER membrane localised multiprotein complex, which includes GRP 78, 
Derlin1/2, P97 ATPase, and SelK. This complex is involved in the UPR, and allows 
for the retrograde-translocation of misfolded proteins from the ER lumen to the cytosol 
for degradation by the ubiquitin proteasome pathway [18]. Seps1, specifically, is 
thought to facilitate the reduction of disulphide bonds as protein are translocated out 
of the ER [18, 179, 180, 342]. 
The physiological and functional significance of the regulation of oxidative and ER 
stress responses by Seps1 is poorly understood. What is known, is based 
predominantly on cell culture studies and limited to two in vivo studies linking reduced 
Seps1 expression with increased inflammation [184, 185]. Seps1 gene suppression in 
vitro is associated with increased oxidative and ER stress leading to reduced cell 
viability [159-162, 180, 330], whilst overexpression is protective [161, 164, 165, 330]. 
However, there is emerging evidence for a more complex role of Seps1 in regulating 
cellular stress responses. The disordered region and a coil-coiled domain within its 
cytosolic tail provide Seps1 with the capacity to bind various proteins [172], thus 
regulating disulphide bond reduction [171-173] and/or acting as an anchor for 
multiprotein complexes to the ER membrane beyond its well described role in the UPR 
[90]. A recent proteomics screen by Turanov et al. in HEK-293T cells found Seps1 to 
be associated with proteins important for Ca2+ homeostasis and signalling, in 
particular, SERCA2a which is essential for Ca2+ reuptake into the ER/SR [90]. The 
redox state of the ER/SR needs to be tightly regulated, as alterations are detrimental to 
all aspects of organelle function [343]. This includes Ca2+ signalling and homeostasis, 
as oxidation of SH- residues on ER/SR resident proteins important for Ca2+ release or 
reuptake alters their function [138].  
Given the intersect between oxidative and ER stress and Ca2+ signalling [343], we 
hypothesised that Seps1 might be a novel selenoprotein capable of modulating skeletal 
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muscle performance. Here, we characterised the expression and cellular localisation 
of SEPS1 in fast and slow twitch mouse hindlimb muscles and human vastus lateralis 
muscle using immunohistochemistry and western blotting. Using adult global Seps1 
deleted mice, we investigated the effects of Seps1 reduction or deletion on the 
contractile function of isolated slow and fast twitch hindlimb muscles and gene 
markers of oxidative and ER stress. Body composition, whole body metabolism and 
spontaneous physical activity were also assessed, given the association of SEPS1 with 
metabolic disease [186, 187]. Here, we established that Seps1 protein expression and 
localisation was fibre type dependent. And that the genetic reduction or deletion of 
Seps1 was associated with reduced spontaneous physical activity and compromised 
hindlimb contractile function in fast, but not slow twitch, hindlimb muscles. This was 
associated with a fibre type specific regulation of gene markers of the thioredoxin 
antioxidant system and ER stress. Despite epidemiological studies linking SEPS1 to 
metabolic disease, the genetic reduction or deletion of Seps1 had no significant effect 
on whole body metabolism and body composition. 
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3.2. Materials and Methods 
3.2.1. Ethics approval 
All animal studies were approved by the Animal Ethics Committees at The University 
of Melbourne (Austin Health) and Deakin University. Animal care, maintenance and 
all procedures were conducted in accordance with the Australian Code of Practice for 
the Care and Use of Animals for Scientific Purposes. Adult male BALB/c mice were 
used to assess Seps1 localisation and expression in extensor digitorum longus (EDL), 
Soleus and tibialis anterior (TA) muscles, as shown in Figures 1 and 4. Vastus lateralis 
muscle biopsies from healthy, recreationally active male subjects (Age (years): 26.7 ± 
2.8, Height (cm): 183.3 ± 2.6, Weight (kg): 81.5 ± 3.0, BMI (kg/m2): 24.2 ± 0.6) were 
used to assess Seps1 expression. These human studies adhered to the standards set by 
the latest revision of the Declaration of Helsinki, and were approved by the Human 
Research Ethics Committee at Deakin University (DUHREC). 
 
3.2.2. Global Seps1 knockout mice  
Global Seps1 knockout mice were a generous gift from A/Prof. Sofianos 
Andrikopoulos (Austin Health, The University of Melbourne), who generated these 
mice on a C57BL/6 background using PGK-Cre. Mice were group housed in standard 
laboratory conditions of 22  2C, with relative humidity of 55  8% and a 12 hour 
light/dark cycle. Water and a standard chow diet were provided ad libitum. The 
following male mice were used in this study: n = 9 Seps1-/- knockout mice, n = 10 
Seps1+/- heterozygous mice and n = 10 wild type littermates. 
 
3.2.3. Whole body metabolism and body composition. 
At approximately 10-11 weeks of age mice were acclimatised for 3 h to the metabolic 
cages (Accuscan Fusion v3.6, Columbus Instruments International, OH, USA). 48 h 
after acclimatisation mice were individually placed in metabolic cages for 24 h to 
determine oxygen consumption (VO2, mL/min), carbon dioxide production (VCO2, 
mL/min), and the respiratory exchange ratio (RER, VCO2/VO2). Resting day and night 
time energy expenditure was calculated according to the abbreviated Weir equation 
(12 hREE = ([3.9 (VO2) + 1.1 (VCO2)] 1.44)/2)[344]. Spontaneous physical activity 
of the mice was measured using infrared sensors inside the metabolic cages (Animal 
Activity Meter: Opto-Varimex-Mini, Columbus instruments). Following assessment 
of whole body metabolism, mice were returned to standard group housing conditions. 
At 12 weeks of age, and immediately prior to muscle function testing, conscious mice 
61 | P a g e  
 
were placed in a rodent MRI (Body Composition Analyser ESF-005, EchoMRI™, 
Houston, USA) to determine body composition. 
 
3.2.4. Ex vivo muscle function testing  
At 12 weeks of age, mice were anaesthetised via intraperitoneal injection of 
medetomidine (0.6 mg/kg), midazolam (5 mg/kg) and fentanyl (0.05 mg/kg), such that 
they were unresponsive to tactile stimuli. Isometric contractile properties of isolated 
fast twitch EDL and slow twitch Soleus hind limb muscles were evaluated ex vivo, as 
described in detail previously [345]. Briefly, EDL and Soleus muscles were tied at the 
proximal and distal tendons with braided surgical silk, surgically excised, and 
transferred to the 1300A Whole Mouse Test System (Aurora Scientific, Ontario, CAN) 
organ bath filled with Krebs Ringer solution (137 mM NaCl, 24 mM NaHCO3, 11 mM 
D-glucose, 5 mM KCl, 2 mM CaCl2, 1 mM NaH2PO4H2O, 1 mM MgSO4, 0.025 mM 
d-tubocurarine chloride), bubbled with Carbogen (5% CO2 in O2, BOC gases, 
Geelong, AUS), and thermostatically maintained at 25 °C. The distal tendon of the 
muscle was tied to an immobile pin and the proximal tendon was attached to the lever 
arm of a dual mode force transducer (300-CLR, Aurora Scientific). EDL and Soleus 
muscles were stimulated via two platinum electrodes that flanked the length of the 
muscle using a supramaximal voltage of 0.2 ms square wave pulses of 350 and 800 ms 
train duration, respectively. All stimulation parameters and contractile responses were 
controlled and measured using Dynamic Muscle Control Software (DMC v5.415), 
with on board controller interfaced with the transducer control/feedback hardware 
(Aurora Scientific).  
Optimal muscle length (Lo) was determined via micromanipulations of muscle length 
and a series of 1 Hz twitch contractions. Following 4 min of rest, maximum isometric 
tetanic force (Po) production was determined from the plateau of the force frequency 
curve (FFC), whereby the EDL was stimulated at 10, 30, 50, 60, 80, 100, and the Soleus 
at 120 Hz and 10, 20, 30, 50, 60, 80 and 100 Hz with 2 min rest between stimulations. 
Muscles were again rested for 4 min. To assess tolerance to repeated contractile 
activity and as an indicator of fatigability, muscles were stimulated sub-maximally (60 
Hz) once every 5 s for 4 min, at optimal length [346-348]. Recovery of Po was 
determined by stimulating the muscles at 60 Hz at 2, 5 and 10 min post fatigue testing. 
The 60 Hz submaximal stimulation was chosen over maximal protocols due to 
improved physiological relevance. 
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Within minutes of completing function testing, muscles were trimmed of tendons, 
weighed and snap frozen in liquid nitrogen. EDL and Soleus muscles excised from the 
contralateral hindlimb were embedded in optimal cutting temperature compound 
(TissueTek OCT Compound, ProSciTech, Kirwan, AUS), and frozen in thawing 
isopentane (Sigma-Aldrich, Castle Hill, AUS) for histological analysis. TA and 
gastrocnemius muscles were also excised and snap frozen in liquid nitrogen for 
biochemical analysis. Muscle cross-sectional area was determined by dividing the 
muscle mass by the product of optimum fibre length (Lf) and 1.06 mg·mm
-3, the 
density of mammalian muscle. Lf was determined by multiplying Lo by previously 
determined Lo/Lf ratios, 0.44 for the EDL and 0.71 for the Soleus [349]. Since Po is 
dependent upon muscle size, Po values were normalised for muscle cross-sectional 
area and expressed as specific force (sPo, kN·m
-2) for the FFC and fatigue and recovery 
data. The FFC data was also expressed as a percentage of max Po. To assess the rate 
of fatigue and force recovery, these data were normalised to the first 60 Hz contraction 
and expressed as a percentage.  
 
3.2.5. Histology  
Transverse 8 μm thick frozen sections were cut from the mid-belly region of EDL and 
Soleus muscles. Haematoxylin and eosin (H&E, Sigma-Aldrich) staining was used for 
muscle morphometric analysis. Digital images of H&E stained muscle were captured 
at 200x magnification (DM1000 upright microscope, Leica). Fluorescently labelled 
wheat germ agglutinin (WGA) was used to measure muscle fibre cross sectional area, 
as previously described [350]. WGA stained muscle cross sections were imaged using 
a Confocal Laser Scanning Microscope (Fluoview FV10i, Olympus, Notting Hill, 
AUS) at 200x magnification. All image analysis was completed using Image-Pro Plus 
software (Media Cybernetics, Rockville, USA). A custom-built macro was set-up to 
isolate cell membrane specific positive fluorescence using thresholding and to 
calculate minimum Feret’s diameter, with 203 ± 46 muscle fibres quantified per cross-
section. Centrally nucleated fibres and areas of degeneration were also analysed and 
normalised to total muscle cross-sectional area examined (1.14 ± 0.06 mm2 per 
sample).  
 
3.2.6. Immunohistochemistry  
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MyHC antibodies were used to assess the fibre type specific localisation of Seps1 in 
mouse EDL and Soleus muscles. Briefly, EDL and Soleus muscle cross-sections from 
wild type BALB/c mice were reacted the anti-Seps1 antibody, as described above, and 
MyHC fibre typing was completed on sequential serial sections following the protocol 
described by Bloemberg and Quadrilatero [351], using anti-MyHC I (BA-F8, DSHB, 
lot: 11515-43ug/ml, diluted 1:20), anti-MyHC IIA (SC-71, DSHB, lot: 81315-
65ug/ml, diluted 1:50) and/or anti-MyHC IIB (BF-F3, DSHB, diluted 1:20) antibodies. 
Following 1-2 h of incubation with the MyHC primary antibodies, sections were 
reacted with an Alexa Fluor 350 goat anti-mouse IgG2b (A21140, Thermo Fischer 
Scientific, lot: 1717023, diluted 1:500) for MyHC1, Alexa Fluor 488 goat anti-mouse 
IgG1 (diluted 1:500) for MyHC IIA and/or Alexa Fluor 555 goat anti-mouse IgM 
(A21426, Thermo Fischer Scientific, lot: 1708371, diluted 1:500) for MyHC IIB for 1 
h. Nuclei were counter stained with DAPI. Sections were imaged on fluorescent light 
imager (Zoe, Bio-Rad) at 200x magnification.  
To confirm the fibre type specific localisation of Seps1, the anti-Seps1 antibody was 
pre-incubated with a blocking peptide, a commercially available Seps1 antigen 
(APrEST71935, Sigma-Aldrich, lot: PRL02206, 5:1), as per manufacturer’s 
recommendations. EDL and Soleus muscle cross-sections from wild type C57BL/6 
mice were reacted the anti-Seps1 antibody with or without blocking peptide, as 
described above. WGA (FITC) was used to stain the sarcolemma [352] and 
extracellular matrix constituents of blood vessels [353], and nuclei were labelled with 
DAPI. Sections were imaged on a benchtop confocal laser scanning microscope 
(Fluoview FV10i, Olympus) at 200x magnification. 
To determine whether the fibre type specific localisation of SEPS1 is also observed in 
human muscles, cross-sections from frozen vastus lateralis muscle biopsies were co-
reacted with an anti-Seps1 antibody (HPA010025, Sigma-Aldrich, lot:A101692, 
diluted 1:200) and an anti-SERCA1 antibody (CaF2-5D2, Developmental Studies 
Hybridoma Bank (DSHB), lot:123115-24ug/ml, diluted 1:1000) or an anti-SERCA2 
antibody (ab2861, Abcam, lot: GR139308-5, diluted 1:100). Briefly, muscle cross-
sections were fixed in 4% paraformaldehyde (PFA), permeabilised with Tris-buffered 
saline (TBS) containing 0.5% Triton X-100, blocked with 10% normal goat serum in 
TBS, and then incubated with the respective primary antibodies for 1-2 h. Following 
which, muscle sections were incubated for 1 h with an Alexa Fluor 594 goat anti-rabbit 
secondary antibody (A11012, Thermo Fischer Scientific, lot: 1652425, diluted 1:1500) 
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to detect Seps1, and an Alexa Fluor 488 IgG1 goat anti-mouse (A21121, Thermo 
Fischer Scientific, lot: 1608647, diluted 1:1000) to detect SERCA1 or an Alexa Fluor 
488 IgG2a goat anti-mouse (A21131, Thermo Fischer Scientific, lot: 1696196, diluted 
1:1000) to detect SERCA2. Nuclei were counter-stained with DAPI. Sections were 
imaged on a benchtop confocal laser scanning microscope (Fluoview FV10i, 
Olympus) at 200x magnification. 
 
3.2.7. Real Time Quantitative PCR (qPCR) 
Whole EDL and Soleus muscles from Seps1 GKO mice were homogenised in Tri-
Reagent® solution (Ambion Inc, Thermo Fischer Scientific). Total cellular RNA was 
extracted and purified using an RNeasy® Mini Kit (Qiagen®, Mulgrave, AUS). An 
iScript cDNA synthesis kit (Bio-Rad) was used to reverse transcribe 0.25 μg of total 
RNA. Quantitative RT-PCR was performed using IQ SYBR Green Super mix (Bio-
Rad) and oligonucleotide primers for the genes of interest (Table 3.1). cDNA 
concentrations were determined using Quant-iT™ OliGreen® ssDNA reagent 
(Thermo Fisher Scientific), and Ct values were normalised to cDNA content.  
 
 
 
 
 
 
 
 
Table 3.1: Mouse primers used for qRT-PCR 
 Forward Primer (5’ to 3’) Reverse Primer (5’ to 3’) 
Chop GTCCCTAGCTTGGCTGACAGA TGGAGAGCGAGGGCTTTG 
Gpx1 CCATCAGTTCGGACACCAGGAG TCACCATTCACTTCGCACTTCTC 
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3.2.8. Western blotting 
Vastus lateralis biopsies and TA, EDL and Soleus muscles from BALB/c mice, and 
TA muscles from Seps1+/- heterozygous and Seps1-/- knockout mice and wild type 
littermates (10-20 μg), as well as proliferating C2C12 myoblasts (positive control), 
were homogenised in radio immunoprecipitation assay buffer (RIPA, Merck 
Millipore, MA, USA) with protease and phosphatase inhibitors (Thermo Fisher 
Scientific). Total protein content was determined using a BCA protein assay (Thermo 
Fisher Scientific). To confirm the genetic reduction or deletion of Seps1, ten 10 μm 
thick EDL and Soleus muscle cross-sections from Seps1+/- heterozygous and Seps1-/ 
homozygous mice and wild type littermates were placed into 50 μL of 2x Laemmelli 
sample buffer (Bio-Rad) and subjected to two freeze-thaw cycles. For SDS-PAGE, 7.5 
µg of unfractionated muscle homogenate or 15 L of cyrosection lysates were 
separated on a 4-15% gradient TGX Stain-Free™ criterion gel (Bio-Rad) at 100 V. 
Following which the gel was activated and proteins visualised using the Chemidoc™ 
XRS system (Bio-Rad). Proteins were then transferred to PVDF membranes using a 
Turbo Blot Transfer System (Bio-Rad) at 2.5 A and 25 V for 12 min. Membranes were 
blocked with 5% skim milk in TBS containing 0.1% Tween-20 (TBS-Tween), before 
being incubated for 1 h with the anti-Seps1 antibody (diluted 1:200 in 1% BSA in 
TBS-Tween). The blots were then incubated for 1 h with a goat anti-rabbit HRP-linked 
secondary antibody (cat #: 111 035 003, Jackson Labs, lot: 120104, diluted 1:2500 in 
1% BSA in TBS-Tween). Blots were imaged using ECL chemiluminescence. Band 
densitometry was performed on the western blots and the stain free gels, to confirm 
even loading, using Quantity One® software (Bio-Rad). Seps1 protein expression was 
Grp78 TTCCTGCGTCGGTGTATTCA GCGGTTGCCCTGATCGT 
Grp94 TCCATCTCTTCTCCCTCATCC CGGCAACACTTCGGTCAG 
Mcp-1 CCCAATGAGTAGGCTGGAGA 
 
 
TCTGGACCCATTCCTTCTTA 
Txnip ATCGTGGCGTGGCAAGAG 
CGTAGATCAGCAAGGAGTATTC
G 
Txr1 
CGTGGTGGACTTCTCTGCTACGT
GGTG 
GGTCGGTATGCATTTGACTTCAC
AGTC 
66 | P a g e  
 
normalised to the optical density of the total protein on the TGX- stain free protein gel 
[354-356].  
 
3.2.9. Citrate synthase enzyme activity  
Gastrocnemius muscles (15 µg) were homogenised on ice in buffer containing 0.175 
M KCl and 2 mM EDTA, before undergoing two freeze thaw cycles and centrifugation 
at 10,000 x g for 60 s, then citrate synthase activity was measured in the supernatant, 
as previously described and normalised to per gram of total protein [357]. The 
gastrocnemius, a mixed muscle, was used for the citrate synthase activity, TBARS and 
the reduced and oxidised glutathione analyses due to sample limitations in EDL and 
soleus muscles. 
 
3.2.10. TBARS Assay  
To assess effects of Seps1 reduction or deletion on lipid peroxidation in skeletal 
muscles, a commercially available TBARS assay kit was used (10009055, Cayman 
Chemical Company, Michigan, USA). Briefly, gastrocnemius muscles (~20 mg) were 
homogenised on ice in RIPA buffer containing protease inhibitors, followed by 
centrifugation 1,600 x g for 10 min at 4 °C. The supernatant was collected for analysis. 
Standards and samples were then prepared as per manufacturer’s instructions and 
TBARS concentrations were assessed using spectrometer (Bio Rad X mark microplate 
spectrometer) and normalised to protein (µg/µl) following BCA assay.  
 
3.2.11. Reduced and oxidised glutathione 
To assess muscle redox state, gastrocnemius muscles (40-50 µg) were homogenised 
on ice in 0.1% formic acid, and then centrifuged at 8000 g for 15 min. The supernatants 
were collected and analysed for GSH) and GSSG content, as previously described 
[358, 359]. The concentration of GSH or GSSG was normalised to the wet weight of 
the gastrocnemius muscle sample.  
3.2.12. Statistical analyses 
All results are presented as mean ± SEM. One-way general linear model ANOVA was 
used to assess differences in Seps1 protein expression in fast and slow twitch mouse 
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hindlimb muscles. For experiments characterising the Seps1 global knockout mice, 
differences between Seps1-/- knockout mice and wild type littermates or Seps1+/- 
heterozygous mice and wild type littermates were investigated using two-tailed 
unpaired t-tests or 2-way GLM ANOVA with Tukey post hoc analyses, as appropriate. 
Effect sizes were calculated using Cohen’s formula (d) [360].  All statistical analyses 
were performed using Minitab statistical software v17 (Sydney, AUS), with P < 0.05 
being statistically significant.  
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3.3. Results 
3.3.1. Differential localisation and expression of Seps1 in fast and slow twitch muscle 
fibres 
In mouse Soleus muscle cross-sections, Seps1 immunoreactivity was greater in fast 
MyHC IIA positive fibres compared to slow MyHC I positive fibres (Fig. 3.1A and B). 
Whereas in EDL muscle cross-sections, where the proportion of MyHC I positive 
fibres is less than 1% [351, 361], Seps1 staining was relatively uniform with 
immunoreactivity observed in MyHC IIA and MyHC IIB positive fibres (Fig. 3.1C 
and D). The specificity of greater Seps1 immunoreactivity in fast twitch fibres was 
confirmed by pre incubating the anti- Seps1 primary antibody with a commercially 
available blocking peptide (Figure 3.2D and J). In muscle fibre cross-sections, Seps1 
expression was predominantly intracellular (Figure 3.2A and G). A lack of co-staining 
with WGA, indicated limited Seps1 localisation to the sarcolemma (Figure 3.2C, F, I 
and L).  This is in line with in vitro observations in HepG2 or U251 cells using similar 
techniques [158]. Seps1 was also highly expressed in blood vessels, and this includes 
vascular smooth muscle cells (Figure 3.2M) [168]. These differences in SEPS1 
immunoreactivity between fast and slow twitch fibres were also observed in human 
vastus lateralis muscle cross-sections (Fig. 3.3A and E), with more prominent SEPS1 
staining in muscle fibres expressing the fast SERCA1 isoform (Fig. 3.3G) versus the 
slow SERCA2 isoform (Fig. 3.3C).  
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Figure 3.1: Seps1 immunoreactivity in mouse hindlimb muscles is fibre type 
specific. A, Seps1 (red) is highly expressed in slow Soleus muscles from wildtype 
BALB/c mice, with variable immunoreactivity between individual muscle fibres. B, 
Serial Soleus muscle cross-sections were probed for MyHC IIA (green) and MyHC 1 
(blue) antibodies. As indicated by the solid and dotted muscle fibre outline, 
respectively, Seps1 immunoreactivity appeared to be greater in fast MyHC IIA 
positive fibres compared to slow MyHC I positive fibres. C, Seps1 (red) is also highly 
expressed in fast EDL muscles. D, Serial EDL muscle cross-sections of were probed 
for MyHC IIA (green) and MyHC IIB (red). As indicated by the solid and dashed 
muscle fibre outline, respectively, Seps1 is expressed in both IIA and IIB fibres. Scale 
bar = 100 μm. n = 3. 
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Figure 3.2: Seps1 immunoreactivity in mouse Soleus and EDL muscles. To 
confirm greater Seps1 immunoreactivity in type II compared to type I fibres, the anti-
Seps1 antibody was pre-incubated with a blocking peptide (a commercially available 
Seps1 antigen). Soleus and EDL muscles were reacted with the anti-Seps1 antibody 
(A and C, G and I) or the anti-Seps1 antibody plus blocking peptide (D and F, J and 
L) and WGA (green) was used to stain glycoproteins in the sarcolemma and 
extracellular matrix (ECM) (B and E, H and K). In Soleus muscles, Seps1 
immunoreactivity was variability between individual fibres (A and C), and no 
sarcolemmal co-localisation observed (C). In EDL muscles, Seps1 was expressed in 
all myofibre (G and I), and again no sarcolemmal co-localisation observed (I). When 
Soleus (D and F) and EDL (J and L) muscles were reacted with the anti-Seps1 antibody 
pre-incubated with a blocking peptide no intra-myofibre staining was observed. M, In 
muscle cross-sections, Seps1 is especially highly expressed in vascular smooth muscle 
of arteries and is co-localised with the blood vessel ECM (N, O). Nuclei are 
counterstained with DAPI (blue). Scale bar = 50 μm. n = 3.  
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Figure 3.3: SEPS1 immunoreactivity in human skeletal muscle is fibre type 
specific. A and E, SEPS1 (red) is highly expressed in human vastus lateralis muscle 
cross-sections, with greater immunoreactivity in fast type II muscle fibres. B, Slow 
type I myofibre were stained with a SERCA2 antibody (green). C, Overlay of SEPS1 
and SERCA2 shows greater SEPS1 staining in type II fibres with no SERCA2 
immunoreactivity. D, Negative control muscle cross-section reacted with the Alexa 
Fluor 594 goat anti-rabbit and Alexa Fluor 488 IgG2a goat anti-mouse secondary 
antibodies. F, Fast type II myofibre were stained with a SERCA1 antibody (green). G, 
Overlay of SEPS1 and SERCA1 shows preferential immunoreactivity of SEPS1 in 
type II fibres (orange). H, Negative control muscle cross-section reacted with the 
Alexa Fluor 594 goat anti-rabbit and Alexa Fluor 488 IgG1 goat anti-mouse secondary 
antibodies. Nuclei are counterstained with DAPI (blue). Scale bar = 50 μm. n = 3.  
 
Fibre type differences in Seps1 expression were further investigated using western 
blotting to assess total protein content in whole muscle lysates, irrespective of cellular 
localisation. Seps1 was readily detected in vastus lateralis whole muscle lysates (Fig. 
3.4A). In mice, total Seps1 protein expression was greater in the slower Soleus 
compared to fast twitch EDL and TA hindlimb muscles (d=5.79, P<0.001, Fig. 3.4B). 
The observations of higher Seps1 protein levels in Soleus compared to EDL or TA 
muscles and the preferential Seps1 immunoreactivity in type II fibres are not 
irreconcilable, given the high proportion of type II fibres, up to 60% to 70%, in mouse 
Soleus muscles [351, 361, 362]. Furthermore, Seps1 is highly expressed in blood 
vessels (Fig 3.2M and O), specifically vascular smooth muscle cells [168, 190]. The 
density of microvascular network, which includes arterioles and venules, is far greater 
in Soleus compared to EDL muscles. This will also contribute to the higher levels of 
Seps1 protein expression in whole tissue lysates from Soleus muscles [363].  
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Figure 3.4: Total SEPS1 protein levels are higher in slow compared to fast twitch 
hindlimb muscles. A, SEPS1 protein expression in vastus lateralis whole muscle 
homogenates B, Seps1 protein expression in mouse EDL, Soleus muscles and TA 
whole muscles homogenates. Proliferating C2C12 myoblast lysates were included as 
a control due to high levels of Seps1 expression. Seps1 protein levels were >2-fold 
higher in whole muscle homogenates from Soleus compared to EDL and TA muscles. 
† P < 0.001 as determined by one-way general linear model ANOVA. Vastus lateralis 
biopsy samples (n = 4), BALB/c mouse hindlimb muscles (n = 6) and C2C12 myoblast 
lysates (n = 2 biological replicates). 
 
3.3.2. Characterisation of Seps1 GKO mice: Body composition, spontaneous physical 
activity and whole body metabolism 
Indicative of the successful genetic deletion or reduction, Seps1 protein expression 
was reduced in TA muscles from Seps1-/- knockout and Seps1+/- heterozygous mice by 
approximately 99% and 50%, respectively, when compared to wild type littermates 
(d=2.13, P=0.01 and d=1.20, P=0.046, respectively, Fig. 3.5A). With similar 
observations made in EDL and Soleus muscles (Fig. 3.5B and C).  
In 12 week old male mice, the genetic reduction or deletion of Seps1 had no significant 
effect on body weight and body composition, with similar fat mass and lean mass 
observed in Seps1-/- knockout, Seps1+/- heterozygous and wild type mice. EDL and 
Soleus muscle weights were also not significantly different between genotypes (Table 
3.2).  
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Figure 3.5: The genetic reduction or deletion of Seps1 protein in fast and slow 
twitch mouse hindlimb muscles. A, In TA whole muscle homogenate Seps1 protein 
expression was reduced by approximately 60% in Seps1+/- heterozygous mice and 
almost completely abolished in the Seps1-/- knockout mice when compared to wildtype 
(WT) littermates. These observations were reproduced in cryosection lysates from B, 
EDL and C, Soleus muscle from Seps1-/- knockout, Seps1+/- heterozygous and wildtype 
mice. * P < 0.05 for Seps1+/- heterozygous versus wildtype mice, + P < 0.01 for Seps1+/- 
heterozygous versus wildtype mice and † P < 0.01 for Seps1-/- knockout versus 
wildtype mice, as determined by an unpaired T-test. Seps1-/- knockout mice (n = 9), 
Seps1+/- heterozygous mice (n = 10) and wildtype littermates (n = 10). 
 
 
Table 3.2: Body Composition and Muscle Weight  
Genotype  Body 
Weight (g) 
Fat Mass  
(g) 
Lean Mass  
(g) 
EDL 
Weight 
(mg) 
SOL 
Weight 
(mg) 
WT  26.65 ± 
0.41 
1.98 ± 0.19 22.60 ± 0.46 10.95 ± 
0.38 
8.10 ± 0.32 
Seps1+/- 26.36 ± 
0.80 
2.34 ± 0.24 22.85 ± 0.66 10.79 ± 
0.51 
9.14 ± 0.63 
Seps1-/- 27.52 ± 
1.09 
2.55 ± 0.42 22.71 ± 0.82 11.14 ± 
0.60 
8.68 ± 0.59 
Values shown are mean ± SEM. Seps1-/- knockout mice (n = 9), Seps1+/- heterozygous 
mice (n = 10) and wildtype littermates (n = 10). 
 
Over a 24 h period, Seps1+/- heterozygous mice were 22% less active than their wild 
type littermates (d=1.10, P=0.029, Fig. 3.6A). Similarly, in Seps1-/- knockout mice a 
trend for reduced spontaneous physical activity was found (16%; d=1.12, P=0.051, 
Fig. 3.6A). Corresponding to the nocturnal increase in activity, resting energy 
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expenditure was higher during the 12 h night period than the 12 h day period (d=0.31, 
P<0.0001, Fig. 3.6B). Despite differences in spontaneous physical activity, the genetic 
reduction or deletion of Seps1 had no significant effect on day or night resting energy 
expenditure, as estimated by the Weir Equation (Fig. 3.6B). Substrate utilisation, as 
reflected by RER, was also not significantly different between Seps1-/- knockout or 
Seps1+/- heterozygous mice and their wild type littermates (Fig. 3.6C). In concordance 
with the whole body metabolism data, the genetic reduction or deletion of Seps1 had 
no significant effect on muscle citrate synthase activity in gastrocnemius muscles (Fig. 
3.6D). Despite being linked to metabolic disease in human populations [187] and 
obesity and insulin resistance in Israeli sand rats (Psammomys obesus) [186], the 
genetic reduction or deletion of Seps1 did not alter any measured parameters of whole 
body and muscle metabolism. 
 
 
Figure 3.6: Analysis of spontaneous physical activity and whole body metabolism 
in Seps1 GKO mice. A, During 24 h in metabolic cages, the total spontaneous 
physical activity of Seps1+/- heterozygous mice was reduced by 22% compared to their 
wildtype litter mates. A trend towards reduced physical activity was also observed in 
the Seps1-/- knockout mice (P = 0.051). B, Resting energy expenditure, during the day 
(6am- 6pm) and at night (6pm - 6am), was similar between Seps1-/- knockout or 
Seps1+/- heterozygous mice and their wildtype littermates. It should be noted that 
energy expenditure at night was greater than during the day. C, The genetic reduction 
or deletion of Seps1 did not significantly affect whole body substrate metabolism as 
indicated by a similar respiratory exchange ratio (RER, VO2/VCO2) during the day or 
night. D, Citrate synthase activity was also not significantly different in gastrocnemius 
muscles from Seps1-/- knockout or Seps1+/- heterozygous mice and their wildtype 
littermates. * P < 0.05 for Seps1+/- heterozygous versus wildtype mice, as determined 
by an unpaired T-test. † P < 0.0001 for night vs day, as determined by an unpaired T-
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test. Seps1-/- knockout mice (n = 9), Seps1+/- heterozygous mice (n = 9) and wildtype 
littermates (n = 9). 
 
 
3.3.3. Contractile properties of isolated EDL and Soleus muscles 
Ex vivo contractile function testing was undertaken to assess whether the genetic 
reduction or deletion of Seps1 would affect muscle performance. The twitch force (Pt), 
time to peak tension (TPT), ½ relaxation time (½ RT) and Lo of EDL and Soleus 
muscle were similar in Seps1-/- knockout, Seps1+/- heterozygous and wild type mice 
(Table 3.3). TPT is indicative of myosin heavy chain composition and Ca2+ sensitivity 
[364-366], whilst ½ RT is reflective of muscle relaxation and Ca2+ reuptake and 
depends on SERCA isoform and function [367]. The rate of force development 
(Dx/Dt) in response to a 1 Hz stimulation was also not significantly altered by Seps1 
reduction or deletion in either EDL or Soleus muscles. 
 
Table 3.3: Twitch contractile properties of the fast EDL and slow Soleus muscles  
Muscle Genotype Pt 
(mN/mm2) 
TPT (s) ½ RT 
(s) 
Dx/Dt 
(mN/s) 
Lo (mm) 
EDL WT 69.2 ± 5.1  0.200 ± 
0.022 
0.023 ± 
0.003  
22312       ±  
7149 
5.595 ± 
0.17 
 Seps1+/- 69.42± 4.1 0.220 ± 
0.001 
0.022 ± 
0.003 
13082       ±  
2758 
5.553 ± 
0.121 
 Seps1-/- 57.4 ± 5.4 0.220 ± 
0.001 
0.019 ± 
0.001 
9002         ±  
2126 
5.589 ± 
0.145 
Soleus WT 40.0      ±  
3.1 
0.236 ± 
0.003 
0.061 ± 
0.010 
20400       ±  
6892 
6.542 ± 
0.787 
 Seps1+/- 37.4      ±  
1.8 
0.234 ± 
0.003 
0.048 ± 
0.005 
12788       ±  
4688 
7.773 ± 
0.104 
 Seps1-/- 40.6      ±  
4.0 
0.233 ± 
0.002 
0.052 ± 
0.007 
6763         ±  
3958 
7.825 ± 
0.082 
Pt, maximum twitch force, TPT, time to peak twitch, ½ RT, one-half relaxation time, 
Dx/Dt, maximal rate of contraction, Lo, fibre length. Values shown are mean ± 
standard error of the mean. Seps1-/- knockout mice (n = 9), Seps1+/- heterozygous mice 
(n = 10) and wildtype littermates (n = 10). 
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When stimulated with increasing frequency (1-120 Hz) to assess maximal, isometric 
force production, EDL muscles from Seps1-/- knockout mice presented with a 
downward shift in the specific (sPo) force frequency curves when compared to wild 
type littermates (d=0.55, P=0.004,  Fig. 3.7A), indicating that the loss of Seps1 is 
associated with decreased muscle strength. The force frequency curves of EDL 
muscles from Seps1+/- heterozygous mice and wild type littermates did not 
significantly differ. When force frequency data was expressed as % of maximum Po, 
to determine whether the genetic reduction or deletion of Seps1 affects muscle force 
output in response to changes in stimulation frequency, EDL muscles from Seps1 -/- 
knockout mice, but not Seps1+/- heterozygous mice, produced less force at submaximal 
stimulation frequencies when compared to EDL muscles from wildtype littermates 
(d=0.54, P<0.05, Fig. 3.7B).  
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Figure 3.7: The genetic reduction or deletion of Seps1 compromises force 
production in isolated fast twitch EDL muscles. A, When force output was 
normalised to muscle cross-sectional area (specific force, sPo), the genetic deletion of 
Seps1still reduced muscle strength, as indicated by a downward shift of the force 
frequency curve (FFC) in EDL muscles of Seps1-/-  knockout mice when compared to 
wildtype littermates. The FFC of EDL muscles from Seps1+/- heterozygous and 
wildtype mice were not significantly different. B, The force frequency data was also 
expressed as % of maximum Po, to determine how the genetic reduction or deletion of 
Seps1 affects muscle force output in response to changes in stimulation frequency. In 
EDL muscles from Seps1-/- knockout mice, but not Seps1+/- heterozygous mice, the 
genetic deletion of Seps1 reduced force production at submaximal stimulation 
frequencies when compared to EDL muscles from wildtype littermates. C, 
Fatigueability, when expressed as % of initial force, was similar between genotypes, 
however, the genetic reduction and or deletion of Seps1 did modulate % force recovery 
when compared to wildtype littermates. D, The specific force produced at 60 Hz 
stimulation from the FFC (red dashed line in A) was compared to the specific force 
produced by the first contraction of the intermittent, submaximal (60 Hz) stimulation 
fatigue protocol (red dashed line in B).  Specific force output was maintained in EDL 
muscles from wildtype mice, whilst a significant decrease was observed in EDL 
muscles from Seps1-/- knockout and Seps1+/- heterozygous mice, indicating a reduced 
tolerance to higher frequency stimulation between 80 and 120 Hz.  *P < 0.05 – main 
effect for genotype in Seps1-/- knockout versus wildtype mice, as determined by 2-way 
repeated measures ANOVA. † P < 0.001 – main effect for genotypes in Seps1-/- 
knockout or Seps1+/- heterozygous mice versus wildtype mice, as determined by 2-way 
repeated measures ANOVA). + P < 0.05 and  ++ P < 0.01  for the difference in force 
output between 60 Hz stimulation from the FFC and the first contraction of the 60 Hz 
fatigue protocol, as determined by a paired T-test. Seps1-/- knockout mice (n = 9), 
Seps1+/- heterozygous mice (n = 10) and wildtype littermates (n = 10). 
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As indicator of endurance and fatigability, EDL muscles underwent 4 min of 
intermittent, submaximal (60 Hz) stimulation, with force recovery assessed at 2, 5 and 
10 min post fatigue. During the intermittent, submaximal stimulation protocol and in 
the recovery period, EDL muscles from Seps1-/- knockout mice or Seps1+/- 
heterozygous mice produced approximately 20% less force than muscles from wild 
type littermates (Po: P < 0.001, d = 0.62 and P = 0.002, d = 0.43, respectively). When 
this force output was expressed as % of initial force, fatigueability was not 
significantly affected by the genetic reduction or deletion of Seps1. These data, in 
addition to similar TPT and ½ RT values and gastrocnemius muscle citrate synthase 
activity, suggest that the genetic reduction or deletion Seps1 was not associated with a 
fibre type shift. However, following the 4 min of intermittent, submaximal stimulation,  
a trend for compromised % force recovery was identified in the Seps1-/- knockout mice 
when compared to wild type littermates (d=0.37, P=0.11, Fig. 3.7C). Perhaps, 
indicative of contraction-induced damage or longer lasting fatigue in the Seps1-/- 
knockout mice. A trend for compromised % force recovery was also observed in the 
Seps1+/- heterozygous mice (d=0.18, P=0.11, Fig. 3.7C).  
To minimise contractile dysfunction and allow for full recovery of force producing 
capacity, isolated EDL and Soleus muscles are rested for 2 min between each 
contraction of the force frequency curve and for 4 min between the end of the force 
frequency curve and the start of the fatigue protocol. Indeed, in EDL muscles from 
wild type mice the force produced at 60 Hz stimulation during the force frequency 
curve was not significantly different from the force produced in response to the first 
60 Hz contraction of the fatigue protocol. Unexpectedly, in EDL muscles from Seps1-
/- knockout and Seps1+/- heterozygous mice, the force produced at 60 Hz stimulation 
at the start of the fatigue protocol was reduced by 10% compared to the force produced 
during the force frequency curve (d=0.31, P<0.002 and d=0.39, P=0.02, respectively, 
Fig. 3.7D). Indicative of a reduced tolerance to high frequency contractions in fast 
twitch EDL muscles with Seps1 reduction or deletion, perhaps due to damage to or 
oxidation of proteins involved in excitation-contraction coupling. 
Unlike in EDL muscles, the genetic reduction or deletion of Seps1 did not affect Soleus 
muscle strength (Fig. 3.8A), nor did it affect submaximal force production (Fig. 3.8B). 
As such, the absolute (Po) force output during 4 min of intermittent, submaximal (60 
Hz) stimulation or at 2, 5 and 10 min recovery was similar in Soleus muscles 
irrespective of genotype (data not shown). The genetic reduction or deletion of Seps1 
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also did not significantly affect the rate of fatigueability and force recovery (Fig. 3.8C). 
Lastly, the force produced by Soleus muscles from Seps1-/- knockout mice, Seps1+/- 
heterozygous mice and wild type littermates did not significantly differ from the 60 
Hz stimulation of the force frequency curve and the first 60 Hz stimulation of the 
fatigue protocol (Fig. 3.8D).  
 
 
Figure 3.8: The genetic reduction or deletion of Seps1 does not alter the 
performance of isolated slow twitch Soleus muscles. A, Muscle strength was similar 
in Soleus muscles from Seps1-/- knockout or Seps1+/- heterozygous compared to 
wildtype littermates, as indicated by similar force frequency curves normalised to 
muscle cross sectional area. B, Similarly, the genetic reduction or deletion did not 
affect specific force production during 4 min of intermittent, submaximal (60 Hz) 
stimulation and at 2, 5 and 10 min of recovery. B, The genetic reduction or deletion of 
Seps1 also had no significant effect on force production at submaximal stimulation 
frequencies. C, The genetic reduction or deletion of Seps1 did not affect the rate of 
fatigue, nor did it affect force recovery. D, The specific force produced at 60 Hz 
stimulation from the FFC (red dashed line in A) was compared to the force produced 
by the first contraction of the intermittent, submaximal (60 Hz) stimulation fatigue 
protocol (red dashed line in B) Specific output was maintained in Soleus muscles from 
Seps1-/- knockout, Seps1+/- heterozygous and wildtype mice. Seps1-/- knockout mice 
(n = 9), Seps1+/- heterozygous mice (n = 10) and wildtype littermates (n = 10). 
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3.3.4. Muscle structure of EDL and Soleus muscles 
Given the effects of Seps1 reduction or deletion on EDL muscle contractile function 
and the fact that mutations in SelN, another ER-resident selenoprotein, cause a muscle 
myopathy characterised by variability in fibre size, degeneration, focal increases in 
connective tissue and centrally nucleated fibres [137, 368], a morphometric analysis 
of muscle cross-sections was undertaken. Muscle fibre cross-sectional area (Fig. 3.9A-
B), the proportion of centrally nucleated fibres (a marker of recent damage and repair, 
Fig. 3.9C-D), and percentage of connective tissue and mononuclear infiltration were 
similar in EDL and Soleus muscles from Seps1-/- knockout or Seps1+/- heterozygous 
mice and their wild type littermates (Fig. 3.9E-F). In line with the normal muscle 
morphology of EDL and Soleus muscles from Seps1-/- knockout or Seps1+/- 
heterozygous mice, the mRNA transcript abundance of Mcp-1, a pro-inflammatory 
cytokine implicated in monocyte and macrophage recruitment, was not significantly 
altered by the genetic reduction or deletion of Seps1 (Fig. 3.9G-H). 
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Figure 3.9: Muscle morphology and markers of degeneration and inflammation 
in EDL and Soleus muscles from Seps1 GKO mice.  A-B, In EDL and Soleus 
muscles, the genetic reduction or deletion of Seps1 did not alter the muscle fibre cross-
sectional area (as measured by the minimal feret diameter). Nor was it associated with 
muscle pathology, as indicated by a similar C-B, proportion of centrally nucleated 
fibres, E-F, percentage of mononuclear infiltrate and connective tissue (CT) in muscle 
cross-sections, and G-H, similar Mcp-1 mRNA transcript abundance from in EDL or 
Soleus muscles from Seps1-/- knockout, Seps1+/- heterozygous and wildtype mice. 
Seps1-/- knockout mice (n = 9), Seps1+/- heterozygous mice (n = 10) and wildtype 
littermates (n = 10). 
 
3.3.5. Gene markers of cellular stress and glutathione redox state 
Cell culture studies have implicated Seps1 in regulating cellular stress responses [159, 
161, 163, 172]. As such, the effects of Seps1 reduction or deletion on the gene 
expression of the thioredoxin antioxidant system and ER stress markers in EDL and 
Soleus muscles was assessed. In the fast twitch EDL muscles from Seps1-/- knockout 
mice, the mRNA transcript abundance of Txnip and Trx1 was reduced when compared 
to wild type littermates (d=1.27, P=0.025  and d=1.38, P=0.012, respectively, Fig. 
3.10A-B). In Soleus muscles, the genetic deletion of Seps1 was associated with 
increased Txnip and Trx-1 mRNA transcript abundance (d=1.05, P=0.045 and d = 
1.50, P=0.009, respectively, Fig. 3.10F-G). The genetic reduction or deletion of Seps1 
had no significant effect on ER stress chaperone Grp78 in EDL or soleus muscles (Fig. 
3.10C and H). However, in EDL muscles from Seps1-/- knockout mice Grp94 (d=1.11, 
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P=0.02, Fig. 3.10D) and Seps1+/- heterozygous mice, Chop (d=0.99, P=0.047, Fig. 
3.10E) mRNA transcript abundance was reduced when compared to wild type 
littermates, whilst no such effect was observed in the Soleus muscles. These findings 
are interesting given that Grp94, in addition to regulating protein folding, is a Ca2+ 
binding protein linked to the regulation of Ca2+ homeostasis in the ER [369]. 
Altogether, the genetic reduction or deletion of Seps1 has distinct effects on the gene 
markers of ER stress and the thioredoxin antioxidant system in EDL compared to 
Soleus muscles. 
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Figure 3.10: mRNA transcript abundance of oxidative and ER stress markers in 
EDL and Soleus muscles from Seps1 GKO mice. In EDL muscles, from Seps1-/- 
knockout mice, but not Seps1+/- heterozygous mice, A, thioredoxin inhibitor protein 
(Txnip) and B, thioredoxin-1 (Trx1) gene expression was reduced when compared to 
wildtype littermates. C, Glucose-regulated protein 78 (Grp78) mRNA transcript 
abundance was not altered by Seps1 reduction or deletion. D, Grp94 gene expression 
was reduced in Seps1-/- knockout mice when compared with wildtype littermates. E, 
Chop gene expression was significantly reduced in Seps1+/- heterozygous mice when 
compared to wildtype littermates. Reduced Chop gene expression also tended to be 
reduced in Seps1-/- knockout mice (P = 0.059). In Soleus muscles, F, Txnip and G, 
Trx1 gene expression was increased in Seps1-/- knockout mice, but not Seps1+/- 
heterozygous mice when compared to wildtype litter mates. The mRNA transcript 
abundance of H, Grp78 or I, Grp94 and J, Chop mRNA levels did not differ between 
genotypes. *P < 0.05 for Seps1-/- knockout versus wildtype mice, as determined by an 
unpaired T-test. +P < 0.05 for Seps1+/- heterozygous mice versus wildtype mice, as 
determined by an unpaired T-test. † P < 0.01 for Seps1-/- knockout versus wildtype 
mice, as determined by an unpaired T-test. Seps1-/- knockout mice (n = 9), Seps1+/- 
heterozygous mice (n = 10) and wildtype littermates (n = 10). 
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As additional markers of oxidative stress, TBARS concentrations (a marker of lipid 
peroxidation) and the redox state the glutathione antioxidant system were quantified 
in gastrocnemius muscles from Seps1-/- knockout, Seps1+/- heterozygous and wild type 
mice. The genetic reduction and deletion of Seps1 did not significantly alter TBARS 
concentrations in gastrocnemius muscle lysates (Fig 3.11A). In concordance with the 
lipid peroxidation data, GSSG content and the reduced to oxidised glutathione ratio 
(GSH: GSSG) also did not differ between genotypes (Fig. 3.11C and D). Although, a 
very modest increase in reduced glutathione content was observed in Seps1-/- knockout 
mice compared to wild type littermates (d=1.00, P=0.045, Fig. 3.11B). The mRNA 
transcript abundance of glutathione peroxidase 1 (Gpx1) was similar in EDL and 
Soleus muscles from Seps1-/- knockout, Seps1+/- heterozygous and wild type 
littermates (Fig. 3.11E and F).  
 
Figure 3.11: Effects of Seps1 reduction or deletion on lipid peroxidation and the 
glutathione antioxidant pool in hindlimb muscles. A, In gastrocnemius muscles the 
genetic reduction or deletion of Seps1 had no significant effect on TBARS 
concentrations, a maker of lipid peroxidation and oxidative stress. B. Reduced 
glutathione (GSH) levels were higher in gastrocnemius muscles from Seps1-/- 
knockout mice, but not Seps1+/- heterozygous, when compared to wildtype littermates. 
C, The genetic reduction or deletion of Seps1 had no effect on oxidised glutathione 
(GSSG) levels. D, The GSH: GSSG ratio also did not differ between gastrocnemius 
muscles from wildtype and Seps1+/- heterozygous or Seps1-/- knockout mice. E, in EDL 
and F,  Soleus mus c le  the genetic reduction of Seps1 had no significant effect on 
glutathione peroxidase 1 (Gpx1) mRNA transcripts. *P < 0.05 for Seps1-/- knockout 
versus wildtype mice, as determined by an unpaired T-test. Seps1-/- knockout mice 
(n = 9), Seps1+/- heterozygous mice (n = 10) and wildtype littermates (n = 10). 
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3.4. Discussion  
In skeletal muscle, the careful regulation of oxidative and ER stress responses is 
necessary for optimal metabolic and contractile function. A transient increase in ROS 
can improve muscle performance [22, 370] and stimulate adaptation to exercise [371, 
372]. Similarly, the unfolded protein response is activated in response to 
unaccustomed contractile activity [274], and also promotes adaptation to exercise 
[152]. ER-resident selenoproteins can regulate ER redox state, the UPR and Ca2+ 
homeostasis, this highlights their physiological relevance to skeletal muscle contractile 
function and adaptation. Indeed, mutations in SelN lead to a myopathy where a hyper-
oxidised ER/SR disrupts Ca2+ release [143] and/or reuptake leading to muscle 
weakness and wasting [138]. Seps1 can regulate ER and oxidative stress responses in 
various cell lines, although its function in vivo has not been well characterised. Here, 
we report for the first time that Seps1 expression and cellular localisation is fibre type 
dependent, and when Seps1 is genetically reduced or deleted, the contractile 
performance of fast twitch, but not slow twitch, muscles is compromised. Thus, 
identifying Seps1 as a novel ER-resident selenoprotein with the potential to modulate 
skeletal muscle contractile function.  
In human vastus lateralis and mouse EDL and Soleus muscles, fast type II muscle 
fibres demonstrated greater intra-myofibre immunoreactivity to the anti-Seps1 
antibody than slow type I muscle fibres. Seps1 sarcolemmal staining was limited, and 
this is in concordance with Bubenik et al., who using immunohistochemcial 
techniques, found that Seps1 to be predominantly localised to the ER [158]. Given its 
localisation to the ER membrane, SR localisation of Seps1 is likely in skeletal muscle 
[18, 373]. Seps1 was also highly expressed blood vessels, and vascular smooth muscle 
cells are known to synthesise Seps1 [168, 190]. Skeletal muscle is a heterogeneous 
tissue comprised of muscle fibres, blood vessels, nerves and extracellular matrix, 
whilst immunohistochemistry provides valuable insight into cellular localisation, 
whole muscle lysates and western blotting are needed to assess total Seps1 protein 
levels. Interestingly, Seps1 protein levels were greater in whole muscle lysates from 
Soleus compared to EDL and TA muscles. We propose that fibre type differences in 
microvasculature, as well as the high proportion (60 to 70%) of type IIA fibres [351, 
361, 362], contribute to the higher levels of Seps1 expression in Soleus muscles.  
In global Seps1 knockout mice, the genetic reduction or deletion of Seps1 decreased 
spontaneous physical activity. This reduction was unlikely the result of an altered 
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metabolic profile, as resting energy expenditure, substrate utilisation (as reflected by 
RER) and gastrocnemius muscle citrate synthase activity were not affected by the 
genetic deletion or reduction of Seps1. Given the global knockout mouse model and 
that Seps1 is highly expressed in the brain (e.g. cerebrum and cerebellum) [168], 
central nervous system effects of Seps1 reduction or deletion on physical activity 
cannot be excluded. With regards to body composition, the genetic reduction or 
deletion of Seps1 had no significant effect on lean and fat mass. This lack of effect on 
fat mass in mice on a standard chow diet ad libitum is in contrast to 3T3-L1 pre-
adipocytes cell culture studies identifying Seps1 as an anti-adipogenic selenoprotein, 
whose degradation (and thus reduced expression) promotes adipocyte differentiation 
[330]. This highlights the importance of in vivo studies to elucidate selenoprotein 
function. The lack of effect of Seps1 on whole body metabolism was also somewhat 
intriguing, given the associations between SEPS1, glucose metabolism and type 2 
diabetes reported in human subjects [187, 188, 190] and the initial observation of 
dysregulated hepatic Seps1 expression in fed and fasted diabetic Israeli sand rats [186]. 
To investigate whether impaired skeletal muscle performance contributed to the 
decrease in physical activity observed with Seps1 deletion or reduction, the isometric 
contractile function of EDL and Soleus muscles was assessed ex vivo. The genetic 
reduction or deletion of Seps1 did not appear to cause a fibre type shift in EDL or 
Soleus muscles, as indicated by similar ½ RT and TPT values in response to a 1 Hz 
(twitch) stimulation. However, it did compromise muscle strength and tolerance of 
high frequency and intermittent, submaximal frequency stimulation in fast twitch EDL 
muscles. As indicated by a downward shift in the force frequency curve and a 
reduction in the submaximal force production of EDL muscles from Seps1-/- knockout 
mice. Furthermore, a decrease in force output between the 60 Hz stimulation of the 
force frequency curve and the first 60 Hz stimulation of the fatigue protocol in both 
the Seps1+/- heterozygous and Seps1-/- knockout mice. Between 60 Hz and 120 Hz 
stimulation, the isometric force produced by EDL muscles increased by approximately 
15%, a rather modest increase in force given the doubling in stimulation frequency. 
High frequency stimulations, especially in isolated whole muscles, can lead to 
inadequate oxygen diffusion and hypoxia induced cellular stress [374], and thus 
compromise contractile performance. This could contribute the impairment in force 
recovery in EDL muscles from Seps1-/- knockout and Seps1+/- heterozygous mice 
following 4 min of intermitted, submaximal stimulation. It also needs to be 
acknowledged, that the Ringer’s solution is bubbled with 95% O2 (Carbogen), which 
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in itself can be a source of damaging oxidants. Unlike in EDL muscles, the genetic 
deletion or reduction of Seps1 did not affect Soleus muscle strength and tolerance of 
high frequency and intermittent, submaximal frequency stimulation. A higher resting 
metabolic rate and greater depletion of high energy phosphates during ex vivo 
contractile function testing [374], may make EDL muscles more vulnerable to 
dysfunction than Soleus muscles. In addition, Soleus muscles may be better protected 
by their greater antioxidant capacity [375, 376] and more oxidative phenotype [367]. 
Thus, the reduction in physical activity in Seps1+/-  heterozygous and Seps1-/- knockout 
mice may be due to impaired contractile function of fast twitch muscles, as these are 
the predominant fibre type in mouse hindlimb muscles [351, 367]. It should be noted, 
that the impairment in EDL contractile function associated with Seps1 reduction or 
deletion did not appear to be the consequence of altered muscle morphology or 
myopathy. As EDL and Soleus muscle cross-sections from Seps1-/- knockout and 
Seps1+/- heterozygous were structurally similar to those from wild type mice, with no 
significant differences in muscle fibre size and markers of degeneration and 
regeneration observed. 
The impairment in contractile function following Seps1 reduction or deletion was 
associated with a differential regulation of gene markers of oxidative and ER stress in 
EDL compared to Soleus muscles. Trx-1 mRNA transcript abundance was decreased 
with Seps1 deletion in EDL muscles, whereas in Soleus muscles it was increased. 
Based on biochemical assays, the oxidoreductase activity of Seps1 against H2O2 is 
thought to be due to its interactions with thioredoxin [172], and here Seps1 is shown 
to be associated with the thioredoxin antioxidant system in vivo for the first time. Txnip 
gene expression was similarly affected by Seps1 deletion, with decreased expression 
in EDL muscles and increased expression in Soleus muscles. As well as being an 
inhibitor of thioredoxin, Txnip can be upregulated in response to ER stress and is 
thought to link ER stress to inflammation [310]. Seps1 reduction or deletion may have 
greater effects on thioredoxin antioxidant system, as Gpx1 mRNA transcript 
abundance in as EDL and Soleus muscles and the GSH: GSSG ratio in gastrocnemius 
muscles did not differ between Seps1-/- knockout or Seps1+/- heterozygous mice and 
their wild type mice. 
Seps1 deletion did not increase the expression of gene markers of ER stress in mouse 
hindlimb muscles. Rather, Grp94 and Chop mRNA transcript abundance was 
significantly decreased in EDL muscles from Seps1-/- knockout mice compared to wild 
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type littermates. Whereas, in Soleus muscle, Seps1 deletion had no significant effect 
on the gene expression of Grp78, Grp94 and Chop. Whilst Seps1 has been shown to 
be protective against ER stress by facilitating the retrograde translocation of misfolded 
proteins out of the ER, this function may be context and cell type dependent. In various 
intestinal cell lines, Seps1 gene knockdown did not exacerbate the UPR in the basal 
state or in response to pharmacologically induced ER stress [182].  
Here, we report that SEPS1 is preferentially localised to type II fibres in mouse 
hindlimb and human vastus lateralis muscles, and may be a novel antioxidant regulator 
of fast twitch muscle contractile function. These findings of a fibre type specific effect 
of Seps1 deletion or reduction align well with our observations in dystrophic mdx mice, 
the murine model of Duchenne muscular dystrophy characterised by chronic 
contraction induced injury, inflammation and oxidative stress [154, 377]. In mdx mice, 
the genetic reduction of Seps1 exacerbated the inflammatory profile of EDL, but not 
Soleus, muscles [185]. In EDL muscles only, the genetic reduction of Seps1 increased 
the expression of gene markers of inflammation (pro-inflammatory cytokines Tgfb1 
and Mcp1, and the macrophage marker F4/80) and this was associated with a reduction 
in myofibre size [185]. Overall, the effects of selenoprotein expression or function on 
fibre type differences are not well described in the literature. In humans, SelN related 
muscle myopathy is associated with atrophy of slow type I fibres [61]. In mice, SelN 
protein expression is higher in EDL than Soleus muscles [142]. Whereas, glutathione 
peroxidase enzyme activity is higher in Soleus muscles than in the deep and superficial 
vastus lateralis muscles [375, 376].  
Further research is required to investigate the differential association between Seps1 
levels, Trx-1 and Txnip gene expression in fast and slow twitch hindlimb muscles. The 
thioredoxin antioxidant system is an important regulator of oxidative, ER and 
inflammatory stress responses [332, 378]. All of which, depending on the biological 
context, mediate skeletal muscle adaptation to exercise [379] or dysfunction in chronic 
disease [154, 281]. The underlying mechanism leading to the impairment in force 
production following the genetic reduction or deletion of Seps1 remains to be 
elucidated. The cytosolic Sec residue of Seps1, either directly or through interactions 
with binding partners, may regulate the redox state of the contractile apparatus, 
SERCA pumps and/or the ryanodine receptor. All of which can affect the cross-bridge 
cycling and Ca2+ release and re-uptake, and ultimately force output [22]. Whether this 
impairment in ex vivo force production in the Seps1+/- heterozygous and knockout-/- 
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mice modulates exercise capacity and adaptation to exercise training remains to be 
determined. 
 
3.4.1. Perspectives and Significance 
Adequate dietary intake of selenium is necessary for skeletal muscle health [380]. In 
certain contexts, selenium supplementation can improve contractile function, 
presumably through increased selenoprotein synthesis [142]. However, the 
mechanisms by which selenoproteins modulate skeletal muscle health and function 
appear to be protein specific and complex. For example, deficiency in SelP, which 
functions as the key selenium transport protein in circulation and is produced mainly 
by the liver, renders mice more responsive to endurance training due to enhanced ROS 
signalling [157]. In contrast, deficiency of the ER-resident selenoproteins, Seps1 and 
SelN [138, 143, 147], is deleterious for skeletal muscle performance. In concordance 
with our previous observations in dystrophic hindlimb muscles from mdx mice [185], 
the genetic reduction (e.g. a 50% decrease in protein Seps1 levels) or deletion of Seps1 
had deleterious effects on fast, but not slow, twitch hindlimb muscles. It is the fast 
twitch muscle fibres which are preferentially vulnerable to contractile dysfunction 
with aging and chronic disease [381], when cellular and inflammatory stressors are 
increased [382] and micronutrient intake, including selenium, is suboptimal [214, 
383].   
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Chapter Four 
Reduction of Selenoprotein S Impairs Exercise Tolerance 
The results in this chapter are in preparation for publication submission in 2018.  
Addinsall AB, Wright CR, Kotsiakos TL, van der Poel C and Stupka N. (2018). 
Reduction of Selenoprotein S (Seps1) Impairs Exercise Tolerance.  
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4.1. Introduction  
Selenium is an essential micronutrient important for skeletal muscle health. Selenium 
is incorporated into selenoproteins through the Sec amino acid and then transported to 
peripheral tissues by SelP, where it is required for selenoprotein synthesis. Including 
SelP, there are 25 selenoproteins in the human selenoproteome which exert the 
biological effect of selenium [83]. As such, there is increasing interest surrounding the 
emerging roles of selenoproteins in skeletal muscle development and regeneration 
[139, 141], contractile function [137, 138, 147] [296] and exercise performance [147, 
157]. Particular attention surrounds the seven ER-resident selenoproteins, due to their 
importance to regulate redox state [11], ER stress [18, 179] and intracellular Ca2+ 
homeostasis [92, 115, 137, 138] (reviewed here [213]). These cellular processes have 
downstream implications for the regulation of inflammatory responses  and contractile 
function [384]. Transient increases in oxidative, ER and inflammatory stress activate 
signalling pathways mediating skeletal muscle growth, adaptation and repair [311, 
385-387]. Failure to regulate these stressors leads to a chronic cellular stress 
environment, commonly associated with disease and detrimental to contractile 
function. [388, 389] [22, 390, 391]. Thus, ER-resident selenoproteins may be required 
for skeletal muscle homeostasis, permitting optimal skeletal muscle health and 
contractile function.   
Seps1 is an ER–resident antioxidant, known to regulate oxidative, ER and 
inflammatory stress in various mammalian cell culture models (Reviewed here, [213]). 
In vitro, gene suppression of Seps1 leads to increased ROS levels [160], whereas, 
overexpression of Seps1 is protective against H2O2 induced cell toxicity [164, 165]. 
As an antioxidant, Seps1 is particularly potent against H2O2, while its optimal 
oxidoreductase activity appears dependent upon interactions with the thioredoxin 
antioxidant system [114, 172, 173].  
Localised to the ER membrane, Seps1 is part of a transmembrane multiprotein 
complex that facilitates the translocation of misfolded proteins out of the ER for 
degradation by the ubiquitin proteasome pathway [18, 179-181]. Validation of this is 
observed through the increase in Seps1 protein expression in response to ER stress 
stimulators, tunicamycin and thapsigargin, in vitro [161]. While the reduction of Seps1 
results in increased ER stress and reduced cell viability [161].  
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SEPS1’s role in inflammation has gained much attention, as gene polymorphisms, 
specifically the -105G>A promotor polymorphism, is associated with elevated 
circulating levels of the pro-inflammatory cytokines IL-1β, IL-6 and TNF-α in humans 
[180]. Seps1 expression is increased in response to the inflammatory stimulation of   
IL-1β and TNF-α [163, 183], while, the genetic reduction of Seps1 increased the 
secretion of IL-6 and TNF-α in vitro [180]. Consequently, Seps1 appears to regulate 
the cellular responses to oxidative, ER and inflammatory stress. As cells rarely 
experience these stressors in isolation, the regulatory capacity of Seps1 is of great 
interest [166, 167].  
Specific to skeletal muscle, the reduction of Seps1 by siRNA amplifies the cellular 
stress state in the glycolytic C2C12 proliferating myoblasts, resulting in reduced cell 
viability (Addinsall et al, Accepted for publication, Chapter 2). Although, this genetic 
reduction of Seps1 has minimal impact on cellular stress and cell viability measures in 
oxidative differentiated myotubes. This apparent glycolytic phenotype of Seps1 in 
skeletal muscle cells translates in vivo, as the genetic deletion of Seps1 in a global 
knockout mouse model impairs the thioredoxin antioxidant system and increases 
markers of ER stress, in the EDL muscle. However, the more oxidative phenotype of 
the Soleus muscle possessed a heightened thioredoxin antioxidant system following 
the deletion of Seps1 [296]. It is therefore becoming apparent that the Seps1 has fibre 
type specific phenotype.  
SEPS1 is highly expressed in fast muscle fibres from human vastus lateralis muscle 
and when genetically deleted in C57BL/6 mice, voluntary physical activity and muscle 
contractile function of the fast phenotype EDL is compromised [296]. However, the 
current mechanistic understanding of how the reduction of Seps1 impairs skeletal 
muscle health and contractile function is limited. One theory surrounds the implication 
in the thioredoxin and glutathione antioxidant pools [172, 296]. Whereas, other notions 
involve the regulation of inflammation, as the reduction of Seps1 amplified the 
inflammatory state and reduced muscle fibre size of the fast twitch EDL muscle in 
Seps1 reduced mdx mice [185]. However this effect on inflammation failed to translate 
into a loss of contractile function like that seen in the C57BL/6 mice [185]. 
Nevertheless, it is apparent that the genetic reduction of Seps1 is worse for fast 
phenotype skeletal muscle, resulting in impaired performance. 
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Tight regulation of cellular and inflammatory stress is crucial to optimal skeletal 
muscle fitness. Skeletal muscle produces ROS, including H2O2 as a result of muscle 
contraction [392]. A single exercise bout can stimulate these acute increases in 
oxidative and ER stressors, prompting cell signalling and in turn exercise adaption 
[264, 393, 394]. If unregulated, cellular stress is damaging to muscle constituents, 
leading to diminished performance [395]. Given the oxidoreductase capabilities of 
Seps1 and the recently observed regulation of cellular stress in glycolytic C2C12 
myoblasts [114, 172], it is of interest to determine if a reduction in Seps1 is beneficial 
or detrimental to exercise performance. Similarly, it was of interest to assess whether 
the genetic reduction or deletion of Seps1 would affect fast twitch TA contractile 
function following exercise in a more physiologically relevant model, in situ, where 
nerve and blood supply remain intact.  
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4.2. Materials and methodology  
4.2.1. Ethical approval  
All animal studies were approved by the Animal Ethics Committee of Latrobe 
University (AEC16-09). Animal care, maintenance and all procedures were conducted 
in accordance with the Australian Code of Practice for the Care and Use of Animals 
for Scientific Purposes. Global Seps1 knockout mice were generated on a C57BL/6 
background using PGK-Cre by A/Prof. Sof Andrikopoulos (Austin Health, The 
University of Melbourne) [185, 296]. Mice were group housed in standard laboratory 
conditions of 22  2 C and relative humidity of 55  8% with a 12 h light/dark cycle 
with access to water and a standard chow diet ad libitum.  
 
4.2.2. Treadmill exercise  
Mice were acclimatised to the rodent treadmill (Exer 3/6, Columbus Instruments, OH, 
USA) by being placed in the treadmill for 10 minutes prior to each bout of exercise. 
For the strenuous endurance exercise bout, mice ran on the rodent treadmill at a 2 º 
incline starting at a warm up speed of 5 m/min for 5 min. Every successive 5 min, the 
speed was increased by 5 m/min until voluntary cessation or a maximal speed 25 
m/min was reached [396]. Voluntary cessation was defined as an inability of the mouse 
to return to running in the third instance within 10 s of direct contact on treadmill rear 
plate. This strenuous endurance exercise protocol was repeated on three consecutive 
days, approximately 24 h apart. This exercise protocol was chosen, as it has previously 
been shown to upregulate ER stress and the unfolded protein response following 
exercise [396]. Exercise capacity was expressed as running time (min) and running 
distance (time (min) x distance (m)). Strenuous treadmill exercise was performed on 
Seps1-/- knockout mice (n =17), Seps1+/- heterozygous mice (n = 17) and wildtype 
littermates (n = 15). 
 
4.2.3. In situ muscle function testing. 
Isometric contractile properties of isolated fast twitch TA muscle was evaluated in situ. 
In situ muscle function testing of TA muscles was undertaken on the fourth day, 
approximately 24 h following the last exercise bout. The in situ contractile apparatus 
permits the assessment of differences in contractile function in a more physiologically 
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relevant environment, where the nerve and blood supply to the muscle remain intact. 
This allows the muscle to rely on perfusion and physiological oxygen concentrations 
to receive oxygen and nutrients and to remove CO2 and waste products of metabolism, 
while the muscle is stimulated directly by the nerve. However, the in situ apparatus is 
only suitable for muscles that possess an accessible insertion point and tendon. The 
anatomical features of the TA determine its suitability to this type of assessment. As 
we have previously shown Seps1 to have a fast fibre type effect on contractile function, 
the fast phenotype nature of the TA provides an advantageous model to further 
characterise the role of Seps1 in muscle contraction.  
The in situ contractile apparatus has previously been described [397, 398]. Briefly, 
mice were anaesthetised via intraperitoneal injection of sodium pentobarbitone 
(Nembutal, 60 µg/g). Once a mouse was unresponsive to tactile stimuli, the distal 
portion of the TA muscle and its tendon were exposed. The tendon was tied with a top 
and bottom knot using two lengths of 5.0 braided surgical thread (Ethicon, Johnson & 
Johnson, NSW, AUS). The distal tendon was then severed, and the TA was carefully 
dissected free from surrounding tissue. The sciatic nerve was exposed by gently 
parting the biceps femoris muscle above the knee joint. The mouse was secured 
proximally via a pin behind the patella tendon and a distal foot clamp on the heated 
platform (37 oC) of an in situ Mouse Apparatus (809B, Aurora Scientific, Ontario, 
Canada). The distal end of the TA was tied firmly to a lever arm attached to an 
isometric force transducer. Throughout the experiment, warmed physiological saline 
(0.9%) was applied to exposed muscle and nerve tissue. 
The TA was stimulated to produce a maximum isometric contraction by applying 
supramaximal square wave pulses (10 V, 0.2 ms square wave pulses, 300 ms train 
duration) to the sciatic nerve using a custom-built hook electrode coupled to a 
stimulator (701C stimulator, Aurora Scientific, Ontario, Canada). All stimulation 
parameters and contractile responses were controlled and measured using Dynamic 
Muscle Contraction 611A software (DMC, Aurora Scientific, Ontario, Canada), with 
on board controller interfaced with the transducer control/feedback hardware.  
The contractile function testing protocol began with a 100 Hz tetanic contraction to 
ensure knots were tight, prior to the determination of Optimal muscle length (Lo) via 
micromanipulations of muscle length and a series of isometric twitch (Pt, 1 Hz) 
contractions. Following a 2 min rest, maximum isometric tetanic force (Po) was 
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determined from the FFC relationship, where muscles were stimulated at 10, 20, 30, 
40, 50, 80, 100, 150 and 200 Hz with 2 min rest between each stimulation.  
Following completion of the FFC, TA muscles were then rested for 4 min, before 
assessing their tolerance to intermittent, repeated contractile activity and as an 
indicator of fatigability. Muscles were maximally (100 Hz) once every 5 s for 4 min. 
Force recovery was assessed at 100 Hz at 30 s, 1 min, 2 min and 3 min post fatigue 
testing. Following which, the muscle was again rested for 2 min before the muscles 
were stimulated at 1, 10, 20, 30 and 100 Hz. These tests determine the reproducibility 
of the results obtained during the FFC, as the reduction of Seps1 has previously shown 
to effect fast twitch contractile function following high frequency stimulation [296].   
Po values were normalised to muscle cross sectional area and expressed as specific 
force (sPo, KN m
-2), as described above [349]. Muscle fibre length (Lf) was determined 
by multiplying Lo by the previously determined Lf/Lo ratio, 0.6 for the TA [399]. 
Within minutes of completing contractile function testing, the mouse was euthanised 
by cardiac puncture, TA were trimmed of tendons, weighed and embedded in optimal 
cutting temperature compound (TissueTek OCT Compound, ProSciTech, Kirwan, 
AUS), and frozen in thawing isopentane (Sigma-Aldrich, Castle Hill, AUS) for 
histological analysis. The contralateral TA was excised and snap frozen in liquid 
nitrogen for gene expression analysis, therefore it must be stated that these muscles 
did not undergo the stress of function testing which is in contrast to muscle used for 
gene analysis in the ex vivo studies by our laboratory [185, 296].  Blood was allowed 
to clot on ice, and then centrifuged at 13,400 rpm for 5 min. The serum was carefully 
collected by separation at 13,500 g for 5 min and stored at -80 oC until analysis for 
creatine kinase enzyme activity and pro-inflammatory cytokines. In situ TA contractile 
function testing was performed on Seps1-/- knockout mice (sedentary, n = 16, 
exercised, n = 14), Seps1+/- heterozygous mice (sedentary, n = 15, exercised, n = 14), 
and wildtype littermates (sedentary, n = 14, exercised, n = 14). 
 
4.2.4. Western blotting 
To assess the protein expression of Seps1, macrophage markers cluster of 
differentiated (CD) 68 and F480, 10 x 10 μm thick TA muscle cross-sections from 
Seps1+/- heterozygous and Seps1-/- homozygous mice and wild type littermates were 
lysed in 50 μL of 2x Laemmelli sample buffer (Bio-Rad), as previously described 
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[296]. Briefly, 5 L cyrosection lysates were separated on a 4-15% gradient TGX 
Stain-Free™ criterion gel (Bio-Rad) at 100 V. Following which the gel was activated 
and proteins visualised using the Chemidoc™ XRS system (Bio-Rad). Proteins were 
then transferred to PVDF membranes using a Turbo Blot Transfer System (Bio-Rad) 
at 2.5 A and 25 V for 12 min. Membranes were blocked with 5% skim milk in TBS 
containing 0.1% Tween-20 (TBS-Tween), before being incubated for 1 h with the anti-
Seps1 antibody (HPA010025, Sigma-Aldrich, diluted 1:200 in 1% BSA in TBS-
Tween), anti-CD68 (ab125212, Abcam, diluted 1:500 in 1% BSA in TBS-Tween) or 
anti-F480 (ab6640, Abcam, diluted 1:1000 in in 1% BSA in TBS-Tween). The blots 
were then incubated for 1 h with a goat anti-rabbit HRP-linked secondary antibody 
(cat #: 111 035 003, Jackson Labs, lot: 120104, diluted 1:2500 in 1% BSA in TBS-
Tween) or anti-rat HRP-linked secondary antibody (cat #: 31470, Thermo Fisher 
Scientific, lot: RF236103, diluted 1:5000 in 1% BSA in TBS-Tween). Blots were 
imaged using ECL chemiluminescence. Band densitometry was performed using 
Quantity One® software (Bio-Rad) on the western blots and on the stain free gels to 
confirm even loading. Protein expression was normalised to the optical density of the 
total protein on the stain free protein gel. [354, 356]. Western blotting was performed 
on TA muscle of Seps1-/- knockout mice (sedentary, n = 6, exercised, n = 7), Seps1+/- 
heterozygous mice (sedentary, n = 6, exercised, n = 7) and wildtype littermates 
sedentary, n = 7, exercised, n = 7). 
 
4.3.5. Histology  
Eight μm thick frozen cross sections were cut from the mid-belly region of TA 
muscles. H&E (Sigma-Aldrich) staining was used to qualitatively examine for muscle 
cross-sections from exercised and sedentary Seps1-/- knockout mice (n = 7), Seps1+/- 
heterozygous mice (n = 7) and wildtype littermates (n = 7) for markers of muscle 
pathology, specifically centrally nucleated fibres and areas of degeneration and 
mononuclear infiltrate. Representative digital images of H&E stained muscle were 
captured at 200x magnification (DM1000 upright microscope, Leica).  
Muscle fibre cross sectional area (CSA) was assessed using fluorescently labelled 
WGA, as previously described [296]. WGA stained muscle cross sections from 
sedentary mice were imaged using a fluorescent light imager at 200x (Zoe, Bio-Rad, 
Hercules, USA). All image analysis was completed using Image-Pro Plus software 
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(Media Cybernetics, Rockville, USA). A custom-built macro was set-up to isolate cell 
membrane specific positive fluorescence using thresholding to calculate minimum 
Feret’s diameter, with 708 ± 28 muscle fibres quantified per cross-section [296]. Fibre 
CSA was assessed in TA muscles from sedentary Seps1-/- knockout mice (n =7), 
Seps1+/- heterozygous mice (n = 8) and wildtype littermates (n = 7). Exercised mice 
were exempt from CSA analysis, as alteration of fibre size occurs weeks after exercise 
initiation, thus the acute exercise utilised here would not alter fibre size 96 h following 
exercise initiation [400].  
 
4.2.6. Immunohistochemistry for inflammatory cell infiltration  
Myeloperoxidase (MPO) is expressed in neutrophils, while CD68 is expressed in 
monocytes and macrophages, thus MPO and CD68 immunohistochemistry was 
undertaken to assess inflammatory cell infiltration in the TA muscle following 
exercise. Muscle sections were fixed in 4% PFA for 10 min and endogenous 
peroxidase activity was blocked with 1.5% H2O2 in 0.5 M TRIS-buffered saline (TBS) 
for 5 min. Sections were permeabilised in 0.5% TBST for 10 min, and then incubated 
with a serum free blocking solution to minimise non-specific staining (Dako, #X0909). 
Positive muscle sections were reacted for 1 h with either anti-MPO (ab65871, Abcam, 
1:100) or anti-CD68 (ab125212, Abcam, 1:500) 1° antibody made up in antibody 
diluent (Dako, #S3022), followed by a 30 min incubation with anti-Rabbit-HRP linked 
2° antibody (111035003, Jackson labs, 1:500-1000). To detect MPO positive 
neutrophils or CD68 positive macrophages, the 3-amino-9-ethylcarbazole (AEC, 
Sigma-Aldrich Cat# AEC10-1) substrate chromogen was used. Nuclei were 
counterstained with haematoxylin (Sigma-Aldrich, Mayer’s solution, cat# MHS32-
1L) for 5 min. A no primary and a no secondary control were included with all analyses 
to control for non-specific peroxidase activity and secondary antibody staining. A 
cross section of a TA from an mdx mouse or wildtype spleen was included as a positive 
control. CD68 positive macrophages were counted under a light microscope by two 
independent persons with a R2 value of 0.966. Representative images were captured at 
400x magnification (DM1000 upright microscope, Leica). Staining was performed on 
TA muscle of Seps1-/- knockout mice (sedentary, n = 7, exercised, n = 7), Seps1+/- 
heterozygous mice (sedentary, n = 9, exercised, n = 7) and wildtype littermates 
(sedentary, n = 7, exercised, n = 7). 
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4.2.7. CK assay  
As a marker of exercise induced damage, serum creatine kinase (CK) activity was 
measured using a commercially available kit (Sigma-Aldrich, MAK116), as per 
manufacturer’s instruction. Neat serum samples were loaded with enzyme substrate 
buffer, before the colorimetric reaction was measured at 340 nm every minute for 25 
min until reaction plateau, ensuring measurement within the linear range. A blank and 
calibrator were included, allowing CK activity to be calculated (((17 min -15 
min)*150)/ (Calibrator-Blank)) and expressed as units/L.  All determinations were 
performed in duplicate with an intraassay coefficient of variation of 3.05% and an 
interassay coefficient of variation of 4.66%. CK was performed on Seps1-/- knockout 
mice (sedentary, n = 13, exercised, n = 16), Seps1+/- heterozygous mice (sedentary, n 
= 13, exercised, n = 16) and wildtype littermates (sedentary, n = 15, exercised, n = 14). 
 
4.2.8. Multiplex assay for serum cytokines 
To assess serum cytokine levels following exercise, IL-6, TNF-α and  MCP-1 were 
measured in serum from sedentary and exercised mice Seps1 GKO mice using a 
custom designed Mouse High Sensitivity T Cell magnetic bead panel (EMD Millipore, 
MHSTCMAG-70k), as per manufacturer’s instructions. Briefly, 25 μl of standards or 
serum were loaded in duplicate with 25 μl of assay buffer and 25 μl of premixed 
antibody coated beads, before the plate was sealed and incubated on a plate shaker 
overnight at 4 oC. Following this incubation, 25 μl of detection antibody was added 
and allowed to incubate for 1 h at room temperature. Samples were incubated in 25 μl 
of streptavidin-phycoerythrin for colorimetric detection for 30 min. Samples were 
resuspended in 150 μl of sheath fluid prior to analysis on the BioPlex Suspension Array 
System (V.5.0, Bio-Rad) using the 5-parameter logistic curve. Multiplex was 
performed on Seps1-/- knockout mice (sedentary, n = 14, exercised, n = 17), Seps1+/- 
heterozygous mice (sedentary, n = 14, exercised, n = 16) and wildtype littermates 
(sedentary, n = 16, exercised, n = 15). 
 
4.2.9. Real Time Quantitative PCR (qPCR) 
Approximately 20 μg of contralateral TA muscles (did not undergo function testing) 
were homogenised in Bacterial lysis (BL) + Tris/Glycine (TG) buffer (Promega, 
Alexandra, AUS). Total cellular RNA was extracted and purified using a RelinaPrepTM 
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RNA Miniprep kit (Promega, Z6112). A GoScriptTM reverse transcription mix 
(Promega, A2790) was used to reverse transcribe 1 μg of total RNA. Quantitative RT-
PCR was performed using GoTaq® qPCR master mix (Promega, A6002) and 
oligonucleotide primers for the genes of interest (Table 4.1). cDNA concentrations 
were determined using Quant-iT™ OliGreen® ssDNA reagent (Thermo Fisher 
Scientific), and Ct values were normalised to cDNA content. Gene expression analysis 
was performed on TA muscle of Seps1-/- knockout mice (sedentary, n = 12, exercised, 
n = 12), Seps1+/- heterozygous mice (sedentary, n = 12, exercised, n = 12) and wildtype 
littermates (sedentary, n = 11, exercised, n = 12). 
 
Table 4.1: Mouse Primers used for qRT-PCR 
 Forward Primer (5’ to 3’) Reverse Primer (5’ to 3’) 
Atf3 GCTGCCAAGTGTCGAAACAAG CAGTTTTCCAATGGCTTCAGG 
Chop GTCCCTAGCTTGGCTGACAGA TGGAGAGCGAGGGCTTTG 
Grp94 TCCATCTCTTCTCCCTCATCC CGGCAACACTTCGGTCAG 
Ho-1 CAGCTCTATCGTGCTCGAATGA GGCGGTCTTAGCCTCTTCTGT 
Il-6 CCGGAGAGGAGACTTCACAG CAGAATTGCCATTGCACAAC 
Mcp-1 GCCTGCTGTTCACAGTTGCC 
GCCTACTCATTGGGATCATCTTG
C 
Tgf-1 TGGAGCAACATGTGGAACTC GTCAGCAGCCGGTTACCA 
Tnf CCCCAAAGGGATGAGAAGTT GGTCTGGGCCATAGAACTGA 
Txnip ATCGTGGCGTGGCAAGAG 
CGTAGATCAGCAAGGAGTATTC
G 
Txr1 
CGTGGTGGACTTCTCTGCTACGT
GGTG 
GGTCGGTATGCATTTGACTTCAC
AGTC 
Xbox1(s
) 
GAGTCCGCAGCAGGTG GTGTCAGAGTCCATGGGA 
 
4.2.10. Statistical analyses 
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All results are presented as mean ± SEM. For experiments characterising the Seps1 
global knockout mice, differences between Seps1-/- knockout mice and wild type 
littermates or Seps1+/- heterozygous mice and wild type littermates were investigated. 
Separate analysis was undertaken as we wished to examine the effects of the deletion 
of Seps1, but also the more physiologically relevant genetic reduction of Seps1 in 
isolation. Treadmill running and contractile function testing experiments were 
analysed using 3-way general linear model (GLM) ANOVA, with the factors being 
genotype, exercise activity, and time or Hz, respectively. Experiments possessing 
factors of analysis including genotype and exercise activity were assessed by 2-way 
GLM ANOVA. The min feret/CSA experiment was analysed by 1-way GLM 
ANOVA, while the comparison of high frequency fatigue was analysed using a 
dependent t test. All statistically significant findings were defined by Tukey post hoc 
analyses. All statistical analyses were performed using Minitab statistical software v17 
(Sydney, AUS), with P < 0.05 being statistically significant.  
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4.3. Results  
4.3.1. The genetic deletion of Seps1 impairs exercise capacity. 
Consistent with previous reports in these mice [296], the genetic reduction of Seps1 
was successful – with a 50% knockdown of Seps1 protein levels in Seps1+/- 
heterozygous mice, while Seps1 protein levels were almost completely abolished in 
Seps1-/-
 
knockout mice (P= 0.001, Fig 4.1A). After three days of treadmill running at 
increasing intensity, Seps1 protein levels were similar in sedentary and exercised wild 
type or Seps1+/- heterozygous mice, suggesting exercise did not affect Seps1 
expression (Fig 4.1A). Similarly, Seps1 mRNA transcripts did not significantly differ 
between sedentary and exercised wild type mice (Fig 4.1B).  
The genetic reduction and deletion of Seps1 impaired exercise endurance. During the 
three days of treadmill running, the Seps1-/-
 
knockout mice ran 17% less distance than 
their wildtype littermates (P< 0.001, Fig 4.1C), while a 9% reduction in distance run 
was evident in the Seps1+/- heterozygous mice (P= 0.027, Fig 4.1C). Completion of 
the exercise protocol was used as an additional measure of exercise capacity. 
Approximately 20% of the wild type mice did not complete the exercise protocol and 
had to be removed from the treadmill in abidance with the voluntary cessation of 
exercise guidelines. In contrast, ~40% of Seps1+/- heterozygous mice and up to ~80% 
of Seps1-/-
 
knockout mice were unable to complete the 25 min exercise protocol (Fig 
4.1D). Thus, it appears that Seps1 mRNA and protein expression is not affected by the 
exercise stimulus utilised in this study, however if expression is reduced then it leads 
to compromised exercise performance.  
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Figure 4.1: Deletion of Seps1 impairs exercise capacity. A, Seps1 Protein levels 
were reduced by ~ 50 and 90% in TA muscle of Seps1+/- heterozygous and Seps1-/-
 
knockout mice, respectively, when compared with wildtype litter mates. Seps1 gene 
(B) and protein (A) expression was not significantly altered by exercise. C, The 
Deletion and the reduction of Seps1 caused reduced exercise distance during three 
consecutive exercise bouts as compared to wildtype littermates. D, The percentage of 
mice which were unable to complete the full exercise protocol was assessed. Seps1-/-
 
knockout and Seps1+/- heterozygous mice were unable to complete consecutive bouts 
of exercise to a greater rate than their wildtype littermates. † P<0.001- Main effect for 
genotype, when compared to wildtype littermates, as determined by 2-way ANOVA. 
 
4.3.2. The genetic reduction or deletion of Seps1 impairs the contractile function of 
fast TA muscles in situ.  
Consistent with our previously published findings [296], body weight, TA muscle 
mass, and the TA muscle mass:body weight ratio were not significantly affected by 
the genetic reduction or deletion of Seps1 (Table 4.2).  
Three bouts of increasing intensity treadmill running, did not significantly alter TA 
twitch contractile properties, Pt, TPT, Dx/Dt or ½RT, in Seps1
+/- heterozygous, Seps1-
/- knockout or their wild type littermates when compared to sedentary mice (Table 4.2). 
Analysis of Pt contractile properties can provide insight into whether the genetic 
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reduction or deletion of Seps1 and/or the exercise protocol affected Ca2+ handling, 
fibre type composition and/or actin-myosin cross-bridge cycling [364-367]. Given the 
short exposure to exercise utilised in this study, changes in fibre type composition are 
unlikely. While observation of any alteration of E-C coupling is improbable as 24 
hours of rest was given to the mice between each exercise bout [401]. 
The genetic reduction or deletion of Seps1 did affect TA twitch contractile properties. 
Specifically, Pt, TPT and Dx/Dt but not ½RT, were reduced in Seps1
-/- knockout mice 
when compared with wildtype littermates (P< 0.001 and P= 0.037, respectively). This 
reduction in TPT was also observed in Seps1+/- heterozygous mice (P=0.038), which 
was accompanied by a trend towards reduced Pt (P= 0.053), however the fate of Pt 
development was unchanged.  
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Values shown are mean ± SEM.TA, tibialis anterior, CSA, Cross sectional area, Pt, maximum twitch force, TPT, time to peak twitch, ½ RT, one-half 
relaxation time, Dx/Dt, rate of twitch force development, Po, maximum tetanic force, sPo, maximum tetanic force normalised to CSA. 
a P < 0.05 – main 
effect for genotype when compared with wildtype littermates, as determined by 2-way repeated measures ANOVA. Seps1-/- knockout mice (Sedentary, 
n =17, Exercised, n = 17), Seps1+/- heterozygous mice (Sedentary, n = 15, Exercised, n = 15) and wildtype littermates (Sedentary, n = 16, Exercised, n = 
15).
Table 4.2: Mouse anthropometrics and twitch contractile properties of the TA muscle 
  Wildtype Seps1 +/- Seps1-/- 
  Sedentary Exercised Sedentary Exercised Sedentary Exercised 
Body Weight (BW, g) 27.34 ± 0.35 26.17 ± 0.63 26.52 ± 0.56 27.39 ± 0.36 26.49 ± 0.44 26.77 ± 0.40 
Muscle Weight (MW, mg) 56.67 ± 1.32 54.98 ± 1.73 53.75 ± 1.72 55.86 ± 1.12 54.84± 0.99 55.44 ± 1.24 
MW:BW ratio 0.002 ± 0.00 0.002 ± 0.00 0.002 ± 0.00 0.002 ± 0.00 0.002 ± 0.00 0.002 ± 0.00 
Muscle Length (mm) 11.73 ± 0.26 11.49 ± 0.15 10.65 ± 0.13a 11.01 ± 0.28a 11.09 ± 0.20a 11.08 ± 0.21a 
CSA (mm2) 7.68 ± 0.30 7.54 ± 0.26 7.97 ± 0.30 7.98 ± 0.30 7.80 ± 0.16 7.71 ± 0.23 
Pt (mN/mm2) 68.59 ± 5.30 69.61 ± 3.94 59.48 ± 4.16 59.71 ± 3.75 57.36 ± 2.35
a 54.43 ± 4.10a 
TPT (ms) 228.79 ± 1.03 226.77 ± 1.09 226.01 ± 0.84 a 225.70 ± 0.62 a 225.53 ± 0.62a 226.41 ± 0.65a 
Dx/Dt (mN/ms) 26.77 ± 1.08 28.11 ± 0.99 25.74 ± 1.26 26.21 ± 1.01 25.30 ± 0.92a 22.80 ± 1.56a 
½ RT (ms) 20.71 ± 1.25 19.67 ± 1.80 18.55 ± 1.14 17.79 ± 1.10 17.54 ± 0.61 18.76 ± 1.11 
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To assess the maximal, isometric force producing capacity, TA muscles were 
stimulated with increasing frequency (1-200 Hz) with 2 min rest between each 
contraction to protect against fatigue. In line with the twitch data, three bouts of 
treadmill running did not significantly alter TA muscle strength, as absolute force (Po) 
and sPo
 (force normalised to muscle size) did not differ in exercised Seps1+/- 
heterozygous mice, Seps1-/- knockout mice or wild type littermates when compared to 
their respective sedentary controls. However, the genetic reduction or deletion of 
Seps1 did impair TA muscle strength. With regards to both Po and sPo, TA muscles 
from sedentary or exercised Seps1+/- heterozygous or Seps1-/-
 
knockout mice presented 
with a downward shift in the FFC, when compared to sedentary or exercised wildtype 
littermates (P< 0.001, Fig 4.2A and B). To determine whether exercise or Seps1 
expression affects force output in response to changes in stimulation frequency, force 
was expressed as a percent of maximal sPo at 200 Hz. Neither exercise, nor the genetic 
reduction or deletion of Seps1 had a significant effect on the rate of maximal force 
production in the TA, which was consistent with finding in the fast twitch EDL muscle 
ex vivo (Fig 4.2C and D)[296].  
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Figure 4.2: Reduction of Seps1 impairs Tibialis anterior force production in situ. 
The genetic  A, reduction and B, deletion of Seps1 reduced muscle strength normalised 
to muscle size (sPo), as indicated by a downward shift of the FFC in TA muscles of 
sedentary and exercised Seps1+/- heterozygous and Seps1-/-
 
knockout mice when 
compared to sedentary and exercised  wildtype littermates. C and D, FFC was also 
expressed as a percentage to determine how the reduction or deletion of Seps1 affects 
muscle force output in response to changes in stimulation frequency. No change in 
force development was observed with the reduction of Seps1-/-
 
knockout mice and 
Seps1+/- heterozygous. * P < 0.001 – main effect for genotype in Seps1+/- heterozygous 
and Seps1-/-
 
knockout when compared with wildtype littermates, as determined by 3-
way repeated measures ANOVA.  
 
 
To determine whether the genetic reduction or deletion of Seps1 affects the endurance 
of fast twitch muscles in sedentary or exercised mice, TA muscles underwent 4 min of 
intermittent stimulation at 100 Hz. Force recovery was assessed 30 sec, 1 min, 2 min 
and 3 min post the fatiguing stimuli. The rate of fatigue and force recovery were 
expressed as a percentage of initial force. In wild type mice, the exercise protocol did 
not significantly alter the rate of fatigue or force recovery (Fig 4.3A). In sedentary 
Seps1+/- heterozygous mice, the rate of fatigue did not significantly differ when 
compared to sedentary, wild type littermates (Fig 4.3A). However, following three 
bouts of treadmill running, the genetic reduction of Seps1 increased fatigability and 
impaired force recovery of Seps1+/- heterozygous TA muscles (P< 0.001, Fig 4.3A). 
The effects of treadmill running on TA muscles from Seps1+/- heterozygous mice were 
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long lasting, as contractile function testing was performed 24 h after the completion of 
the last exercise bout.  
TA muscles from sedentary Seps1-/- knockout mice fatigued more than TA muscles 
from sedentary wild type littermates (P< 0.001, Fig 4.3B). This increase in fatigue, 
was also observed in TA muscles from exercised Seps1-/- knockout mice albeit to a 
less extent (P< 0.001). The exercise protocol therefore stimulated adaptations in TA 
muscles from Seps1-/- knockout mice, such that the rate of fatigue and force recovery 
was attenuated when compared to TA muscles from sedentary Seps1-/- knockout mice.  
We have previously shown that the genetic reduction and deletion of Seps1 impaired 
EDL force production ex vivo following high frequency stimulations. Here, in TA 
muscles tested in situ, no such force deficit was observed in Seps1-/- knockout or 
wildtype mice when the force output of the first 100 Hz stimulation of the fatigue was 
compared to the 100 Hz force output of the FFC. However, in Seps1+/- heterozygous 
mice, the additional stress of exercise led to an 8% reduction in force between the FFC 
and the first stimulation of the fatigue protocol (P= 0.023, Fig 4.3C). These 
observations, together with the in situ fatigueability data, suggest that exercise 
stimulates specific adaptions to muscle endurance which differ depending on whether 
Seps1 is reduced or deleted. Whereas, the effects of Seps1 on muscle strength appear 
independent of exercise. 
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Figure 4.3: Reduction of Seps1 impairs Tibialis anterior fatigue tolerance in situ. 
A and B, Rate of fatigue, was expressed as percent (%) of initial force, to determine 
how the reduction of Seps1 effects rate of fatigue. The genetic A, reduction and B, 
deletion of Seps1 effects the rate of fatigue in TA muscle of exercised Seps1+/- 
heterozygous and sedentary and exercised Seps1-/- knockout mice when compared with 
exercised wildtype littermates. The reduction and deletion of Seps1 continues to impair 
rate of recovery up to 3 minutes post fatigue, as seen in the exercised Seps1+/- 
heterozygous and sedentary Seps1-/- knockout mice, when compared with exercised 
wildtype littermates. C, The specific force produced at 100 Hz stimulation from the 
FFC was compared to the specific force produced by the first contraction of the 
intermittent, submaximal (100 Hz) stimulation fatigue protocol (FAT).  Specific force 
output was maintained in TA muscles from wildtype mice, whilst a significant 
decrease was observed in TA muscles from Seps1+/- heterozygous mice (C). D, 
Specific force of TA of Seps1-/- knockout was not significantly affected. † P < 0.05 – 
Genotype*Activity interaction in when compared with exercised wildtype littermates, 
as determined by 3-way repeated measures ANOVA. * P < 0.001 – Main effect for 
Genotype when compared with wildtype littermates, as determined by 3-way repeated 
measures ANOVA. ‡ P < 0.001 – Main effect for activity when compared with 
exercise, as determined by 3-way repeated measures ANOVA. + P < 0.05 for the 
difference in force output between 100 Hz stimulation from the FFC and the first 
contraction of the 100 Hz fatigue protocol, as determined by a paired T-test. 
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4.3.3. Altered Seps1 expression fails to effect muscle morphology 
H&E staining was used to examine muscle morphology, specifically, the proportion 
of centrally nucleated fibres and the areas of degeneration and mononuclear infiltrate 
in sedentary and exercised Seps1 GKO mice (Fig 4.4A-F). H&E staining of sedentary 
or exercised Seps1+/- heterozygous and Seps1-/- knockout mice was comparable to 
sedentary or exercised wild type littermates. Specifically, there was no apparent 
increase in mononuclear infiltrate and centrally nucleated fibres, hallmarks of muscle 
damage and repair (Fig 4.4A-F). This is in concordance with quantitative analyses in 
the EDL and Soleus muscles from Seps1 global knockout mice [296] (refer chapter 3). 
Given that muscle fibre cross-sectional area can affect muscle strength [402], minimal 
feret diameter was measured in TA muscle cross-sections from sedentary Seps1+/- 
heterozygous, Seps1-/- knockout or their wild type littermates. WGA staining as used 
to determine whether the downward shift in the FFC could be mediated by a reduction 
in muscle fibre size. As was previously observed in fast EDL and slower Soleus 
hindlimb muscles [296], the genetic reduction or deletion of Seps1 had no significant 
effect on TA muscle fibre size (Fig. 4.4G and 5H).  
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Figure 4.4: The reduction of Seps1 has no effect on muscle morphology. 
Representative images of sedentary (A, B and C) and exercised (D, E and F) Seps1+/+ 
wildtype, Seps1+/- heterozygous and Seps1-/- knockout mice TA morphology, 
respectively. G, The reduction or deletion has no effect on cross sectional area (CSA) 
of sedentary TA myofibre, as determined by min feret diameter. H, Nor did the 
reduction or deletion effect fibre size distribution of sedentary TA muscles. Scale= 
50µm 
 
4.3.4. Exercise has modest effects on inflammation with the reduction of Seps1.  
Multiplex analysis was employed to measure serum cytokine levels on samples 
collected immediately following contractile function testing 24 h post exercise. In 
Seps1-/- knockout mice and wild type litter mates, circulating IL-6 concentrations 
tended to be elevated 24 h following the third bout of treadmill running, however failed 
to reach significance (P= 0.08, Fig 4.5A). IL-6 is known to be an exercise responsive 
myokine, secreted by contracting muscles [403, 404]. Following the commencement 
of strenuous exercise, circulating IL-6 is elevated. However upon cessation of exercise 
IL-6 dramatically drops, highlighting a brief window in which IL-6 response to 
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exercise may be detected [405, 406]. These data suggest that exercise may have 
stimulate the immune system, although measurement 24 h post exercise may have been 
too late to comprehensively assess the transient inflammatory stress responses 
associated with exercise. The concentration of circulating pro-inflammatory cytokines 
MCP-1 and TNFα are associated with muscle damage [407], however these were not 
increased in response to the exercise protocol. Moreover, the genetic reduction or 
deletion of Seps1 did not affect circulating IL-6 and MCP-1 concentrations (Fig 4.5A 
and 4.5B, respectively). However, in sedentary Seps1+/- heterozygous mice circulating 
TNFα levels were increased when compared to sedentary wild type littermates (P< 
0.005, Fig 4.5C). This effect in Seps1+/- heterozygous mice was lost with exercised. To 
confirm this was not a result of muscle damage, serum CK activity, a well-recognised 
maker of muscle damage was measured [408, 409]. CK levels did not increase in 
response the exercise protocol and/or the genetic reduction or deletion of Seps1 (Fig 
4.5D). 
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Figure 4.5: Circulating inflammatory profile in Seps1-/- GKO mice is unaffected 
by exercise.  As a marker of circulating inflammation Interlukin-6 (IL-6, A), Monocyte 
chemoattractant protein-1 (MCP-1, B) and Tumour necrosis factor-α (TNF-α, C) were 
measured in serum of sedentary and exercised Seps1+/- heterozygous, Seps1-/- knockout 
and their wildtype littermates. Neither the exercise bout or genetic reduction or 
deletion of Seps1 had statistical effect upon serum A, IL-6 or B, MCP-1, however C, 
TNF-α concentration were amplified in sedentary Seps1+/- heterozygous when 
compared to sedentary wildtype littermates. As a measure of exercise induced damage 
creatine kinase (CK) was measured, however neither the genetic reduction or exercise 
bout increased CK levels 24 hours post exercise (D). † P < 0.05 – Genotype*Activity 
interaction in when compared with exercised wildtype littermates, as determined by 2-
way repeated measures ANOVA. 
 
To comprehensively assess the effects of Seps1 reduction or deletion and exercise on 
muscle inflammation, neutrophil, monocyte and macrophage infiltration was assessed 
in muscle cross-sections using immunohistochemistry. Immunoreactivity for MPO 
was used to assess neutrophil infiltration, while CD 68 was used to assess monocyte 
and macrophage infiltration in TA muscle cross-sections. In line with serum CK, 
MCP-1 and TNFα data, the exercise protocol failed to stimulate the infiltration of MPO 
positive neutrophils, while mdx and spleen positive controls ensured the integrity of 
these observations (data not shown). The number of CD68 positive monocytes and 
macrophages did not significantly differ between sedentary or exercised Seps1+/- 
heterozygous mice, Seps1-/- knockout mice and their wildtype littermates when 
normalised to muscle cross sectional area (Fig4. 6A-F and J). This result was 
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confirmed in whole TA muscle lysates by immunoblotting, as no change was detected 
in CD68 and F480 [410] protein levels (Fig 4.6K and L).  
 
 
Figure 4.6: Monocyte infiltration is unchanged with the reduction of Seps1. 
Representative images of sedentary (A, B and C) and exercised (D, E and F) Seps1+/+ 
wildtype, Seps1+/- heterozygous and Seps1-/- knockout mice TA muscle CD68 positive 
macrophages. G, mdx Positive control. H, Primary antibody control. I, Secondary 
antibody control. Neither the genetic J, reduction, nor deletion of Seps1 or exercise 
had an effect on CD68 positive macrophages in TA of Seps1+/- heterozygous and Seps1-
/- knockout mice when compared with wildtype littermates. K, CD68 and L, F480 
protein expression was unaltered by exercise or the reduction or deletion of Seps1. 
Scale= 100µm. 
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Even in the absence of overt muscle damage, skeletal muscle can be a source of 
cytokines, such as IL-6 [411] and MCP-1 [412], which can act in paracrine manner, 
initiating cellular adaptation[413, 414]. Therefore, qRT-PCR was used to assess 
whether exercise and or the genetic deletion or reduction of Seps1 affects the mRNA 
transcript abundance of Il-6, Mcp-1, Tnfα, and Tgfβ in a muscle specific manner in TA 
muscle. At 24 h post exercise, Il-6 mRNA expression was not significantly affected by 
exercise, nor was it was affected by the genetic reduction or deletion of Seps1 in the 
contralateral TA muscle, which did not undergo in situ contractile function testing (Fig 
4.7A). Interestingly, these results in muscle differ from that observed in circulation, as 
circulating IL-6 tended in increase following exercise (Fig 4.5A). However, given the 
short half-life of circulating IL-6, one must also consider that the elevated transcript 
levels of Il-6 may also have been surpassed when measured 24 hours post exercise.  
In Seps1-/- knockout mice and wild type littermates, the exercise bout was associated 
with a modest decrease in mRNA transcript abundance of Mcp-1, Tnfα and Tgfβ (P= 
0.033, P= 0.021 and P= 0.011, respectively, Fig 4.7). This modest effect of exercise 
on the gene expression of these pro-inflammatory cytokines was lost when Seps1+/- 
heterozygous mice and wild type littermates were compared (Fig 4.7). Irrespective of 
exercise, the genetic reduction or deletion of Seps1 did not alter the Mcp-1, Tnfα or 
Tgfβ mRNA transcript abundance. Combined, this data demonstrates that in a 
sedentary or exercised mouse model, without significant damage or disease, the 
genetic reduction or deletion of Seps1 has minimal effect on muscle specific 
inflammation.  
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Figure 4.7: Exercise impairs the inflammatory profile in TA of Seps1-/- knockout 
mice. Gene expression of sedentary (solid) and exercised (striped) Seps1+/+ wildtype, 
Seps1+/- heterozygous and Seps1-/- knockout mice TA muscle. A, inflammation 
Interleukin-6 (Il-6), B, Monocyte chemoattractant protein-1 (Mcp-1), C, Tumour 
necrosis factor-α (Tnf-α), or D, Transforming growth factor β (Tgf-β) was no 
significantly changed by the reduction or deletion of Seps1 in sedentary mice. Whereas 
exercise significantly reduced Mcp-1, Tnf-α, and Tgf-β gene expression in TA muscle 
of Seps1-/- knockout mice. * P < 0.05 – Main effect for Activity, as determined by 2-
way repeated measures ANOVA.  
 
4.3.5. Exercise alters gene markers of cellular stress in TA muscles from Seps1 deleted 
mice. 
To investigate whether the genetic reduction or deletion of Seps1 altered cellular stress 
responses in sedentary or exercised mice, qRT-PCR was used to assess the expression 
of ER and oxidative stress associated genes in contralateral TA muscles (which had 
not undergone contractile function testing). As a measure of ER stress, the mRNA 
transcript abundance of the spliced variant of X box binding protein 1 (Xbox1s), the 
chaperone Grp94, the ER stress initiated apoptotic marker Chop, and the ER stress 
associated Activating transcription factor 3 (Atf3) were measured. Approximately 24 
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h following the last bout treadmill running, the mRNA transcript abundance of Xbox1s, 
Grp94 and Atf3 did not significantly differ between TA muscles from sedentary or 
exercised Seps1+/- heterozygous mice, Seps1-/- knockout mice and wild type 
littermates. The mRNA transcript abundance of Chop was greater in TA muscles from 
sedentary Seps1-/- knockout mice compared to muscles from sedentary wildtype 
littermates (P = 0.005, Fig 4.8C). In response to the exercise protocol, Chop gene 
expression was reduced such that mRNA transcript abundance no longer differed 
between TA muscles from Seps1-/- knockout mice and wild type littermates. When 
Seps1+/- heterozygous mice were compared to wildtype littermates, Chop mRNA 
transcript abundance was modestly increased in response to exercise (P = 0.049, Fig 
4.8C), but was not significantly affected by the genetic reduction of Seps1. These data 
suggest that the reduced exercise capacity and impaired TA contractile function in 
these mice may not be due to basal increases in ER stress.  
As a marker of oxidative stress, the mRNA transcript abundance of Ho-1, a marker of 
second phase antioxidant responses [307], was assessed in Seps1 GKO mice. The 
genetic reduction or deletion of Seps1 did not significantly alter Ho-1 mRNA transcript 
abundance.  Although, a reduction in Ho-1 gene expression was observed in Seps1-/- 
knockout mice and wildtype littermates in response to the treadmill running protocol 
(P < 0.001, Fig 4.8E). In Seps1+/- heterozygous, no such difference was observed in 
response to exercise, nor the reduction of Seps1 when compared with wildtype 
littermates. Given the potential association between Seps1 and the thioredoxin 
antioxidant system [172], Txnip and Trx1 gene expression was also assessed. However, 
neither exercise nor the genetic reduction or deletion of Seps1 has a significant effect 
on the mRNA transcript abundance of Txnip and Trx1 (Fig 4.8F and G). This is in 
contrast to findings previously observed in EDL muscle (which did undergo ex vivo 
function testing) of Seps1-/- knockout mice, as the deletion of Seps1 reduced Txnip and 
Trx1 [296], suggesting the impairments in contractile function may not be in response 
to alteration of the thioredoxin antioxidant system.  
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Figure 4.8: Exercise alters cellular stress of Seps1 deleted mice. Neither exercise 
(striped), nor the genetic reduction or deletion of Seps1 had statistical effect on ER 
stress markers A, Spliced X-Box binding protein 1 (Xbox1(s)), B, Glucose regulated 
protein 94 (Grp94) or D, Activating transcription factor 3 (Atf3). C, mRNA transcripts 
of ER apoptotic marker, CCAAT-enhancer-binding protein homologous protein (Chop) 
were elevated in Seps1-/- knockout mice when compared with their wildtype littermates 
at rest. However, following exercise in the exercised Seps1-/- knockout mice Chop 
transcripts returned to sedentary wildtype levels, while in Seps1+/- heterozygous mice 
Chop mRNA levels increased following the exercise protocol. To ascertain alteration 
of oxidative stress levels, E, Heme oxygenase 1 (Ho-1), F, Thioredoxin inhibitor 
protein (Txnip) and G, Thioredoxin 1 (Trx1) gene expression was measured in TA of 
Seps1+/- heterozygous and Seps1-/- knockout. While the genetic alteration of Seps1 had 
no effect on Ho-1 levels, exercise stimulated an increase in Ho-1 in the Seps1-/- 
knockout mice and wildtype littermates at the mRNA level. Neither, the genetic 
reduction or deletion of Seps1 significantly affected Txnip or Trx1 transcript levels in 
the TA of sedentary or exercised Seps1-/- knockout mice or their wildtype littermates - 
*P<0.05- main effect for activity for activity as determined by 2-way repeated 
measures ANOVA. † P<0.01- Genotype*Activity interaction in sedentary Seps1-/- 
knockout when compared with sedentary wildtype litter mates, as determined by 2-
way repeated measures ANOVA.   
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4.4. Discussion  
4.4.1. The genetic reduction or deletion of Seps1 impairs exercise capacity and the 
contractile performance of fast twitch hindlimb muscles 
We have previously shown that the genetic reduction or deletion of Seps1 is associated 
with a decline in spontaneous physical activity and impaired muscle strength in fast 
twitch muscles when contractile function was assessed in an organ bath, ex vivo [296]. 
However, it was unknown whether this reduction in spontaneous physical activity 
would compromise exercise capacity and tolerance of short term, high intensity 
endurance exercise. Similarly, it was also unknown whether the deficit in fast twitch 
muscle contractile function would persist if TA muscle performance were to be tested 
in situ with intact nerve and blood supply, which when compared to ex vivo contractile 
function testing represents a more physiologically relevant context.  
Here, we report that in 10-12 week old male mice, the genetic reduction or deletion of 
Seps1 diminished exercise capacity, as defined by a reduction in the distance run and 
an increase in the number of mice that were unable to complete the three bouts of 
treadmill running at increasing exercise intensity. The effect of selenoprotein deletion 
on exercise capacity appears complex and context dependent. For example, the 
presence of SelP impairs exercise performance, as its deletion enhances exercise 
performance in mice following high fat diet [157]. The SelP associated exercise 
benefits do translate into human populations, as reduced SelP expression was observed 
in postmenopausal women with greater VO2max [157]. However, like those found in 
mice, these results must be interpreted with caution, as measures of obesity, such as, 
BMI or waist hip ratios of these participants, which can influence exercise 
performance were not presented in this study. Thus, factors such as weight cannot be 
excluded from the exercise benefits observed with reduced SelP levels. Similarly, 
SelN-/- mice are more fatigue resistant than their wildtype littermates following forced 
treadmill running [147]. However, much of the SelN muscle phenotype in mouse 
models is stress dependent. This is witnessed through decreased physical activity 
following a vitamin E deficient diet, or that the progression of spinal rigidity and 
reduced motility in these mice is only evident following 3 months of forced swimming 
[147, 156]. The stimulus induced phenotype of these SelP and SelN mice are therefore 
far less severe than the human diseases in which they aim to emulate. For example, 
SEPN1 gene mutations consists of a number of conditions including axial muscle 
weakness, minicores, respiratory insufficiency, insulin resistance, and scoliosis [60-
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64]. It is therefore important to acknowledge that in contrast to these context dependent 
selenoprotein phenotypes, the muscle and activity phenotype in Seps1+/- heterozygous 
and Seps1-/- knockout mice demonstrated by our laboratory is evident in sedentary, 
chow fed conditions [296]. Additionally, the majority of mouse models assessing 
protein function or disease utilise a homozygous knockout mouse. However, to date 
our laboratory is the only laboratory to study the effect of both the reduction and 
deletion of selenoprotein levels via a heterozygous and homozygous deletion, 
respectively. While, no SEPS1 genetic diseases have been found to date, known SNPs, 
thought to decrease SEPS1 expression are associated with ischemic stroke, CVD, 
metabolic disease and Hashimoto's Thyroiditis [189, 191, 194, 341]. Thus, the use of 
Seps1+/- heterozygous mice gives us the ability to draw out more complex phenotypes 
which might be better related to human disease. 
As previously observed ex vivo [296], the genetic reduction or deletion of Seps1 led to 
a reduction in TA muscle strength in sedentary Seps1+/- heterozygous and Seps1-/- 
knockout mice when compared to sedentary wildtype mice. The additional stress of 
three bouts of treadmill exercise did not affect TA muscle isometric strength, as muscle 
strength was compromised to a similar extend in the exercised Seps1+/- heterozygous 
and Seps1-/- knockout mice. When the rate of fatigue of TA muscles was assessed in 
sedentary mice in situ, the genetic deletion was impaired when compared with 
wildtype littermates. When the rate of fatigue of the fast twitch EDL muscles from 
Seps1+/- heterozygous and Seps1-/- knockout mice were assessed ex vivo, no such 
change in fatigability was observed [296]. This highlights the advantage of the in situ 
apparatus, which incorporates blood and neural factors that may account for the 
alteration in fatigue observed here, while also limiting excessive ROS which could 
conceal more subtle effects. 
24 h following three bouts of high intensity treadmill running, the reduction of Seps1 
was associated with increased fatigue. However, the Seps1 knockout mice appeared to 
adapt to the exercise stimulus, leading to improved fatigue resistance and force 
recovery in the TA muscles. This suggests that cellular responses to short-term 
exercise training in fast twitch muscles differ whether Seps1 is absent or reduced, as 
the adaptive ability of the Seps1+/- heterozygous mice appeared to be compromised 
when compared to that of the Seps1-/- knockout mice. This adaptation in the Seps1-/- 
knockout mice could be due to compensatory upregulation of other selenoproteins. 
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Therefore, future research should investigate gene and protein levels of ER-resident 
selenoproteins which may counteract the loss the antioxidant potential of Seps1. 
The muscle contractile function phenotype found with the reduction or deletion of 
Seps1 is greater than that previously observed in other ER-resident selenoprotein 
mutants. Specifically, the genetic deletion of SelN failed to significantly affect strength 
of the EDL or Soleus ex vivo, or the TA in situ, while small improvement in fatigue 
resistance was observed in the Soleus of SelN deficient mice [147, 156]. Altogether 
our findings suggest that the genetic reduction or deletion of Seps1 has a strong fast 
twitch contractile function phenotype, however, the cellular mechanisms mediating 
these differences in contractile function remain to be determined. 
 
4.4.2. Potential mechanisms mediation the reduction of exercise capacity following 
the genetic reduction or deletion of Seps1  
The acute exercise protocol utilised in this study permits the investigation of not only 
exercise performance, but also the implication of Seps1 in tolerance to strenuous 
exercise and muscle adaptation. Acute exercise can stimulate changes including 
cellular and inflammatory signalling [415], mitochondria quality [416-418], blood 
flow [419] and E-C coupling [420], leading to improved exercise performance. Thus, 
the potential cellular responses to acute exercise were explored to elucidate potential 
mechanisms mediating the impairment in exercise performance with the genetic 
reduction or deletion of Seps1. In this study it was found that the impairment in 
exercise capacity and isometric TA muscle strength observed in the Seps1+/- 
heterozygous and Seps1-/- knockout mice did not appear to be the consequence of 
increased muscle damage and inflammation in either the sedentary or exercised state. 
Markers of muscle damage including, serum CK, centrally nucleated fibres and 
neutrophil and macrophage infiltration were unchanged by exercise or the genetic 
reduction or deletion of Seps1. Moreover, no decrease in TA muscle fibre cross-
sectional area, which is known to be correlated with reduced muscle strength, was 
observed in the Seps1+/- heterozygous Seps1-/- knockout mice when compared to their 
wild type littermates. This is in contrast to Wright et al [185], where the genetic 
reduction of Seps1 exacerbated the pro-inflammatory profile of fast-twitch EDL 
muscles of mdx mice at the mRNA level, leading to a consequential reduction of 
muscle fibre size. However, the mdx mouse model is a severe model of muscle 
inflammation, as it demonstrates continual muscle damage and asynchronous repair 
122 | P a g e  
 
sequences, paired with excessive inflammation [421], whereas, exercise stimulates a 
more coordinated immune response [405, 422]. Circulating cytokines were not 
measured in Seps1 reduced mdx mice [185], however Curran et al previously 
demonstrate that promoter gene polymorphisms of SEPS1, thought to reduce SEPS1, 
increases circulating cytokines TNF-α and IL-6 in humans [180]. Similarly, sedentary 
Seps1+/- heterozygous mice demonstrate heightened TNF-α levels, however following 
exercise this increase is lost. While this was not observed in sedentary Seps1 -/- 
knockout mice, upon exercise, there was a trend for increased IL-6. Whilst the genetic 
reduction of Seps1 and exercise both stimulated mild increases in circulating 
inflammation and discrete reductions at the gene level, no general inflammatory trends 
were observed. Thus, inflammation does not appear to be responsible for the 
impairment of exercise capacity and fatigue resistance of the Seps1+/- heterozygous, 
nor the adaptation to exercise observed in TA muscles of Seps1-/- knockout mice.  
A single exercise bout can stimulate mitochondrial biogenesis [416, 417] and increase 
mitochondrial content [418] within hours of exercise stimulus, resulting in positive 
adaptation to mitochondria and exercise performance. Cellular metabolism is 
dependent on ATP from the mitochondria, however it is well established that the 
mitochondrial respiratory chain is a major source of ROS [423]. Additionally, 
disrupted Ca2+ homeostasis at the ER, leads to increased mitochondrial Ca2+ levels and 
results in increased oxidative stress production [424]. Failure to regulate oxidative 
stress at the mitochondria impairs mitochondrial function resulting in pro-apoptotic 
pathways and loss of cellular viability [425].  Selenoproteins regulate redox state of 
the ER and the mitochondria [138, 426, 427] and a reduction of Seps1 increases 
oxidative and ER stress in an array of tissues, including proliferating skeletal muscle 
cells [213]. When Seps1 was knocked down in hepatoma cells, Ca2+ homeostasis was 
dysregulated in the ER leading to increased mitochondrial Ca2+ uptake [294]. 
Consequentially, ROS levels increase and the loss of the mitochondrial membrane 
potential results, leading to apoptosis [294]. Provided the regulatory capacity of Seps1 
in cellular stress in liver cells, it is tempting to hypothesise that the genetic reduction 
or deletion of Seps1 may alter mitochondrial respiratory capacity, Ca2+ buffering and 
quality in skeletal muscle. Such deficit may explain the mild inactivity phenotype 
previously observed in these mice, while the metabolic stress of exercise may further 
emphasise this flaw, which may explain the inability of Seps1+/- heterozygous mice to 
sustain exercise capacity. However, the adaptive fatigue resistant response of the 
Seps1-/- knockout mice to exercise in situ prompts further inquiry. Thus, future 
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investigation is required to ascertain the effects of less Seps1 on mitochondrial 
biogenesis, oxidative capacity and mitophagy, providing a more complete 
understanding of Seps1 and the mitochondrion and potential mechanistic 
understanding for the adaptive nature of the Seps1-/- knockout mice.   
Given the role of the selenoproteome in blood flow and angiogenesis [428, 429] and 
the high expression of Seps1 in blood vessels [296], vascular smooth muscle [168] and 
endothelial cells [430], the implication of Seps1 in blood flow regulation is 
conceivable and may provide an additional explanation for the impairment in exercise 
performance of Seps1-/- knockout mice. Exercise training increases capillary density 
in muscle [431, 432], however these structural changes take time and are therefore 
beyond the scope of the 3 day exercise protocol utilised in this study. Yet, blood flow 
and perfusion may be influenced by a single bout of exercise [433]. A single exercise 
session can improve endothelium-dependent vasodilatation up to 48 h post exercise 
[433], as vascular endothelial growth factor (VEGF), a key angiogenic growth factor, 
is increased at the transcript level as little as 4 hours following a single bout of exercise 
[434, 435]. Selenoproteins are known to influence angiogenesis, as suppression of 
thioredoxin reductase increases angiogenesis by inducing the production of VEGF in 
endothelial cells [428], while the addition of 5µg/ml of SelP reduced VEGF-induced 
proliferation and migration of HUVECs [429]. Given the VEGF regulation by 
selenoproteins it would be interesting to measure VEGF in these samples. Further 
research could then investigate the effect the reduction or deletion of Seps1 may have 
on blood flow, measures of angiogenesis and blood perfusion in skeletal muscle. 
 
4.4.3. Potential mechanisms mediation the reduction of in muscle strength following 
the genetic reduction or deletion of Seps1  
To investigate whether impairment in exercise capacity observed in Seps1+/- 
heterozygous and Seps1-/- knockout mice was related to muscle strength the contractile 
properties of TA muscles were assessed in situ. When assessed with an intact nerve 
and blood supply, the genetic reduction and deletion of Seps1 impaired Pt. Reduction 
of Pt translated into a downward shift in the FFC and reduced maximal TA sPo in 
Seps1+/- heterozygous and Seps1-/- knockout mice. However, the strenuous stimuli of 
exercise failed to affect the TA FFC, which suggests the relationship between Seps1 
and strength may be independent of exercise and fatigue. When exploring these 
deficiencies with the reduction or deletion of Seps1 at the single twitch level, Pt was 
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associated with a faster TPT in Seps1+/- heterozygous and Seps1-/- knockout mice. 
While Seps1-/- knockout mice presented with a slower rate of muscle contraction 
(Dx/Dt) in the TA, this was not observed in Seps1+/- heterozygous mice. While faster 
TPT value can be associated with reduced Pt, a slower Dx/Dt and faster TPT are 
indicative of a number of elements responsible for initiation of muscle contraction. 
Thus, the additional effect on Dx/Dt in the Seps1-/- knockout mice, but not the Seps1+/- 
heterozygous mice may suggest a dose response to Seps1 protein levels. 
Upon stimulation of muscle, the dihydropyridine receptor (DHPR) is excited resulting 
in Ca2+ release for the SR [228]. Structures responsible for Ca2+ release, such as the 
DHPR and RyR can be sensitised by changes in their redox state [436-438]. These 
changes can lead to altered Ca2+ handling including the speed and amplitude of Ca2+ 
release, which may be observed through alteration of Pt, TPT, Dx/Dt parameters. This 
can be dependent upon SR Ca2+ stores, which are susceptible to increased leak via the 
RyR or impaired reuptake which is dependent on SERCA activity [22, 438, 439]. 
Additionally, the sensitivity and cooperativity of myofibrils to readily bind Ca2+ may 
alter the speed and force of a muscle contraction, as efficiency of the Ca2+-troponin 
relationship is responsible for the exposure of myosin binding sites on the actin 
filament and consequentially cross bridge cycling [25, 440]. Provided the redox 
regulation previously observed in skeletal muscle, the reduction or loss of Seps1 may 
lead to the oxidation of the contractile apparatus and result in improper contractile 
function. In support of this theory, ER-resident selenoproteins such as SelN causes 
redox induced dysfunctional Ca2+ handling, where SelN has been associated with Ca2+ 
leak and impaired Ca2+ release at the RYR from the SR [137, 143, 147] and reuptake 
by SERCA2 [138]. More recently, Seps1 has been associated with disrupted Ca2+ 
homeostasis in liver cells, where the reduction of Seps1 lead to disrupted Ca2+ handling 
at the ER, resulting in increased mitochondrial Ca2+ dump [294]. Combined, these 
findings provide evidence that the impairment of contractile function in Seps1+/- 
heterozygous and Seps1-/- knockout mice may be a result of disrupted Ca2+ handling 
and improper cross bridge cycling. 
 
4.4.4. Significance and Future Directions 
While a balanced dietary selenium intake has previously been shown to be necessary 
to skeletal muscle health [380], the importance of optimal selenoprotein synthesis to 
skeletal muscle performance is becoming evident in the literature [147, 296]. 
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Consistent with our previous observations in fast phenotype EDL muscles of Seps1 
GKO mice, the genetic reduction or deletion of Seps1 in the TA muscle impaired 
contractile function and lack of spontaneous activity translated to a compromised 
exercise capacity. While the cellular mechanisms mediating these differences in 
contractile function remain to be determined, findings in this study suggest 
inflammation is not responsible. Findings of this study add to a growing body of 
evidence that the family of selenoproteins affect skeletal muscle health [138, 143, 147, 
185, 296]. Upregulation of selenoproteins by selenium supplementation can improve 
skeletal muscle contractile function and exercise performance, as supplementation has 
shown to augment Ca2+ release from the SR, leading to improved muscle strength in 
EDL and Soleus muscles [142]. Selenium supplementation [441-443] and 
selenoprotein overexpression [444] have shown to promote mitochondrial biogenesis 
and improves mitochondrial functional, leading to increased running speed and 
exercise duration [142]. As selenium supplementation has shown to increase Seps1 
expression [445], it is intriguing to speculate that the upregulation Seps1 may in turn 
improve exercise capacity and contractile function. Although, the targeting of 
individual selenoproteins remains complicated, due to individual effects on skeletal 
muscle contractile function and exercise capacity [147]. Nonetheless, an adequate 
dietary intake of selenium remains necessary for optimal selenoprotein expression, 
cellular and inflammatory stress regulation and skeletal muscle contractile function.  
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Chapter Five 
Selenoprotein S Blood Protein Levels Are Not Associated With Human Skeletal 
Muscle Health 
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5.1. Introduction  
The importance of selenium to skeletal muscle health is well established [446, 447]. 
Yet, the emergence of the role for particular selenoproteins in skeletal muscle health 
and performance suggests the biological effect of selenium may be exerted through the 
selenoproteome [137, 138, 296, 383]. Selenoproteins are a family of 25 mammalian 
proteins characterised by the incorporation of Sec amino acid [55]. Whilst limited 
characterisation of members of this family, including glutathione peroxidase and 
thioredoxin reductase has revealed their role as potent antioxidants, the function of 
many selenoproteins remains unknown [448].  
There is increasing research interest into the seven ER-resident selenoproteins (15-
kDa selenoprotein, type 2 iodothyronine deiodinase and selenoproteins S, N, K, M and 
T) due to their emerging role in regulating redox signalling [11], ER stress responses 
[18, 179] and intracellular Ca2+ homeostasis [92, 115, 137, 138, 294]. Within skeletal 
muscle, a specialised smooth ER, termed SR, is central to skeletal muscle function by 
means of Ca2+ signalling, redox homeostasis and protein folding. Failure to support 
these integral pathways compromises skeletal muscle function, leading to increased 
cellular stress, contractile dysfunction, metabolic dysregulation and ultimately a loss 
of muscle health [25, 391, 449]. This has previously been demonstrated by ER-resident 
SelN (SELENON), as mutation of the SelN gene results in SEPN1-reated myopathy, a 
conglomerate of conditions ranging from  minicores and axial muscular dystrophy to 
spinal rigidity and insulin resistance (Reviewed here;[135]). Recently Seps1 
(SELENOS) has gained attention for muscle health [296]. 
Seps1 is an ER–resident antioxidant, known to regulate oxidative, ER and 
inflammatory stress in various mammalian cell culture models (Reviewed here; [213]). 
Seps1 was originally discovered as a metabolic candidate gene; however, much of the 
research surrounding Seps1 has focused on the association with its regulatory role in 
inflammation. SEPS1 possesses single nucleotide polymorphisms (SNPs), such as the 
105G>A promotor polymorphism, thought to reduce SEPS1 expression. The 105G>A 
polymorphism is associated with increased circulating pro inflammatory cytokines IL-
6, TNFα and IL-1β [180]. Seps1 is ubiquitously expressed in tissues including the 
brain, skeletal muscle, adipose tissue, pancreas, kidney, and blood vessels, while it is 
secreted solely by the liver [168, 196]. SEPS1 is highly expressed in metabolically 
active tissues including skeletal muscle, in particular fast twitch fibres of human vastus 
lateralis muscle. In mdx mice, a model of muscular dystrophy, the genetic reduction 
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of Seps1 resulted in an amplified inflammatory state in the fast twitch EDL muscle 
[185]. Furthermore, Seps1 is protective in skeletal muscle, as the genetic reduction of 
Seps1 by siRNA in C2C12 myoblasts resulted in loss of cell viability as a consequence 
of dysregulated oxidative and ER stress. In contrast, its reduction in more oxidative 
myotubes failed to substantially impact muscle health, as defined by cell viability 
(Addinsall et al, Accepted for publication, Chapter 2). When Seps1 is genetically 
deleted in Seps1 GKO mice, exercise performance was reduced [296]. This was 
associated with impairment in the contractile function of fast twitch hindlimb muscles 
[296]. However, the reduction of Seps1 did not significantly affect strength, muscle 
fibre size, cellular stress and inflammatory profile of slow twitch hindlimb muscles 
[185, 296].  
To date, the mechanism by which Seps1 regulates skeletal muscle and exercise 
performance remain to be elucidated. Nonetheless, the regulatory capacity of Seps1 in 
skeletal muscle performance has been consistently demonstrated in mouse models by 
our laboratory [296] (Addinsall et al, Accepted for publication, Chapter 2), yet its 
implication in human skeletal muscle remains unknown. Consequently, there is a need 
to investigate the translational potential of SEPS1 in skeletal muscle health in a human 
population. While skeletal muscle biopsies are ideal for measuring protein 
characteristics at the tissue level, in large epidemiological studies, non-invasive blood 
measures are more feasible. In such studies, objective measures of skeletal muscle 
mass, strength and endurance are practical markers for characterising skeletal muscle 
health. Blood cells have shown to be an accurate, non-invasive biomarker of 
musculoskeletal health, as neutrophils and peripheral blood mononuclear cells are 
associated with factors such as, physical function, strength, mitochondrial function and 
responses to exercise [450-453]. Given the close associated with Seps1 and circulating 
inflammatory cells, leukocytes may assess the association between SEPS1 and muscle 
health in a non-invasive manner [180]. The aim of this study was, therefore, to measure 
the protein expression of SEPS1 in blood cell pellets and determine if there is an 
association between SEPS1 protein levels in blood and skeletal muscle mass, strength 
and endurance in a sample of men from the Geelong Osteoporosis Study (GOS).  
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5.2. Materials and methods 
5.2.1. Study participants 
This cross-sectional study was conducted as part of the GOS, a population-based 
cohort study set in the Barwon Statistical Division in south-eastern Australia. The 
region has a large population and includes individuals from a range of social, cultural 
and geographical settings, representative of the wider Australian population. 
Participants were selected at random from the Commonwealth electoral roll, which 
provides an ideal sampling frame for epidemiological research in Australia, as 
registration with the Australian Electoral Commission is compulsory for residents 
aged 18 years and over. A detailed background to the GOS has been published [454]. 
This study utilises measurement of a subset comprising the first 306 men (ages 33-92 
yr.) assessed in the 15-year follow up phase. All participants provided written, 
informed consent and the study was approved by the Barwon Health and Deakin 
University Human Research Ethics Committees (00/56 and 2013-320, respectively). 
 
5.2.2. Lifestyle factors  
Lifestyle exposures such as tobacco smoking, alcohol consumption, and physical 
activity were documented by self-report. Smoking was described as current; alcohol 
consumption was documented via the Cancer Council Victoria’s food frequency 
questionnaire and high levels of alcohol recognised if consumed in excess of 2 drinks 
per week (20g equivalent) [455] and habitual physical activity level described as very 
active if vigorous exercise was performed regularly (described as: moves, walks and 
works energetically and participates in vigorous activity), otherwise they were 
described as inactive [456]. The diabetic population was identified by measurement of 
fasting plasma glucose (FPG) levels following an overnight fast, using an adaptation 
of the hexokinase-glucose-6-phosphate dehydrogenase method. Diabetes was 
described as a FPG greater than or equal to 7.0 mmol/L (126 mg/dL) and/or self-report 
and/or use of anti-hyperglycaemic medications. 
 
5.2.3. Anthropometry and measures of body compositions 
Body weight was measured to ± 0.1 kg using electronic scales, standing height was 
measured to ± 0.001 m using a wall mounted stadiometer, and BMI calculated as 
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weight/height2 (kg/m2). Waist (minimal abdominal) and hip (maximum gluteal) 
circumferences were measured to ± 0.1 cm using a narrow metal anthropometric tape, 
and the waist/hip ratio (W:H) was calculated. Measures of total body lean and fat mass 
were determined using whole body DXA (Prodigy; GE Lunar, Madison, WI, USA) 
and expressed as percentages of total body weight. Lean tissue assessed by this 
technology includes non-fat and non-bone tissue, and this estimate correlates well with 
skeletal muscle mass quantified by magnetic resonance imaging [457]. Appendicular 
lean mass was calculated as the sum of lean mass for the arms and legs, and normalised 
to height (rALM; kg/m2). Android (waist) fat mass was determined for the region 
between the ribs and the pelvis, where the upper boundary was 20% of the distance 
between the iliac crest and the neck, while the lower boundary was at the top of the 
pelvis. The gynoid (hip) region lay between the head of the femur and the mid-thigh. 
The upper demarcation was below the top of the iliac crest at a distance of 1.5 times 
the android height and the total height was two times the height of the android region 
[458]. Data were also expressed as a ratio of android to gynoid (A:G) fat mass 
distribution. 
 
5.2.4. Muscle strength measures  
Maximal hand grip strength and endurance were assessed in each hand using the 
Vernier Hand Dynamometer (Vernier Software & Technology, Beaverton, USA; HD-
BTA), powered by Logger Pro® software (Vernier Software & Technology), which 
has previously been validated to accurately assess muscle strength [459]. The 
measurement technique was demonstrated whereby participants were seated, with 
their elbow at 90 degrees and wrist in a neutral position. Grip strength was assessed 
three times on each hand, and participants were verbally encouraged to squeeze the 
dynamometer as hard as possible. Hand grip endurance was defined as the area under 
the curve (integration). Endurance was assessed in each hand, whereby subjects were 
verbally encouraged to squeeze the dynamometer as hard as possible until 50% of 
maximum force or failure was reached. The largest hand grip strength and endurance 
were recorded for either the right‐hand or left‐hand side, rather than classified by 
dominant and non-dominant hand, as grip strength is not always reached in the 
dominant hand [460]. 
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5.2.5. Selenoprotein S protein expression 
Venous blood was collected after an overnight fast in a collection tube containing 
potassium oxalate and sodium fluoride, which prevent coagulation and glycolysis, 
respectively. Samples were subjected to centrifugation in order to separate plasma 
from the blood cell pellet, which contained a mixture of leukocytes and erythrocytes. 
Both fractions were subsequently stored at -80 ºC for batch analysis of glucose 
concentration and SEPS1 protein expression.  
To assess the protein expression of SEPS1, 5 μL of blood cell pellet from each 
participant was lysed in 50 μL of 2x Laemmelli sample buffer (Bio-Rad, Hercules, 
USA). A standardised aliquot of pooled blood cell samples was used to create a 
calibration curve that was run on every gel, allowing comparisons of SEPS1 protein 
expression across gels [354]. 2 L blood cell lysates and calibration curve were then 
separated on a 4-15% gradient TGX Stain-Free™ criterion gel (Bio-Rad) at 100 V. 
Following gel activation, proteins were visualised using the Chemidoc™ XRS system 
(Bio-Rad). Proteins were then transferred to PVDF membranes at 100 V for 60 min. 
Membranes were blocked with 5% bovine serum albumin (BSA) in TBS containing 
0.1% Tween-20 (TBS-Tween), before being incubated for 1 h with the anti-SEPS1 
antibody (HPA010025; Sigma-Aldrich; lot: A101692; diluted 1:200 in 1% BSA in 
TBS-Tween) at room temperature. The blots were incubated for 1 h with a goat anti-
rabbit (cat #: 111 035 003; Jackson Labs; lot: 120104; diluted 1:2500 in 1% BSA in 
TBS-Tween) HRP-linked secondary antibody and subsequently imaged using ECL 
chemiluminescence (Bio-Rad). Band densitometry was performed using Quantity 
One® software (Bio-Rad) on the western blots and on the stain free gels to confirm 
even loading. Total protein and specific protein densities were each expressed relative 
to their respective calibration curves (Fig 3A) and subsequently each protein was 
normalised to the total protein content visualised on the stain free protein gel [222].  
 
5.2.6. Statistical analyses 
Participant characteristics were described using mean (SD) for parametric and median 
(IQR) for non-parametric data. As the distribution of SEPS1 was skewed, values were 
natural-log transformed (Ln-SEPS1) to normalise the data for analysis. The Pearson 
product moment correlation coefficient was used to describe the degree of linear 
relationship between anthropometry scores, measures of body mass, age and grip 
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strength or endurance. For categorical data, differences between Ln-SEPS1 values 
were assessed using Student’s t-tests. Multivariable linear regression models were 
used to test the relationship between Ln-SEPS1 and indices of body composition and 
muscle performance. For developing the models, the a priori decision was made to 
select variables to be considered as potential confounders if their correlation with both 
the dependent and independent variables was <0.1. Potential confounders included 
age, anthropometry, smoking status, alcohol consumption, physical activity levels and 
diabetes. Statistical analyses were performed using Minitab statistical software (v17; 
State College, PA, USA), with P < 0.05 being statistically significant. 
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5.3. Results  
5.3.1. Participant characteristics 
Participant characteristics are shown in Table 5.1. The following factors were 
positively correlated with age: percent fat mass (r = 0.142; P = 0.013), waist 
circumference (r = 0.193; P = 0.001), W:H ratio (r = 0.253; P < 0.0001) and A:G ratio 
(r = 0.229; P < 0.001). Whereas, the following were inversely correlated with age: 
weight (r = -0.136; P = 0.017), percent lean mass (r = -0.145; P = 0.011), ALM (r = -
0.247; P < 0.001) or rALM (r = -0.132; P = 0.021). There was no association detected 
between age and BMI (r = 0.055; P = 0.337). 
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Table 5.1: Participant characteristics.  
 n = 306 
Age (yr.) 67 (57-74) 
Height (m) 1.74 ± 0.07 
Weight (kg) 85.14 ± 14.06 
BMI (kg/m2) 28.05 ± 4.14 
Lean mass (kg) 56.49 ± 6.38 
Percent lean mass (%) 66.56 ± 6.57 
Appendicular lean mass (ALM; kg) 35.21 ± 6.23 
Relative ALM (kg/m2) 11.59 ± 1.81 
Fat mass (kg)  26.05 ± 9.41 
Percent fat mass (%) 29.58 ± 6.81 
Android fat mass (kg) 2.79 ± 1.12 
Gynoid fat mass (kg) 3.90 ± 1.40 
Android: Gynoid ratio (A:G) 0.71 ± 0.16 
Waist circumference (cm)  101.8 ± 11.6 
Hip circumference (cm) 106.1 ± 7.9 
Waist: Hip (W:H) Ratio 0.96 ± 0.07 
Grip strength (kg) 25.96 ± 8.68 
Muscle endurance (N/s) 10349.77 ± 5335.01 
Currently smoking  9 (6%) 
Alcohol (>2 drinks per wk.) 200 (68%) 
Physically active  87 (30%) 
FPG (mmol/L)  5.43 ± 1.15 
Diabetes  39 (15%) 
SEPS1 (A.U) 1.11 ± 0.65 
Data are shown as median (interquartile range), mean ± standard deviation or number 
(%). IQR; interquartile range, BMI, Body Mass Index; ALM, Appendicular lean mass; 
FPG, Fasting plasm glucose; A.U, arbitrary unit. 
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5.3.2. Grip strength measures 
Grip strength was inversely associated with age (P< 0.001; Fig 1A), percent fat mass 
(P= 0.016; Fig 1B) and W:H ratio (P< 0.001; Fig 1C). However, grip strength was 
positively associated with ALM (P< 0.001; Fig 1D), and rALM (P= 0.029; Fig 1E).  
 
 
Figure 5.1: Grip strength measures. The linear associations between A, Age (Years), 
B, percent body fat (%), C, Waist to hip ratio (W:H), D, lean appendicular mass (ALM) 
and E, relative appendicular lean mass (rALM) with grip strength. The regression line 
(solid) and prediction interval (dashed), together with the correlation coefficient (r) 
and P-values are shown. 
 
 
5.3.3. Grip endurance measures 
Grip strength was positively associated with grip endurance (P < 0.001; Fig 2A). Grip 
endurance was inversely associated with age (P < 0.001; Fig 2B), percent fat mass (P 
< 0.001; Fig 2C) and W:H ratio (P < 0.001; Fig 2D). However, grip endurance was 
not associated with ALM (Fig 2E) or rALM (Fig 2F).  
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Figure 5.2: Grip endurance measures. The linear associations between A, grip 
strength B, Age (Years), C, percent body fat (%), D, Waist to hip ratio (W:H), E, lean 
appendicular mass (ALM) and F, relative appendicular lean mass (rALM) with hand 
grip endurance. The regression line (solid) and prediction interval (dashed), together 
with the correlation coefficient (r) and P-values are shown. 
 
5.3.4. SEPS1 blood protein expression and body composition and lifestyle factors 
SEPS1 protein expression was detected in all blood samples (Fig 3A). Ln-transformed 
SEPS1 blood protein levels were normally distributed (Fig 3B). No associations were 
detected between Ln-SEPS1 and age (Fig 4A), weight (r = 0.042, P = 0.459) height (r 
= -0.023, P = 0.692), waist circumference (r = 0.051, P = 0.373), BMI (r = 0.055, P = 
0.337), ALM (Fig 4B) or percent body fat (Fig 4C). However, Ln-SEPS1 tended to be 
positively associated with measures of fat distribution, including W:H ratio (P= 0.065; 
Fig 4D) and A:G ratio (P= 0.115; Fig 4E). No differences were detected in Ln-SEPS1 
values for lifestyle factors including, smokers vs non-smokers (mean ± SD: -0.020 ± 
0.706 vs -0.065 ± 0.578, P = 0.788), drinkers vs non-drinkers (-0.091 ± 0.603 vs -0.039 
± 0.573, P = 0.614), very active vs inactive (-0.086 ± 0.601 vs -0.053 ± 0.581, P = 
0.769) or the presence of diabetes (-0.041 ± 0.653 vs -0.074 ± 0.582, P = 0.772).  
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Figure 5.3: SEPS1 blood protein expression. Quantification and distribution of 
SEPS1 protein expression. A, A representative image of the quantification of SEPS1 
protein levels in blood cells. B, the distribution of SEPS1 expression following normal 
logarithmic transformation. 
 
 
Figure 5.4: SEPS1 expression and body composition. Unadjusted associations 
between A, Age (Years), B, lean appendicular mass (ALM), C, percent body fat (%), 
D, Waist to hip ratio (W:H) and E, Android: Gynoid (A:G) ratio and Ln-SEPS1. The 
regression line (solid) and prediction interval (dashed), together with the correlation 
coefficient (r) and P-values are shown. 
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5.3.5. SEPS1 blood protein expression and muscle strength and endurance 
No associations were detected between Ln-SEPS1 and measures of muscle strength 
(Fig 5A) or muscle endurance (Fig 5B). No multivariable regression models were 
developed, as no potential confounders were identified. 
 
 
 
Figure 5.5: SEPS1 and muscle strength and endurance. Unadjusted associations 
between muscle A, strength and B, endurance and Ln-SEPS1. The regression line 
(solid) and prediction interval (dashed), together with the correlation coefficient (r) 
and P-values are shown. 
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5.4. Discussion 
Here we report that SEPS1 protein levels can be measured by western blot in whole 
blood cell pellets. When these samples were used to measure the association between 
SEPS1 and muscle health, no associations were detected with muscle mass, grip 
strength or grip endurance in a male cohort representative of the wider Australian 
population. However, a trend for a positive association between SEPS1 protein levels 
and central fat accumulation was observed.  
Using cell culture and mouse models, Seps1 regulates cellular and inflammatory 
stressors, which play a prominent role in maintaining cellular signalling, growth and 
adaptation and ultimately skeletal muscle health (Addinsall et al, Accepted for 
publication, Chapter 2)[386, 387]. Indeed, findings from our laboratory indicate Seps1 
is highly expressed in skeletal muscle and that the genetic reduction or deletion of 
Seps1 impairs exercise performance, muscle contractile function and in specific 
contexts, can increase gene markers of inflammation in mice [185, 296]. To date, the 
significance of the selenoproteome in skeletal muscle of humans has been restricted to 
SelN, whereby mutation of the SEPN1 gene encoding SelN result in a multivariate 
myopathy in humans [135, 461]. Thus, the relevance of SEPS1 to skeletal muscle 
health and performance in human subjects was investigated here. 
When whole blood cell pellets are used as a biomarker for skeletal muscle health, the 
results of this study do not support an association between SEPS1 proteins levels and 
indices of muscles performance. The measurement of SEPS1 protein expression in 
whole blood cell pellets, rather than separated blood cell fractions should have no 
weight on this result, as the erythrocytes incorporated in these samples possess no 
cellular organelles of known Seps1 expression [168, 462]. Furthermore, confidence 
may be held in these results due to the quality of grip strength analysis in this study. 
Consistent with the literature, grip strength is positively associated with ALM, while 
inversely related to percent fat mass and age [463, 464]. However, the limitations of 
our current study need to be acknowledged, as no direct measurements of SEPS1 
expression in muscle were undertaken. Whereas, in mouse models, the relationship 
between Seps1 expression and skeletal muscle strength and endurance was 
investigated directly in fast and slow twitch hindlimb muscles [296]. Therefore, we 
cannot exclude the possibility that a tissue specific relationship between SEPS1 and 
human skeletal muscle health and performance exists with future research 
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investigating the relationship between SEPS1 protein levels and muscle health directly 
from muscle biopsies.  
Skeletal muscle mass is a key determinant of whole body metabolism [465]. In this 
study, we demonstrate that SEPS1 blood protein levels had no apparent association 
with lean mass. This is consistent with observation in our laboratory, where neither the 
genetic reduction nor deletion of Sesp1 in mice have any effect on muscle mass or size 
under basal or physiological stressed environments [296]. The exception to this is 
observed in the Duchenne muscular dystrophy mouse model, the mdx mouse, where 
the reduction of Seps1 resulted in reduced fibre size in the fast twitch EDL muscle 
[185]. This was observed in conjunction with a slower development of lean mass 
between 6-12 weeks of age, however muscle wet weight was not significantly different 
at 12 weeks of age [185]. These developmental deficits in this model may be a result 
of the amplified inflammatory profile of these mice and therefore the implication of 
Seps1 as a protective antioxidant in severe disease characterised by heightened 
inflammation cannot be ruled out. This is consistent with human populations, where 
the 105G>A SNP in the promoter region of SEPS1 thought to reduce SEPS1 
expression, is associated with elevated circulating cytokine levels [180]. Therefore, 
the implication of inflammation in SEPS1 related skeletal muscle health and function 
warrants future investigation in human populations. 
Like its role in skeletal muscle health, the current understanding of the biological 
relevance of Seps1 to obesity is unclear. SEPS1 mRNA transcripts are elevated in 
subcutaneous adipose tissue from obese study participants [189], while circulating 
serum SEPS1 protein levels are reportedly inversely associated with waist 
circumference [190]. Although, the liver is the predominant tissue source of secreted 
SEPS1, adiposity and obesity are important markers of metabolic risk, therefore DXA 
was employed to clarify the relationship between SEPS1 and obesity in human 
populations. When the association between SEPS1 blood protein levels were measured 
against percent total body fat, no significant relationship was detected. However, these 
results do not discount alteration of fat distribution. Unlike results of Olsson et al, W:H 
ratio in this study tended to be positively associated with SEPS1 protein levels, which 
were supported by similar trends in the A:G ratio [189]. Waist or android fat 
distribution is associated with visceral abdominal fat accumulation and increased 
metabolic risk [466, 467]. Thus, provided the measurement of SEPS1 at the protein 
levels and the sensitive measurement of fat mass by DXA, it may therefore be 
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postulated that although there is no apparent association between SEPS1 and total fat 
mass, an association with central fat distribution should not be discounted.  
The major strengths of this study include a wide participant age range in a sample of 
men who were not selected on the basis of disease, objective measures of body 
composition using DXA, muscle strength and endurance using a dynamometer. 
Furthermore, the measurement of SEPS1 protein levels in an epidemiological study is 
a significant advantage, as previous population studies to date have relied on the 
measurement of SEPS1 SNPs or mRNA levels. We also acknowledge several potential 
weaknesses, which include the use of blood cell pellets rather than muscle biopsies 
and the potential lack of generalisable findings, as the cohort comprised mainly (99%) 
of white men [454.]. Therefore, these findings might not be pertinent to other 
populations and should be interpreted with caution.  
In conclusion, we report that no association was identified between muscle phenotype 
and SEPS1 protein levels in human blood cell pellets in this human population. 
Specifically, SEPS1 protein levels were not associated with measures of muscle 
strength and endurance, as determined by hand grip dynamometer. Moreover, no 
associations were detected between SEPS1 protein levels and appendicular lean mass 
or total fat mass, as determined by DXA. However, a trend for positive association for 
central fat accumulation was discovered. Thus, SEPS1 protein levels in blood may not 
be a suitable biomarker of skeletal muscle health.  However, it must be considered that 
the lack of association in this study may be a result of tissue specific effects and further 
research should investigate the muscle specific effect of SEPS1 in human muscle 
health using tissue specific biopsy studies and more comprehensive analyses of 
skeletal muscle strength and endurance.   
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Chapter Six 
Discussion and Future Directions 
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6.1. Research rationale   
Skeletal muscle is essential to human health, responsible for respiration, metabolism 
and locomotion. Skeletal muscle is a highly plastic tissue, which continually remodels 
in response to stimuli, including oxidative, ER and inflammatory stress. Muscle 
contractile activity transiently increases cellular and inflammatory stress, which are 
crucial for adequate muscle growth, repair and adaptation [311, 387]. This is beneficial 
in the context of exercise, leading to improved contractile function and metabolism. 
Chronic stress dysregulates the stress responses and leads to impaired muscle 
performance and increased likelihood of chronic disease and a reduced quality of life 
[389, 391]. Indeed, many chronic diseases are associated with increased skeletal 
muscle oxidative, ER and inflammatory stress, however these stressors rarely occur in 
isolation [166, 167]. The ER is integral to skeletal muscle health and function, as it is 
a critical site of Ca2+ homeostasis, redox regulation, protein folding and modification. 
The ER shares a close relationship the mitochondria, where cross-talk between the ER 
and mitochondria is important in regulating cellular signalling, stress responses and 
energy production [323, 324]. The ER is sensitive to changes in cellular stress, which 
have been shown to disrupt Ca2+ homeostasis, cell signalling, inflammation, 
metabolism and E-C coupling. Therefore, careful regulation of cellular stress at the ER 
is imperative for muscle health and performance. 
The antioxidant defences of the ER include seven ER-resident selenoproteins; 
specifically, Seps1, SelN, SelK, Sep15, SelM, SelT and Dio2. These ER-resident 
antioxidants have been implicated in the regulation of oxidative and ER stress, 
inflammation, metabolism and intracellular Ca2+ homeostasis [213]. However, with 
the exception of SelN and, as investigated in this thesis, Seps1, the physiological and 
mechanistic understanding of these ER residents in skeletal muscle remains relatively 
uncharacterised. SelN is implicated in skeletal muscle health, as mutation of the 
SEPN1 gene result in a myopathy characterised by respiratory muscle and axial muscle 
weakness and spinal rigidity [135]. Seps1 was discovered as a candidate gene for T2D 
in the Psammomys obesus [186] and gene sequence variations have been associated 
with diseases characterised by a heightened pro-inflammatory state, including 
ischemic stroke, CVD, metabolic disease and Hashimoto's thyroiditis [180, 189, 191, 
194, 341]. Given role of SelN in skeletal cellular stress and muscle health and that of 
Seps1 in metabolism and cellular stress regulation, this thesis aimed to characterise the 
physiological function of Seps1 in skeletal muscle.  
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6.2. Relevance of the Seps1 to skeletal muscle cellular stress regulation in vitro  
Seps1 is an ER-resident antioxidant implicated in cellular stress regulation in various 
mammalian cell culture models in vitro; however, prior to this thesis research little was 
known about the physiological function of Seps1 in vivo. Seps1 is also highly 
expressed in skeletal muscle, yet this is the first study that aimed to investigate the 
function of Seps1 in skeletal muscle [160, 161, 164, 165, 213]. In chapters 2 and 3 we 
demonstrate for the first time that Seps1 is indeed, implicated in cellular responses in 
cultured C2C12 muscle cells and mouse EDL and Soleus muscles. Most interestingly, 
the antioxidant properties and regulatory capacity of Seps1 appears to be dependent 
on metabolic phenotype and cell cycle state. Specifically, Seps1 knockdown by siRNA 
amplified oxidative and ER stress in the glycolytic, proliferating C2C12 myoblasts, 
resulting in increased oxidative stress, reduced cell viability and decreased 
proliferation. The addition of metabolic stress, in the form of palmitate, further 
exacerbated these cellular responses. Whereas, the more oxidative, differentiated 
C2C12 myotubes were more resistant to the knockdown of Seps1. Nonetheless, Seps1 
knockdown in myotubes was associated with a slight increase in cell death, but 
interestingly, a mild reduction in cellular ROS production was observed. This outcome 
is reasonably well established in the literature, as compared to differentiated myotubes, 
proliferating myoblasts have a more glycolytic phenotype [170, 315], fewer 
mitochondria [316, 317] and are more susceptible to cellular stress [318, 319].  
These results are the first to demonstrate the antioxidant capacity of Seps1 in skeletal 
muscle cells. The loss of cell viability as a consequence of these reduced protective 
properties is supported by the literature in other cell types including, astrocytes, 
adipocytes and vascular smooth muscle cells [160, 168, 468]. However, to the best of 
our knowledge, this is the first time the reduction of Seps1 has been implicated in 
disrupting the cell cycle leading to reduced DNA synthesis and cell cycle arrest. The 
differential influence of Seps1 on cellular state has however been observed more 
recently in adipocytes, as the degradation of Seps1 by peroxisome proliferator-
activated receptor (PPAR) γ is required for adipogenesis and differentiation into 
mature adipocytes [330, 469].   
The major limitation of this work surrounds the lack of mechanism by which Seps1 
regulates the ROS in these cells. In addition to the H2O2-induced apoptosis, Seps1 is 
implicated in ER stress-induced macrophage and hepatocyte cell death [161, 162], 
suggesting there is more than one pathway responsible for Seps1-related loss of cell 
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viability.  More recently, Seps1 has been implicated in the regulation of Ca2+ at the 
ER, leading to increased mitochondrial Ca2+ uptake, loss of mitochondrial membrane 
potential, increased ROS and consequentially, cellular death [294]. Therefore it may 
be hypothesised that the altered cellular stress profile of myoblasts and myotubes 
following Seps1 gene knockdown may be mediated by dysregulation of ER Ca2+ 
homeostasis and a reduced mitochondrial buffering capacity. Therefore future 
investigation should use primary muscle cultures from the heterozygous and 
homozygous Seps1 GKO mice to examine if the reduction or deletion of Seps1 
disrupts Ca2+ homeostasis at the ER/mitochondria in muscle cells. Use of primary 
cultures from the heterozygous and homozygous Seps1 GKO mice could provide 
models of both a 50% reduction and an almost complete deletion of the Seps1 protein, 
rather than the approximate 50% reduction achieved by siRNA. While primary 
cultures can be more difficult to establish and maintain, they preserve the morphology 
and many important markers and functions of the cell in vivo, which may be lost by 
the infinite nature of cell cultures [470, 471]. To investigate if the reduction or deletion 
of Seps1 alters Ca2+ content and flux between these organelles in myoblasts fluorescent 
Ca2+ labels, including Rhod2 acetoxymethylester (AM; for mitochondria), Mag-Fluo-
4 AM (for ER) and Fluo-4 AM (for Cytosol) may be employed. Following which, ROS 
levels may be measured using a DCFDA detection kit, as per chapter 2, to investigate 
the implication of disrupted Ca2+ homeostasis and ROS induced cell death observed in 
muscle cells in vitro.  
 
6.3. Relevance of the Seps1 to skeletal muscle contractile function, metabolism 
and exercise capacity 
Parallels can be drawn between the differing metabolic profiles of proliferating 
myoblasts and differentiated myotubes and those of fast and slow twitch muscle fibres. 
Like myoblasts, fast twitch fibres rely on more glycolytic metabolism and are more 
susceptible to cellular stress. Slow twitch fibres and myotubes possess more 
mitochondria, providing a more oxidative metabolic phenotype and therefore do not 
readily encounter cellular stress due to the preferred metabolic pathways of ATP 
generation [472]. To build on our findings in cultures, human muscle tissue was used 
to investigate Seps1 expression and cellular localisation, while the novel Seps1 GKO 
mouse model was used to investigate the role of Seps1 in whole body metabolism and 
skeletal muscle contractile function. To characterise whole body metabolism, these 
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mice were subjected to 24 hours of calorimetric analysis. While no differences were 
observed in the metabolic profiles of Seps1+/- or Seps1-/- mice, the voluntary physical 
activity was reduced with the genetic reduction or deletion of Seps1. To further 
investigate whether this difference in physical activity was due to metabolic deficits, 
a citrate synthase assay was undertaken, however no statistical differences were 
observed between Seps1+/- heterozygous, Seps1-/- knockout and their wildtype 
littermates. Citrate synthase is well established measure of mitochondrial content, 
however provides no measure of mitochondrial quality or functional capacity, 
therefore imaging techniques and mitochondrial function assays may provide further 
explanation of this activity deficit [473](See section 6.5). It should however be 
considered that these mice are sedentary and fed a chow diet, and therefore were not 
subjected to any metabolic challenges. Given the reduction in spontaneous physical 
activity, the exercise capacity should be investigated in these mice. In chapter 4, 
Seps1+/- heterozygous, Seps1-/- knockout or their wildtype littermates underwent 3 
bouts of increasing intensity treadmill running on three consecutive days, where mice 
were run at a speed of 5 m/min, increasing to 25 m/min, every 5 min until completion 
or voluntary cessation. The reduction and deletion of Seps1 reduced the distance run 
by Seps1+/- heterozygous and Seps1-/- knockout mice. Exercise completion was also 
reduced in Seps1+/- heterozygous and Seps1-/- knockout mice, as they were removed 
from the treadmill in abidance with the voluntary cessation of exercise guidelines. 
Thus, the lack of spontaneous activity observed in these mice translated to a 
compromised exercise capacity.  
In Chapter 3 we demonstrated that SEPS1 is preferentially localised in fast twitch 
muscle fibres in human vastus lateralis muscle. Yet, comparison of whole muscle 
tissue homogenates determined slow twitch mouse Soleus to possess greater Seps1 
protein levels than that of the fast twitch EDL. This discrepancy in protein expression 
may be reconciled by the high expression of Seps1 in blood vessels [168], as the 
oxidative phenotype of the Soleus requires greater oxygen delivery and thus increased 
blood vessel density. Given the preferential expression of Seps1 in glycolytic fibres, it 
was not surprising that the genetic deletion of Seps1 impaired the contractile function 
of fast twitch EDL, but not slow twitch Soleus muscles, ex vivo. In EDL muscles, the 
genetic deletion of Seps1 resulted in impaired muscle strength, while muscle fatigue 
and force recovery following submaximal, intermittent stimulation, was unaffected. 
EDL muscles of Seps1+/- heterozygous and Seps1-/- knockout mice also demonstrate a 
reduced tolerance to high frequency contractions, which led to reduced force output. 
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It must be noted that these changes in EDL muscle contractile function were not due 
to reductions in muscle fibre size, nor increased degeneration and inflammation in 
Seps1+/- heterozygous or Seps1-/- knockout mice. However, these fibre type differences 
in contractile function were associated with differential expression of gene markers of 
cellular stress. Thus, the reduction of the antioxidant potential in fast twitch skeletal 
muscle with the deletion of Seps1 may have implications on skeletal muscle strength, 
while the heightened thioredoxin antioxidant system in the more oxidative phenotype 
of the Soleus may be protective. Even though these cellular stress markers may be 
associated with these impairments of physical activity and strength, the mechanistic 
understanding of how Seps1 is implicated in these findings requires further 
investigation, as these conclusions may be limited by the assessment of contractile 
function ex vivo.   
Contractile function was initially assessed ex vivo in order to characterise the role of 
Seps1 in muscle strength and endurance, as it permitted the assessment of both fast 
and slow twitch hindlimb muscles, the EDL and Soleus, respectively. However, 
assessment of contractile function ex vivo requires the removal of the muscle from its 
native environment, where the blood and nerve supply are severed, before the muscle 
is placed in to physiological saline and bubbled with 95% O2 [345]. As such, the 
contractile function is assessed in a hyper-oxidised environment, which in itself may 
have detrimental implication on contractile function [22]. This may influence the role 
Seps1 has on muscle contraction, as subtle differences in redox regulation may be 
hidden, or alternatively, exaggerated effects may overshadow its physiological 
relevance.  
To validate the impaired fast twitch contractile function ex vivo, TA muscles from 
sedentary and exercised Seps1+/- heterozygous and Seps1-/- knockout mice and wild 
type littermates underwent in situ contractile function testing, where the blood and 
nerve supply remains intact [397, 398]. In this study we confirmed that both the 
heterozygous and homozygous deletion of Seps1 impaired fast twitch TA muscle 
contractile function. Similar to the ex vivo observations in EDL muscles, the muscle 
strength was decreased in Seps1+/- heterozygous and Seps1-/- knockout mice when 
compared to wild type littermates, as indicated by a downward shift in the force 
frequency curve. The addition of the exercise protocol did not affect muscle force 
output irrespective of Seps1 expression. Similar to our observations in EDL muscles, 
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the decrease in force producing capacity associated with the genetic reduction or 
deletion of Seps1 was not due to increased muscle damage and inflammation.  
In contrast to isometric force, an interaction between exercise and Seps1 expression 
levels was observed when TA muscle fatigueability and force recovery were assessed 
following 4 min of intermittent stimulation at 100 Hz. In sedentary mice the reduction 
of Seps1 failed to affect the rate of muscle fatigue, whereas, fatigueability was 
increased in TA of Seps1 deleted mice. The added physiological stress of exercise was 
differentially regulated in TA of Seps1 reduced and deleted mice, as the reduction of 
Seps1 lead to an increased rate of fatigue, while, the deletion adapted to the exercise 
stimuli and were more resistant to fatigue. The observation of a fatigue phenotype with 
the reduction and deletion of Seps1 in situ, was absent through ex vivo assessment. 
This discrepancy may be due to the addition of an intact blood supply in situ, however 
future studies are required to investigate this.   
In chapter 4, the reduction and deletion of Seps1 reduced exercise capacity and 
impaired contractile function. However it appears that these results may be 
independent of each other, as the loss of TA strength with the reduction or deletion of 
Seps1 is independent of exercise. Whereas, the rate of TA fatigue is influenced by the 
impaired exercise tolerance of these mice, and thus may be separate mechanism to that 
of muscle strength. The following sections will discuss the potential mechanisms and 
future research directions.  
 
6.4 Future directions – Excitation-Contraction Coupling  
A limitation of this thesis and an opportunity for future research is a lack of a definitive 
mechanism of action of Seps1 function in skeletal muscle. In chapters 3 and 4 we have 
shown that the deletion of Seps1 impaired the contractile function of fast twitch mouse 
hindlimb muscles ex vivo and in situ. Analysis of TA twitch (Pt) contractile properties 
in situ found that the genetic reduction and deletion of Seps1 altered properties 
pertaining to the release of Ca2+, initiation of contraction or myofibular sensitivity in 
the TA, specifically the time to peak tension (TPT) and the rate of force production 
(Dx/Dt). These differences at the twitch level of the TA were not observed in the EDL 
ex vivo, however this may be in part due to the more physiologically relevant model 
of contractile assessment in the TA. Pt contractile properties provide insight into 
alteration of Ca2+ handling, fibre type composition and actin-myosin cross-bridge 
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cycling. These properties may be examined at the single muscle fibre level, permitting 
a detailed assessment of E-C coupling [440, 474, 475]. Provided the novel role of 
Seps1 in fast twitch muscle contractile regulation and its maintenance of cellular stress 
homeostasis in muscle, single fibre analysis may unearth potential redox modifications 
of the contractile apparatus. Oxidation of myofibular proteins in fast twitch fibres can 
lead to a loss of Ca2+ sensitivity, in turn affecting myofibular function [25, 401, 476]. 
However this reduced Ca2+ sensitivity has little impact on action potential-induced 
contraction in muscle fibres [474, 477]. 
Heightened oxidative stress, as seen in muscle disease may also alter the function of 
ryanodine receptors and SERCA2 pumps affecting Ca2+ release and reuptake [22, 25, 
401, 476]. SelN, a family member of Seps1, interacts with RYR and SERCA, where 
mutation of SelN leads to redox modifications to both Ca2+ channels, disrupting Ca2+ 
handling [138, 143, 147]. Recently, the reduction of Seps1 was shown to disrupt Ca2+ 
homeostasis in mouse Hepa1-6 hepatoma cells, leading to increased mitochondrial 
Ca2+ uptake [294]. Seps1 has also been shown to bind to SERCA2A in HEK cells, 
suggesting Seps1 may regulate Ca2+ reuptake at the SR [90]. Therefore, future research 
should investigate if Seps1 impacts E-C coupling through mechanically skinned single 
fibres models and SERCA function via SERCA activity assays and Ca2+ imaging. 
These investigations may provide greater insight into the mechanism in which Seps1 
impairs muscle performance.  
 
6.5 Future directions – Exercise performance and mitochondrial function  
In addition to the exploration of mechanistic understanding of the role of Seps1 in E-
C coupling and muscle strength at the single cell level, future research is required to 
further understand the reduction in exercise capacity observed with the reduction and 
deletion of Seps1. It must be acknowledged that the mouse model used within this 
study is a whole body knockout, and thus the reduction of Seps1 in tissues other than 
skeletal muscle may be responsible for the deficit in exercise capacity. However, given 
the exercise associated impairment and adaptation of fatigueability in TA muscle of 
Seps1+/- heterozygous and Seps1-/- knockout mice, respectively, future research should 
investigate the implication of Seps1 in muscle mitochondria.  
Seps1 has shown to differentially regulate cellular stress dependent on metabolic state 
in skeletal muscle and we hypothesise that the reduction or deletion of Seps1 may 
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disrupt Ca2+ homeostasis at the ER leading to an increased reliance on mitochondrial 
Ca2+ buffering. In fast twitch, glycolytic muscles, the reduction or deletion of Seps1 
may impair mitochondrial function, resulting in poor exercise capacity. Hence, 
functional mitochondrial capacity should be examined in fast twitch EDL and slow 
twitch Soleus hindlimb muscles from Seps1+/- heterozygous and Seps1-/- knockout 
mice via the Seahorse bio-analyser [478]. These measures will indicate if the reduction 
or deletion of Seps1 affect basal, maximal and non-mitochondrial respiration in 
skeletal muscle tissue [478, 479]. 
Additional investigation should examine mitochondrial quality following the 
reduction and deletion of Seps1 via gene markers of mitochondrial fission and fusion. 
Fission and fusion occur in response to metabolic and environmental stressors by 
regulating the size and number of mitochondria, while removing damaged 
mitochondria, facilitated by mitophagy [480]. Consequentially, these processes alter 
mitochondrial morphology, which may be observed through electron microscopy. 
Aligning with findings by Li et al, 2018, mitochondrial ROS should also be measured 
in skeletal muscle tissue. Using single fibres, mitochondrial superoxide may be 
measured fluorometrically by MitoSox probe [481], while the conversion to H2O2 may 
be examined in permeabilised fibre bundles by Amplex red fluorescent probe [482]. 
ROS is required for mitochondrial adaptation, however failure to regulate these 
stressors lead to dysfunction and the development of disease pathogenesis. These 
combined assessments should equip us with a greater insight into overall 
mitochondrial health and may unearth potential deficits of mitochondrial function that 
may explain the loss of exercise capacity with the reduction of Seps1. 
 
6.6 Relevance of the SEPS1 to human skeletal muscle health 
Given the regulation of contractile function in mice in chapter 3 and 4, the translational 
potential of the role of SEPS1 in muscle health was assessed in a human population. 
Specifically, SEPS1 protein levels were measured in whole blood cell pellets collected 
from men participating the Geelong Osteoporosis Study. While skeletal muscle 
biopsies are ideal for measuring protein characteristics at the tissue level, in large 
epidemiological studies, non-invasive blood measures are more ethically feasible. 
SEPS1 protein expression has been measured in human serum previously, however 
these levels are not representative of SEPS1 in skeletal muscle, as it is predominantly 
liver cells which secrete Seps1 into circulation [168, 196]. SEPS1 is however closely 
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associated with circulating inflammatory cells [161, 180], therefore leucocytes may 
provide a non-invasive measure of SEPS1 protein expression. Leucocytes have been 
used as a non-invasive biomarkers of skeletal muscle health and performance, 
including mitochondrial respiration [450-452] and physical function of older adults 
(including strength, balance and muscle quality) [451], thus enabling the translational 
potential of SEPS1 in skeletal muscle health to be ascertained. Whereas, previously 
acknowledged determinants of muscle health, including lean mass, handgrip strength 
and endurance were assessed by DXA and handgrip dynamometer, respectively. 
SEPS1 blood protein levels in blood cell pellets were found to have no association on 
indices of human skeletal muscle health, as no significant associations between SEPS1 
and muscle mass, strength or endurance were observed. This also suggests SEPS1 
protein levels in blood cell pellets may not be a suitable biomarker of skeletal muscle 
health. These conclusions can be drawn, as the measurement of grip strength were a 
strength of this study, aligning with that of the literature, as grip strength was positively 
associated with appendicular lean mass, while inversely associated with age and 
percent body fat [463, 464]. Whilst these results do not appear to align with those 
found in mice, it must be acknowledged that in mice studies we have direct access to 
muscle tissue and techniques that measure muscle contractile responses. Whereas, in 
human populations we utilise clinical measures of strength. Similarly, the genetic 
variation of SEPS1 protein levels in a human population appears less severe than the 
genetic deletion observed in the Seps1 GKO mouse model. Therefore, future research 
should further investigate the translational potential of SEPS1 muscle protein levels 
and muscle strength and health. Specifically, upper and lower limb one repetition 
maximum strength and endurance and exercise capacity should be ascertained in a 
population of young and old participants. The association between measures of muscle 
performance and SEPS1 protein levels should be ascertained in skeletal muscle tissue 
following biopsy. Both young and old participants should be assessed, as selenium 
levels decline with increasing age [483, 484], which has shown to govern gene 
transcription of selenoproteins, including Seps1 [295, 485]. This would therefore 
provide assessment of the direct translation of results observed in mice and potentially 
validate the importance of SEPS1 in human skeletal muscle function. 
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6.7 Overall Conclusions and Perspectives 
 
  
Figure 6.1: Role of Selenoprotein S in skeletal muscle health and function. The 
genetic reduction of Seps1 by siRNA in glycolytic myoblasts leads to a disrupted 
cellular stress and loss of cell viability. However, these responses appear to be 
dependent on metabolic context, as the reduction of Seps1 has little impact on the more 
oxidative myotubes, albeit with a small reduction in ROS and increase in cell death. 
Consistent with that in cells, the genetic reduction and deletion of Seps1 in 
heterozygous and homozygous GKO mice also appears to affect muscle performance 
in a metabolic manner, as the strength of the glycolytic fast phenotype EDL and TA 
muscles was impaired by the deletion of Seps1, while the slow phenotype Soleus 
muscle remain unaffected. In addition to the strength phenotype in these mice, the 
deletion of Seps1 also reduced voluntary physical activity, which translated to an 
impaired exercise capacity when following consecutive bouts of treadmill running.  
 
The data contained within this thesis is the first characterisation of Seps1 in skeletal 
muscle metabolism, cellular stress regulation and performance. Prior to this thesis, the 
physiological role of Seps1 was mostly dependent on cell culture studies and the in 
vivo understanding was limited. The results gained here provide novel insight into the 
role of Seps1 in skeletal muscle contractile function, where the genetic reduction or 
deletion lead to poor regulation of cellular stress, muscular strength and exercise 
performance. It appears that the protective function of Seps1 is dependent up the 
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cellular metabolic phenotype, as Seps1 is preferentially expressed in fast muscle fibres 
and the genetic reduction of Seps1 impacts the more glycolytic proliferating myoblasts 
and fast twitch muscles, when compared with the more oxidative myotubes and slow 
twitch muscles. These findings build on emerging data of ER-resident selenoproteins, 
their regulation of cellular stress, inflammation and intracellular Ca2+ homeostasis and 
their potential in metabolic and muscle health and performance [147, 157, 213]. While 
the significance of optimal selenium levels to human health is well established, the 
biological efficacy of selenium through selenoproteins is gaining more attention. As 
such, in cases of suboptimal nutritional capacity, modulation of dietary selenium levels 
and thus ER-resident selenoprotein function may be beneficial for optimal metabolic 
health and muscle performance.  
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